Compound containing amide-substituted aromatic ring, and pharmaceutical composition and use thereof

By developing compounds containing amide-substituted aromatic rings, inhibiting HPK1 targets, the problem of poor therapeutic effects of HPK1 targets in the prior art has been solved, better pharmacodynamic and pharmacokinetic characteristics have been achieved, and better pharmacokinetic characteristics have been improved. Effects on treatment of cancer and other diseases.

WO2024240242A1PCT designated stage expired Publication Date: 2024-11-28CHIA TAI TIANQING PHARMA GRP CO LTD

Patent Information

Application Number
PCT/CN2024/095076
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-17
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The lack of selective inhibitors targeting hematopoietic progenitor kinase 1 (HPK1) in the prior art leads to poor pharmacodynamic and pharmacokinetic effects in the treatment of related diseases such as cancer.

Method used

Compounds containing amide-substituted aromatic rings or pharmaceutically acceptable salts thereof are developed for the preparation of pharmaceutical compositions with selective inhibitory activity or improved pharmacodynamics and pharmacokinetics for targeted therapy against HPK1.

Benefits of technology

Through these compounds, the activity of HPK1 can be effectively inhibited, potentially improve the therapeutic effect on diseases such as cancer, and provide better pharmacodynamic and pharmacokinetic properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024095076_28112024_PF_FP_ABST
    Figure CN2024095076_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to the field of pharmaceutical chemistry, relates to a compound containing an amide-substituted aromatic ring, and specifically relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof in treatment of diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Compounds containing amide-substituted aromatic rings, pharmaceutical compositions and uses thereof

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This disclosure claims the benefit of and priority to the following four Chinese invention patent applications, the entire contents of which are hereby incorporated by reference in their entirety:

[0003] Chinese invention patent application No. CN 202310596815.X filed with the State Intellectual Property Office of China on May 25, 2023,

[0004] Chinese invention patent application No. CN 202311185790.0 filed with the State Intellectual Property Office of China on September 13, 2023,

[0005] Chinese invention patent application No. CN 202311692854.6 filed with the State Intellectual Property Office of China on December 8, 2023, and

[0006] Chinese invention patent application No. CN 202410621157.X submitted to the State Intellectual Property Office of China on May 17, 2024. Technical Field

[0007] The present disclosure relates to compounds containing an amide-substituted aromatic ring or pharmaceutically acceptable salts thereof, methods for preparing the compounds, pharmaceutical compositions containing the compounds, and uses thereof in treating diseases (eg, cancer). Background Art

[0008] Hematopoietic progenitor kinase 1 (HPK1), also known as mitogen-activated protein kinase 1 (MAP4K1), is a mammalian Ste20-related serine / threonine protein kinase. It is a microtubule-associated protein and a member of the mitogen-activated protein kinase (MAP4K) family, which also includes five isoforms: GCK / MAP4K2, GLK / MAP4K3, HGK / MAP4K4, KHS1 / MAP4K5, and MINK1 / MAP4K6. Unlike the other five MAP4K isoforms that are widely expressed in tissue cells, HPK1 is exclusively expressed in hematopoietic tissue cells. It can regulate signal transduction in the hematopoietic system, including lymphocytes, by mediating multiple cell signaling pathways (including MAPK signaling, antigen receptor signaling, and cytokine signaling).

[0009] Studies have found that HPK1 primarily inhibits immune cell responses through the c-Jun N-terminal kinase (JNK) and extracellular signal-regulated protein kinases (ERK) signaling pathways. In T cells, upon T cell receptor (TCR) activation, HPK1 interacts with numerous TCRs and is phosphorylated by the tyrosine kinases Lck and Zap70. Activated HPK1 further phosphorylates the T cell receptor adaptor protein SLP-76, establishing a docking site for the negative regulator 14-3-3. This ultimately destabilizes the TCR signaling complex (lato-gads-SLP76) and hinders downstream mitogen-activated protein (MAP kinase) signaling, negatively regulating TCR signaling and subsequently inhibiting T cell proliferation. A similar negative feedback mechanism also exists in B cells. B cell receptor (BCR) signaling, through HPK1-mediated phosphorylation and activation of B-cell linker protein (BLNK), hinders downstream signaling and inhibits B cell proliferation. Furthermore, HPK1 also exerts negative feedback on NK cells (natural killer cells) and dendritic cells (DCs).

[0010] Currently, there are no drugs targeting HPK1 on the market, and there is still a need in this field to develop compounds with selective inhibitory activity, or better pharmacodynamics, or better pharmacokinetics.

[0011] Summary of the Invention

[0012] The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof,

[0013] in,

[0014] X 1 、X 2 or X 3 Each independently selected from N or CR a’ ;

[0015] Y is selected from a bond, -CH2-, -O-, -S-, -NR a -、-S(O)2NR a -、-S(O)-、-S(O)NR a -, -C(O)-, -C(O)O-, -C(O)NR a -、-C(O)N(R a )O-、-OC(O)-、-OC(O)NR a -、-N(R a )C(O)O-、-N(R a )C(O)-or-N(R a )S(O)2-;

[0016] Ring A is selected from 5-14 membered partially unsaturated heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;

[0017] R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d 、-NH2、-NHR d 、-N(R d )2, -OH, -SH, -OR d 、Halogen、-COR d 、-COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d)2, -SO2R d 、-PO(R d )2. C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 6-10 aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl or 3-14 membered heterocyclyl, wherein the C 1-12 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl, 3-14 membered heterocyclyl, C 2-12 Alkenyl or C 2-12 Alkynyl is optionally substituted with one or more R b replace;

[0018] R 2 is selected from 5-6 membered heteroaryl, 5-6 membered monocyclic heterocycloalkenyl, 8-12 membered saturated, partially saturated or aromatic bicyclic group, or 9-16 membered saturated, partially saturated or aromatic tricyclic group, wherein the bicyclic group or tricyclic group contains 0-6 heteroatoms independently selected from N, O or S, and the R 2 Optionally, one or more R c replace;

[0019] Every R a’ Each is independently selected from hydrogen, deuterium, halogen, -CN, -NH2, -OH, -NO2, -SH or the following groups optionally substituted by one or more substituents: -OC 1-12 Alkyl, -C 1-12 Alkyl, -NH(C 1-12 Alkyl), -N(C 1-12 alkyl)2, 3-14 membered cycloalkyl, 3-14 membered heterocycloalkyl, -NH-3-14 membered cycloalkyl, -SO2C 1-12 Alkyl, -OSO2C 1-12 Alkyl, -OC 1-12 Alkyl-SO2C 1-12 Alkyl, -C 1-12 Alkyl-sulfonyl imide, -OSO2C 1-12 Alkyl, -C(C 1-12 Alkyl)2SO2C 1-12 Alkyl, -SO2NHC 1-12 Alkyl, -SO2N(C 1-12 Alkyl)2, -OC 1-12 Alkyl-N(C 1-12 Alkyl)2, -C 1-12 Alkyl (3-14 membered heterocycloalkyl), -C(O)(C 1-12alkyl), -C(O)NH(C 1-12 alkyl), -CH2C(O)NH(C 1-12 alkyl), -C(O)(3-14 membered heterocycloalkyl), -NH-3-14 membered heterocycloalkyl, -C(O)(3-14 membered cycloalkyl), -C(O)NH(3-14 membered cycloalkyl) or -C(O)NH(3-14 membered heterocycloalkyl);

[0020] Every R a are each independently selected from hydrogen, or C optionally substituted by one or more substituents 1-12 Alkyl, 3-14 membered heterocycloalkyl, 3-14 membered cycloalkyl or 3-14 membered cycloalkenyl;

[0021] Every R b Each independently selected from deuterium, halogen, -OH, -NH2, -CN, or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, -SC 1-12 Alkyl, C 1-12 Alkyl, -C(O)C 1-12 Alkyl, -NHC(O)(C 1-12 alkyl), -C(O)N(C 1-12 Alkyl)2, -C(O)NH(C 1-12 alkyl), 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl, 3-14 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)-3-14 membered cycloalkyl, -C(O)-3-14 membered heterocycloalkyl, -C(O)-3-14 membered heterocycloalkenyl, -NH-3-14 membered cycloalkyl, -NH-3-14 membered heterocycloalkyl or -NH-3-14 membered heterocycloalkenyl;

[0022] Every R c are each independently selected from deuterium, halogen, -OH, -NH2 or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, C 1-12 Alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl;

[0023] Every R d are each independently selected from the following groups optionally substituted by one or more substituents: C 1-12 Alkyl, C 3-14Cycloalkyl or 3-14 membered heterocycloalkyl;

[0024] m is selected from 0, 1, 2, 3, 4, 5 or 6.

[0025] In some embodiments, the present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein,

[0026] X 1 、X 2 or X 3 Each independently selected from N or CR a’ ;

[0027] Y is selected from a bond, -CH2-, -O-, -S-, -NR a -、-S(O)2NR a -、-S(O)-、-S(O)NR a -, -C(O)-, -C(O)O-, -C(O)NR a -、-C(O)N(R a )O-、-OC(O)-、-OC(O)NR a -、-N(R a )C(O)O-、-N(R a )C(O)-or-N(R a )S(O)2-;

[0028] Ring A is selected from 5-14 membered partially unsaturated heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;

[0029] R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d 、-NH2、-NHR d 、-N(R d )2, -OH, -SH, -OR d , halogen, -COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d )2, -SO2R d 、-PO(R d )2. C 1-12 Alkyl, C2-12 Alkenyl, C 2-12 Alkynyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl, 3-14 membered heterocyclyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein the C 1-12 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl or 3-14 membered heterocyclyl, C 2-12 Alkenyl or C 2-12 Alkynyl is optionally substituted with one or more R b replace;

[0030] R 2 is selected from 5-6 membered heteroaryl, 5-6 membered monocyclic heterocycloalkenyl, 8-12 membered saturated, partially saturated or aromatic bicyclic group, or 9-16 membered saturated, partially saturated or aromatic tricyclic group, wherein the bicyclic group or tricyclic group contains 0-6 heteroatoms independently selected from N, O or S, and the R 2 Optionally, one or more R c replace;

[0031] Every R a’ Each is independently selected from hydrogen, deuterium, halogen, -CN, -NH2, -OH, -NO2, -SH or the following groups optionally substituted by one or more substituents: -OC 1-12 Alkyl, C 1-12 Alkyl, -NH(C 1-12 Alkyl), -N(C 1-12 alkyl)2, 3-14 membered cycloalkyl, 3-14 membered heterocycloalkyl, -NH-3-14 membered cycloalkyl, -SO2C 1-12 Alkyl, -OSO2C 1-12 Alkyl, -OC 1-12 Alkyl-SO2C 1-12 Alkyl, C 1-12 Alkyl-sulfonyl imide, -OSO2C 1-12 Alkyl, -C(C 1-12 Alkyl)2SO2C 1-12 Alkyl, -SO2NHC 1-12 Alkyl, -SO2N(C 1-12 Alkyl)2, -OC 1-12 Alkyl-N(C 1-12 Alkyl)2, -C 1-12 Alkyl (3-14 membered heterocycloalkyl), -C(O)(C 1-12 alkyl), -C(O)NH(C 1-12 alkyl), -CH2C(O)NH(C 1-12alkyl), -C(O)(3-14 membered heterocycloalkyl), -NH-3-14 membered heterocycloalkyl, -C(O)(3-14 membered cycloalkyl), -C(O)NH(3-14 membered cycloalkyl) or -C(O)NH(3-14 membered heterocycloalkyl);

[0032] Every R a are each independently selected from hydrogen, or C optionally substituted by one or more substituents 1-12 Alkyl, 3-14 membered heterocycloalkyl, 3-14 membered cycloalkyl or 3-14 membered cycloalkenyl;

[0033] Every R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2 or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, C 1-12 Alkyl, -C(O)C 1-12 Alkyl, -NHC(O)(C 1-12 alkyl), -C(O)N(C 1-12 Alkyl)2, -C(O)NH(C 1-12 alkyl), 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl, 3-14 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)-3-14 membered cycloalkyl, -C(O)-3-14 membered heterocycloalkyl, -C(O)-3-14 membered heterocycloalkenyl, -NH-3-14 membered cycloalkyl, -NH-3-14 membered heterocycloalkyl or -NH-3-14 membered heterocycloalkenyl;

[0034] Every R c are each independently selected from deuterium, halogen, -NH2, -OH or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, C 1-12 Alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl;

[0035] Every R d are each independently selected from the following groups optionally substituted by one or more substituents: C 1-12 Alkyl or C 3-14 Cycloalkyl;

[0036] m is selected from 0, 1, 2, 3, 4, 5 or 6.

[0037] In some embodiments, the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof,

[0038] in,

[0039] X 1 、X 2 or X 3 Each independently selected from N or CR a’ ;

[0040] Y is selected from a bond, -CH2-, -O-, -S-, -NR a -、-S(O)2NR a -、-S(O)-、-S(O)NR a -, -C(O)-, -C(O)O-, -C(O)NR a -、-C(O)N(R a )O-、-OC(O)-、-OC(O)NR a -、-N(R a )C(O)O-、-N(R a )C(O)-or-N(R a )S(O)2-;

[0041] Ring A is selected from 5-14 membered partially unsaturated heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl;

[0042] R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d 、-NH2、-NHR d 、-N(R d )2, -OH, -SH, -OR d , halogen, -COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d )2, -SO2R d 、-PO(R d )2. C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 6-10aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl or 3-14 membered heterocyclyl, wherein the C 1-12 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl or 3-14 membered heterocyclyl is optionally substituted by one or more R b replace;

[0043] R 2 is selected from 5-6 membered heteroaryl, 5-6 membered monocyclic heterocycloalkenyl, 8-12 membered saturated, partially saturated or aromatic bicyclic group, or 9-16 membered saturated, partially saturated or aromatic tricyclic group, wherein the bicyclic group or tricyclic group contains 0-6 heteroatoms independently selected from N, O or S, and the R 2 Optionally, one or more R c replace;

[0044] Every R a’ Each is independently selected from hydrogen, deuterium, halogen, -CN, -NH2, -OH, -NO2, -SH or the following groups optionally substituted by one or more substituents: -OC 1-12 Alkyl, C 1-12 Alkyl, -NH(C 1-12 Alkyl), -N(C 1-12 alkyl)2, 3-14 membered cycloalkyl, 3-14 membered heterocycloalkyl, -NH-3-14 membered cycloalkyl, -SO2C 1-12 Alkyl, -OSO2C 1-12 Alkyl, -OC 1-12 Alkyl-SO2C 1-12 Alkyl, C 1-12 Alkyl-sulfonyl imide, -OSO2C 1-12 Alkyl, -C(C 1-12 Alkyl)2SO2C 1-12 Alkyl, -SO2NHC 1-12 Alkyl, -SO2N(C 1-12 Alkyl)2, -OC 1-12 Alkyl-N(C 1-12 Alkyl)2, -C 1-12 Alkyl (3-14 membered heterocycloalkyl), -C(O)(C 1-12 alkyl), -C(O)NH(C 1-12 alkyl), -CH2C(O)NH(C 1-12 alkyl), -C(O)(3-14 membered heterocycloalkyl), -NH-3-14 membered heterocycloalkyl, -C(O)(3-14 membered cycloalkyl), -C(O)NH(3-14 membered cycloalkyl) or -C(O)NH(3-14 membered heterocycloalkyl);

[0045] Every R a are each independently selected from hydrogen, or C optionally substituted by one or more substituents 1-12 Alkyl, 3-14 membered heterocycloalkyl, 3-14 membered cycloalkyl or 3-14 membered cycloalkenyl;

[0046] Every R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2 or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, C 1-12 Alkyl, -C(O)C 1-12 Alkyl, -NHC(O)(C 1-12 alkyl), 3-14 membered cycloalkyl or 3-14 membered cycloalkenyl;

[0047] Every R c are each independently selected from deuterium, halogen, -NH2, -OH or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, C 1-12 Alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl;

[0048] Every R d are each independently selected from the following groups optionally substituted by one or more substituents: C 1-12 Alkyl or C 3-14 Cycloalkyl;

[0049] m is selected from 0, 1, 2, 3, 4, 5 or 6;

[0050] And the following conditions are met at the same time:

[0051] 1) When R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen;

[0052] 2) When the structure for When R a’ Not hydrogen;

[0053] 3) When the structure for When ring A is not C 6-10 aryl;

[0054] 4) When R 1Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0055] a) Ring A is a 5-membered heteroaryl group, and R a’ Not selected from cyclopropyl, OCH3 and NHCH3;

[0056] b) Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused with the heterocyclic group;

[0057] c)R 1 is a 3-14 membered heterocyclic group, and R b Any one or more substituents selected from the following groups: =O, -C(O)C optionally substituted by one or more substituents 2-4 Alkyl, -C(O)CH3 substituted by halogen, or C substituted by Cl or -NH2 1-4 alkyl;

[0058] Among them, the Y in 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ;

[0059] R 3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl;

[0060] R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups;

[0061] R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups.

[0062] In some embodiments, the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof,

[0063] in,

[0064] X 1 、X 2 or X 3 Each independently selected from N or CR a’ ; Y, R 1 , and R 2 is as defined in this application;

[0065] Ring A is selected from C 6-14 Aryl or 5-14 membered heteroaryl;

[0066] R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d 、-NH2、-NHR d 、-N(R d )2, -OH, -SH, -OR d , halogen, -COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d )2, -SO2R d 、-PO(R d )2. C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl, 3-14 membered heterocyclyl, or two R 1 Connected to form a 3-14 membered heterocyclic group or C 4-14 Cycloalkenyl, wherein the C 1-12 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl or 3-14 membered heterocyclyl or C 4-14 The cycloalkenyl group is optionally substituted with one or more R b replace;

[0067] Every R a’Each independently selected from hydrogen, deuterium, halogen, -CN, -NO2, -SH or the following groups optionally substituted by one or more substituents: -NH2, -OH, -OC 1-12 Alkyl, C 1-12 Alkyl, -NH(C 1-12 Alkyl), -N(C 1-12 alkyl)2, 3-14 membered cycloalkyl, 3-14 membered heterocycloalkyl, -NH-3-14 membered cycloalkyl, -SO2C 1-12 Alkyl, -OSO2C 1-12 Alkyl, -OC 1-12 Alkyl-SO2C 1-12 Alkyl, C 1-12 Alkyl-sulfonyl imide, -OSO2C 1-12 Alkyl, -C(C 1-12 Alkyl)2SO2C 1-12 Alkyl, -SO2NHC 1-12 Alkyl, -SO2N(C 1-12 Alkyl)2, -OC 1-12 Alkyl-N(C 1-12 Alkyl)2, -C 1-12 Alkyl (3-14 membered heterocycloalkyl), -C(O)(C 1-12 alkyl), -C(O)NH(C 1-12 alkyl), -CH2C(O)NH(C 1-12 alkyl) or -C(O)(3-14 membered heterocycloalkyl); each R b Each independently selected from deuterium, halogen, -CN, Or the following groups optionally substituted by one or more substituents: -OH, -NH2, -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, C 1-12 Alkyl, 3-14 membered cycloalkyl or 3-14 membered cycloalkenyl;

[0068] Every R c are each independently selected from deuterium, halogen, Or the following groups optionally substituted by one or more substituents: -NH2, -OH, -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, C 1-12 Alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl;

[0069] m is selected from 1, 2, 3, 4, 5 or 6;

[0070] And the following conditions are met at the same time:

[0071] 1) When R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen;

[0072] 2) When the structure for When R a’ Not hydrogen;

[0073] 3) When the structure for When ring A is not C 6-10 aryl;

[0074] 4) When R 1 When there is no phosphorus atom, R 2 is not a substituent:

[0075] in,

[0076] Y 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ;

[0077] R 3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl;

[0078] R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups;

[0079] R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups.

[0080] In some embodiments, when X 1 、X 2 and X3 When at most one of them is N, the compound of formula (I) does not include Both as substituents R 1 .

[0081] In some embodiments, the compound of formula (I) does not include the following compounds:

[0082] In some embodiments, the heteroaryl and heterocycloalkyl groups contain 1, 2, 3, or 4 heteroatoms independently selected from N, O, S, or P, with the remaining ring atoms selected from carbon. In some embodiments, the heteroaryl and heterocycloalkyl groups contain 1, 2, or 3 heteroatoms independently selected from N, O, or S, with the remaining ring atoms selected from carbon. In some embodiments, the heteroaryl and heterocycloalkyl groups contain 1, 2, or 3 heteroatoms independently selected from N or O, with the remaining ring atoms selected from carbon. In some embodiments, the heteroaryl and heterocycloalkyl groups contain 1 or 2 heteroatoms independently selected from N or O, with the remaining ring atoms selected from carbon.

[0083] In some embodiments, the "by one or more" is each independently selected from "by 1, 2, 3, 4, 5 or 6".

[0084] In some embodiments, the "by one or more" is each independently selected from "by 1, 2, 3, 4 or 5".

[0085] In some embodiments, the "by one or more" is each independently selected from "by 1, 2, 3 or 4".

[0086] In some embodiments, the "by one or more" is each independently selected from "by 1, 2, or 3".

[0087] In some embodiments, when R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen.

[0088] In some embodiments, when the moiety for When R a’ is not hydrogen, where X 1 、X 2 , and X 3 The definition of is as described in this disclosure.

[0089] In some embodiments, when the moiety for When ring A is not C 6-10 Aryl, wherein X 1 、X 2, and X 3 The definition of is as described in this disclosure.

[0090] In some embodiments, when R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0091] a) Ring A is a 5-membered heteroaryl group, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3;

[0092] b) Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused with the heterocyclic group;

[0093] c) There is at least one R 1 C 1-6 Alkyl, 4-14 membered cycloalkyl, 3-14 membered heterocyclic group, C 2-12 Alkenyl or C 2-12 Alkynyl, and the C 1-6 The alkyl group is replaced by one or more selected from -SC 1-6 alkyl, or an optionally substituted 3-14 membered cycloalkyl substituted with one or more substituents selected from -OH, halogen, optionally substituted C 1-6 Alkyl, optionally substituted -OC 1-6 alkyl, optionally substituted -(CH2) 0-2 N(C 1-6 alkyl)2, or optionally substituted -C(O)N(C 1-6 alkyl) 2, the 3-14 membered heterocyclic group is substituted by at least one or more selected from =O, optionally substituted by one or more substituents -C(O)C 2-4 alkyl, -C(O)CH3 substituted by one or more halogens, optionally substituted -C(O)N(C 1-6 Alkyl)2, C substituted by Cl or -NH2 1-4 Alkyl, or -C (O) -3-8 membered cycloalkyl substituents; said C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with one or more R b replace;

[0094] Among them, the Y in 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3 CR3 , when Y 3 When N, Y 1 CR 3 ;

[0095] R 3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl;

[0096] R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups;

[0097] R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups.

[0098] In some embodiments, Ring A is a 5-membered heteroaryl, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3.

[0099] In some embodiments, Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused to the heterocyclic group.

[0100] In some embodiments, at least one R 1 C 1-6 Alkyl, 4-14 membered cycloalkyl, 3-14 membered heterocyclic group, C 2-12 Alkenyl or C 2-12 Alkynyl, and the C 1-6 The alkyl group is replaced by one or more selected from -SC 1-6 alkyl, or an optionally substituted 3-14 membered cycloalkyl substituted with one or more substituents selected from -OH, halogen, optionally substituted C 1-6 Alkyl, optionally substituted -OC 1-6 alkyl, optionally substituted -(CH2) 0-2 N(C 1-6 alkyl)2, or optionally substituted -C(O)N(C 1-6 alkyl) 2, the 3-14 membered heterocyclic group is substituted by at least one or more selected from =O, optionally substituted by one or more substituents -C(O)C 2-4alkyl, -C(O)CH3 substituted by one or more halogens, optionally substituted -C(O)N(C 1-6 Alkyl)2, C substituted by Cl or -NH2 1-4 Alkyl, or -C (O) -3-8 membered cycloalkyl substituents; said C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with one or more R b replace.

[0101] In some embodiments, when R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0102] a) Ring A is a 5-membered heteroaryl group, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3;

[0103] b) Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused with the heterocyclic group;

[0104] c) There is at least one R 1 C 1-6 Alkyl, 4-14 membered cycloalkyl, 3-14 membered heterocyclic group, C 2-12 Alkenyl or C 2-12 Alkynyl, and the C 1-6 The alkyl group is substituted with one or more substituents selected from optionally substituted 3-14 membered cycloalkyl, the 4-14 membered cycloalkyl group being substituted with one or more substituents selected from halogen or -N(C 1-6 alkyl) 2, the 3-14 membered heterocyclic group is substituted by at least one or more selected from =O, optionally substituted by one or more substituents -C(O)C 2-4 Alkyl, -C(O)CH3 substituted by halogen, C substituted by Cl or -NH2 1-4 Alkyl, or -C(O)-3-8 membered cycloalkyl substituent;

[0105] Among them, the Y in 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ;

[0106] R3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl;

[0107] R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups;

[0108] R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups.

[0109] In some embodiments, when R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0110] a) Ring A is pyrazolyl, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3;

[0111] b) Ring A is a phenyl group, and the phenyl group is fused with a 4-10 membered heterocyclic group;

[0112] c) There is at least one R 1 is methyl, ethyl, cyclobutyl, cyclopentyl, azetidinyl, azocyclopentyl, piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, 2,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2,7-diazaspiro[3.5]nonane, 2,7-diazaspiro[4.4]nonane, octahydropyrrolo[3,4-c]pyrrole, or ethynyl, and the methyl or ethyl group is replaced by one or more -SC 1-4 alkyl, or a substituent of an optionally substituted 3-6 membered cycloalkyl, wherein the cyclobutyl or cyclopentyl is substituted by one or more substituents selected from -OH, F, C 1-4 Alkyl, optionally substituted -OC 1-4 Alkyl, optionally substituted -N(C 1-4 alkyl)2, optionally substituted -CH2N(C 1-4 alkyl)2, or optionally substituted -C(O)N(C 1-4alkyl) 2 substituents; the azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, 2,6-diazaspiro [3.3] heptane, 2,6-diazaspiro [3.4] octane, 2,7-diazaspiro [3.5] nonane, 2,7-diazaspiro [4.4] nonane, or octahydropyrrolo [3,4-c] pyrrole is at least one or more selected from =O, -C(O)C 2-4 Alkyl, -C(O)CH3, -C(O)N(C 1-4 Alkyl)2, C substituted by Cl or -NH2 1-3 alkyl, or -C(O)-3-6 membered cycloalkyl, wherein the ethynyl group is substituted by one or more C 1-4 Alkyl, -C(O)N(C 1-4 Alkyl)2, -C(O)NH(C 1-4 alkyl), 3-6 membered cycloalkyl, or -C(O)-3-6 membered heterocycloalkyl;

[0113] Among them, the Y in 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ;

[0114] R 3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl;

[0115] R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups;

[0116] R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups.

[0117] In some embodiments, when R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0118] a) Ring A is pyrazolyl, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3;

[0119] b) Ring A is a phenyl group, and the phenyl group is fused with a 4-10 membered heterocyclic group;

[0120] c) There is at least one R 1 for

[0121] Among them, the Y in 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ;

[0122] R 3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl;

[0123] R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups;

[0124] R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups.

[0125] In some embodiments, the present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof that satisfies the following conditions:

[0126] 1) When R2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen;

[0127] 2) When the structure for When R a’ Not hydrogen;

[0128] 3) When the structure for When ring A is not C 6-10 aryl;

[0129] 4) When R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0130] a) Ring A is a 5-membered heteroaryl group, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3;

[0131] b) Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused with the heterocyclic group;

[0132] c) There is at least one R 1 C 1-6 Alkyl, 4-14 membered cycloalkyl, 3-14 membered heterocyclic group, C 2-12 Alkenyl or C 2-12 Alkynyl, and the C 1-6 The alkyl group is substituted with one or more substituents selected from optionally substituted 3-14 membered cycloalkyl, the 4-14 membered cycloalkyl group being substituted with one or more substituents selected from halogen or -N(C 1-6 alkyl) 2, the 3-14 membered heterocyclic group is substituted by at least one or more selected from =O, optionally substituted by one or more substituents -C(O)C 2-4 Alkyl, -C(O)CH3 substituted by halogen, C substituted by Cl or -NH2 1-4 Alkyl, or -C (O) -3-8 membered cycloalkyl substituents; said C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with one or more R b replace;

[0133] Among them, the Y in 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3CR 3 , when Y 3 When N, Y 1 CR 3 ;

[0134] R 3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl;

[0135] R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups;

[0136] R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups.

[0137] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof described in the present disclosure satisfies the following conditions simultaneously:

[0138] 1) When R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen;

[0139] 2) When the structure for When R a’ Not hydrogen;

[0140] 3) When the structure for When ring A is not C 6-10 aryl;

[0141] 4) When R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0142] a) Ring A is a 5-membered heteroaryl group, and R a’ Not selected from cyclopropyl, OCH3 and NHCH3;

[0143] b) Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused with the heterocyclic group;

[0144] c)R 1 is a 4-12 membered heterocyclic group, and R b Any one or more substituents selected from the following groups: =O, -C(O)C optionally substituted by halogen 2-4 alkyl, -C(O)CH3 substituted by one or more F, or -C(O)CH3 substituted by Cl or -NH2 1-4 alkyl;

[0145] Among them, the Y in 1 、Y 2 and Y 3 are each independently selected from N or CH.

[0146] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof described in the present disclosure satisfies the following conditions simultaneously:

[0147] 1) When R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen;

[0148] 2) When the structure for When R a’ Not hydrogen;

[0149] 3) When the structure for When ring A is not C 6-10 aryl;

[0150] 4) When R 1 When there is no phosphorus atom, R 2 The following substituents are not optionally substituted: Among them, Y 1 、Y 2 and Y 3 are each independently selected from N or CH.

[0151] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof described in the present disclosure satisfies the following conditions simultaneously:

[0152] 1) When R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen;

[0153] 2) When the structure for When R a’ Not hydrogen;

[0154] 3) When the structure for When ring A is not C 6-10 aryl;

[0155] 4) When R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0156] a) Ring A is pyrazolyl, and R a’ Not selected from cyclopropyl, OCH3 and NHCH3;

[0157] b) Ring A is a phenyl group, and the phenyl group is fused with a 4-10 membered heterocyclic group;

[0158] c)R 1 is a 5-9 membered heterocyclic group, and R b Any one or more substituents selected from the following groups: =O, -C(O)C optionally substituted by halogen 2-3 alkyl, -C(O)CH3 substituted by one or more F, or -C(O)CH3 substituted by Cl or -NH2 1-3 alkyl;

[0159] Among them, the Y in 1 、Y 2 and Y 3 are each independently selected from N or CH.

[0160] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof described in the present disclosure satisfies the following conditions simultaneously:

[0161] 1) When R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen;

[0162] 2) When the structure for When R a’ Not hydrogen;

[0163] 3) When the structure for When ring A is not C 6-10 aryl;

[0164] 4) R 2 The following substituents are not optionally substituted: Among them, Y 1 、Y 2 and Y 3 are each independently selected from N or CH.

[0165] In some embodiments, when R 2When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen.

[0166] In some embodiments, when the moiety for When R a’ is not hydrogen, where X 1 、X 2 , and X 3 The definition of is as described in this disclosure.

[0167] In some embodiments, when the moiety for When ring A is not C 6-10 Aryl, wherein X 1 、X 2 , and X 3 The definition of is as described in this disclosure.

[0168] In some embodiments, when R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0169] a) Ring A is a 5-membered heteroaryl group, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3;

[0170] b) Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused with the heterocyclic group;

[0171] c) There is at least one R 1 C 1-6 Alkyl, 4-14 membered cycloalkyl, 3-14 membered heterocyclic group, C 2-12 Alkenyl or C 2-12 Alkynyl, and the C 1-6 The alkyl group is substituted with one or more substituents selected from optionally substituted 3-14 membered cycloalkyl, the 4-14 membered cycloalkyl group being substituted with one or more halogen or - selected from -N(C 1-6 alkyl) 2, the 3-14 membered heterocyclic group is substituted by at least one or more selected from =O, optionally substituted by one or more substituents -C(O)C 2-4 Alkyl, -C(O)CH3 substituted by halogen, C substituted by Cl or -NH2 1-4 Alkyl, or -C (O) -3-8 membered cycloalkyl substituents; said C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with one or more R b replace;

[0172] Among them, the Y in 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N is

[0173] Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ;

[0174] R 3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl.

[0175] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof described in the present disclosure satisfies the following conditions simultaneously:

[0176] 1) When R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen;

[0177] 2) When the structure for When R a’ Not hydrogen;

[0178] 3) When the structure for When ring A is not C 6-10 aryl;

[0179] 4) When R 1 Does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions:

[0180] a) Ring A is a 5-membered heteroaryl group, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3;

[0181] b) Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused with the heterocyclic group;

[0182] c) There is at least one R 1 C1-6 Alkyl, 4-14 membered cycloalkyl, 3-14 membered heterocyclic group, C 2-12 Alkenyl or C 2-12 Alkynyl, and the C 1-6 The alkyl group is substituted with one or more substituents selected from optionally substituted 3-14 membered cycloalkyl, the 4-14 membered cycloalkyl group being substituted with one or more halogen or - selected from -N(C 1-6 alkyl) 2, the 3-14 membered heterocyclic group is substituted by at least one or more selected from =O, optionally substituted by one or more substituents -C(O)C 2-4 Alkyl, -C(O)CH3 substituted by halogen, C substituted by Cl or -NH2 1-4 Alkyl, or -C (O) -3-8 membered cycloalkyl substituents; said C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with one or more R b replace;

[0183] Among them, the Y in 1 、Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N is

[0184] Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ;

[0185] R 3 independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl.

[0186] In some embodiments, X 1 and X 3 Select N, and X 2 Selected from CR a’ .

[0187] In some embodiments, X 1 and X 2 Select N, and X 3 Selected from CR a’ .

[0188] In some embodiments, X 2 and X 3 Select N, and X 1 Selected from CR a’ .

[0189] In some embodiments, X 1 and X 3 Each independently selected from CR a’ , and X 2 Selected from N.

[0190] In some embodiments, X 2 and X 3 Each independently selected from CR a’ , and X 1 Selected from N.

[0191] In some embodiments, X 1 and X 2 Each independently selected from CR a’ , and X 3 Selected from N.

[0192] In some embodiments, X 1 、X 2 and X 3 Each independently selected from CR a’ .

[0193] In some embodiments, Y is selected from a bond, -S-, -NR a -、-S(O)2NR a -、-S(O)-、-S(O)NR a -, -C(O)-, -C(O)O-, -C(O)NR a -、-C(O)N(R a )O-、-OC(O)-、-OC(O)NR a -、-N(R a )C(O)O-、-N(R a )C(O)-or-N(R a )S(O)2-.

[0194] In some embodiments, Y is selected from a bond, -S-, or -NR a -.

[0195] In some embodiments, Y is selected from -NR a In some embodiments, Y is selected from -NH-.

[0196] In some embodiments, Ring A is selected from 5-10 membered partially unsaturated heterocyclyl, C 6-10aryl or 5-14 membered heteroaryl.

[0197] In some embodiments, Ring A is selected from 5-10 membered partially unsaturated heterocyclyl, C 6-10 Aryl or 5-14 membered heteroaryl, and the ring heteroatoms of the 5-10 membered partially unsaturated heterocyclic group and the 5-14 membered heteroaryl have and only have N, O or S; or, the ring heteroatoms have and only have N and O; or, the ring heteroatoms have and only have N; or, the ring heteroatoms have and only have S.

[0198] In some embodiments, ring A is selected from a 5-8 membered partially unsaturated heterocyclyl, a phenyl, a naphthyl, or a 5-6 membered heteroaryl, wherein the phenyl is optionally fused to a 4-10 membered (e.g., a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, or 10-membered) heterocyclyl, and the naphthyl is optionally fused to a 4-6 membered (e.g., a 5-membered or 6-membered) heterocyclyl.

[0199] In some embodiments, ring A is selected from a 5-8 membered partially unsaturated heterocyclyl, a phenyl, a naphthyl, or a 5-6 membered heteroaryl, wherein the phenyl is optionally fused with a 4-10 membered (e.g., a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, or 10-membered) heterocyclyl to form 2 or 3 rings, and the naphthyl is optionally fused with a 4-6 membered (e.g., a 5-membered or 6-membered) heterocyclyl to form 3 rings.

[0200] In some embodiments, ring A is selected from a 5-8 membered partially unsaturated heterocyclyl, phenyl, naphthyl, or a 5-6 membered heteroaryl, wherein the ring heteroatoms of the 5-8 membered partially unsaturated heterocyclyl or the 5-6 membered heteroaryl are N, O, or S; or, the ring heteroatoms are N and O; or, the ring heteroatoms are N; or, the ring heteroatoms are S.

[0201] In some embodiments, Ring A is selected from a 5-6 membered partially unsaturated heterocyclyl, a phenyl group, or a 5-6 membered heteroaryl group, wherein the phenyl group is optionally fused to a 4-10 membered (e.g., a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, or 10-membered) heterocyclyl group.

[0202] In some embodiments, ring A is selected from phenyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrazolyl, pyridinyl, pyrazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiazolyl, imidazolyl, oxazolyl, The ring A is optionally substituted with one or more R 1 replace.

[0203] In some embodiments, ring A is selected from phenyl, pyridinyl, thiazolyl, pyrazolyl, dihydropyridinyl, The ring A is optionally substituted with one or more R 1 replace.

[0204] In some embodiments, Ring A is selected from , the ring A is optionally replaced by one or more R 1 replace.

[0205] In some embodiments, Ring A is selected from The ring A is optionally substituted with one or more R 1 replace.

[0206] In some embodiments, Ring A is selected from C 6-10 aryl or 5-10 membered heteroaryl.

[0207] In some embodiments, Ring A is selected from C 6-10 Aryl or 5-10 membered heteroaryl, and the ring heteroatoms of the 5-10 membered heteroaryl include and only N, O or S; or, the ring heteroatoms include and only N.

[0208] In some embodiments, Ring A is selected from C 6-8 aryl or 5-8 membered heteroaryl.

[0209] In some embodiments, Ring A is selected from C 6-8 Aryl or 5-8 membered heteroaryl, and the ring heteroatoms in the 5-8 membered heteroaryl include and only N, O or S; or, the ring heteroatoms include and only N.

[0210] In some embodiments, Ring A is selected from phenyl or 5-6 membered heteroaryl.

[0211] In some embodiments, ring A is selected from phenyl or 5-6 membered heteroaryl, wherein the phenyl is optionally fused with a 4-10 membered (eg, 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, or 10-membered) heterocyclic group to form 2 or 3 rings.

[0212] In some embodiments, Ring A is selected from C 6-8 Aryl or 5-6 membered heteroaryl, and the ring heteroatoms in the 5-6 membered heteroaryl include and only N, O or S; or, the ring heteroatoms include and only N.

[0213] In some embodiments, Ring A is phenyl or a 5-6 membered heteroaryl group containing 1 or 2 heteroatoms selected from N, O, or S.

[0214] In some embodiments, ring A is phenyl or a 5-6 membered heteroaryl group containing 1 or 2 heteroatoms selected from N, O or S, and the ring heteroatoms are and only N, O or S.

[0215] In some embodiments, Ring A is phenyl or a 5-6 membered heteroaryl containing 1 or 2 N atoms.

[0216] In some embodiments, ring A is phenyl or a 5-6 membered heteroaryl group containing 1 or 2 N atoms, and the ring heteroatom is only N.

[0217] In some embodiments, ring A is phenyl or a 5-6 membered heteroaryl group containing 2 N atoms, and the ring heteroatom is only N.

[0218] In some embodiments, Ring A is phenyl, pyridyl, pyrazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiazolyl, imidazolyl, or oxazolyl.

[0219] In some embodiments, Ring A is phenyl, pyridyl, pyrazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl.

[0220] In some embodiments, Ring A is phenyl, pyridyl, pyrazolyl, or thiazolyl.

[0221] In some embodiments, Ring A is phenyl or pyridinyl. In some embodiments, Ring A is thiazolyl. In some embodiments, Ring A is pyrazolyl. In some embodiments, Ring A is phenyl.

[0222] In some embodiments, the ring directly attached to the parent structure of Ring A is aromatic.

[0223] In some embodiments, when Ring A is selected from an aryl group, the ring directly attached to the parent structure is a benzene ring; when Ring A is selected from a heteroaryl group, the ring directly attached to the parent structure is a heteroaryl ring.

[0224] In some embodiments, R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d 、-NH2、-NHR d 、-N(R d )2, -OH, -SH, -OR d 、Halogen、-COR d 、-COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d )2, -SO2R d 、-PO(R d )2. C 1-10 Alkyl, C 2-10 Alkenyl, C2-10 Alkynyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocyclyl, or two R 1 Connected to form a 3-10 membered heterocyclic group or C 4-10 Cycloalkenyl, wherein the C 1-10 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocyclyl, C 4-10 Cycloalkenyl, C 2-10 Alkenyl or C 2-10 Alkynyl is optionally substituted with one or more R b replace.

[0225] In some embodiments, R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d 、-NH2、-NHR d 、-N(R d )2, -OH, -SH, -OR d , halogen, -COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d )2, -SO2R d 、-PO(R d )2. C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocyclyl, or two R 1 Connected to form a 3-10 membered heterocyclic group or C 4-10 Cycloalkenyl, wherein the C 1-10 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocyclyl or C 4-10 The cycloalkenyl group is optionally substituted with one or more R b replace.

[0226] In some embodiments, R1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d , halogen, -NH2, -NHR d 、-N(R d )2、-OH、-OR d 、-COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d )2, -SO2R d 、-PO(R d )2. C 1-6 Alkyl, C 5-6 Aryl, 5-10 membered heteroaryl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocycloalkyl, 5-10 membered heterocycloalkenyl, or two adjacent R 1 Connected to form a 5-10 membered heterocyclic group or C 5-10 Cycloalkenyl, wherein the C 1-6 Alkyl, C 5-6 aryl, 5-10 membered heteroaryl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocycloalkyl, 5-10 membered heterocycloalkenyl, 5-10 membered heterocyclyl or C 5-10 The cycloalkenyl group is optionally substituted with one or more R b Substituted, the R d Each independently selected from C 1-2 Alkyl or C 3-4 Cycloalkyl.

[0227] In some embodiments, R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d , halogen, -NH2, -NHR d 、-N(R d )2、-OH、-OR d 、-COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d)、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d )2, -SO2R d 、-PO(R d )2. C 1-4 Alkyl, C 5-6 aryl, 5-8 membered heteroaryl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-8 membered heterocycloalkyl or 5-8 membered heterocycloalkenyl, wherein the C 1-4 Alkyl, C 5-6 Aryl, 5-8 membered heteroaryl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-8 membered heterocycloalkyl, or 5-8 membered heterocycloalkenyl is optionally substituted with one or more R b Substituted, the R d Each independently selected from C 1-4 Alkyl or C 3-4 In some embodiments, R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d , halogen, -NH2, -NHR d 、-N(R d )2、-OH、-OR d 、-COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d )2, -SO2R d 、-PO(R d )2. C 1-4 Alkyl, C 5-6 aryl, 5-8 membered heteroaryl, 5-8 membered cycloalkyl, 5-8 membered cycloalkenyl, 5-8 membered heterocycloalkyl or 5-8 membered heterocycloalkenyl, wherein the C 1-4 Alkyl, C 5-6 Aryl, 5-8 membered heteroaryl, 5-8 membered cycloalkyl, 5-8 membered cycloalkenyl, 5-8 membered heterocycloalkyl or 5-8 membered heterocycloalkenyl are optionally substituted by one or more R b Substituted, the R d Each independently selected from C 1-2 Alkyl or C 3-4 Cycloalkyl.

[0228] In some embodiments, R 1 Each independently selected from -PO(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 4-8 membered cycloalkyl, or 4-8 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 4-8 membered cycloalkyl, or 4-8 membered heterocycloalkyl is optionally substituted by one or more R b replace.

[0229] In some embodiments, the R 1 The heteroatom in the heterocyclyl, heterocycloalkyl or heterocycloalkenyl is selected from N, O, S or P; or, is selected from N, O, S; or N, O, P.

[0230] In some embodiments, the R 1 The two R's 1 "Interconnected" means "two adjacent R 1 Connected to each other".

[0231] In some embodiments, the R 1 The heterocyclyl in is a heterocyclyl containing 1, 2 or 3 P atoms; alternatively, the heterocycloalkyl is a heterocycloalkyl containing 1, 2 or 3 P atoms; alternatively, the heterocycloalkenyl is a heterocycloalkenyl containing 1, 2 or 3 P atoms.

[0232] In some embodiments, R 1 Each is independently selected from -CN, -CON(CH3)2, oxo, -OSO2CH3, halogen, -NH2, -NHCH3, -N(CH3)2, -OH, C 1-4 Alkyl, -OC 1-4 Alkyl, -C(O)-C 1-4 Alkyl, -C(O)-4-10 membered heterocycloalkyl, -COOCH3, -OCOCH3, -CONH(CH3), -NHSO2(CH3), -NS(O)(CH3)2, -SO2NH(CH3), -SO2N(CH3)2, -SO2CH3, -PO(C 1-4 Alkyl)2, -N(C 1-3 alkyl)C(O)C 1-3 alkyl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-10 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, wherein the C1-4 Alkyl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-10 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, C 2-6 Alkynyl or C 2-6 The alkenyl group is optionally substituted with one or more R b replace.

[0233] In some embodiments, R 1 Each is independently selected from -CN, -CON(CH3)2, oxo, -OSO2CH3, halogen, -NH2, -NHCH3, -N(CH3)2, -OH, C 1-4 Alkyl, -OC 1-4 Alkyl, -COOCH3, -OCOCH3, -CONH(CH3), -NHSO2(CH3), -NS(O)(CH3)2, -SO2NH(CH3), -SO2N(CH3)2, -SO2CH3, -PO(C 1-4 Alkyl)2, -N(C 1-3 alkyl)C(O)C 1-3 alkyl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-10 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, wherein the C 1-4 Alkyl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-10 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, C 2-6 Alkynyl or C 2-6 The alkenyl group is optionally substituted with one or more R b replace.

[0234] In some embodiments, R 1 Each independently selected from -CN, -CON(CH3)2, oxo, -OSO2CH3, halogen, -NH2, -NHCH3, -N(CH3)2, -OH, C 1-4 Alkyl, -OC 1-4 Alkyl, -COOCH3, -OCOCH3, -CONH(CH3), -NHSO2(CH3), -NS(O)(CH3)2, -SO2NH(CH3), -SO2N(CH3)2, -SO2CH3, -PO(C 1-4 Alkyl)2, -N(C 1-3 alkyl)C(O)C 1-3 alkyl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-8 membered heterocycloalkyl or 5-8 membered heterocycloalkenyl, wherein the C 1-4Alkyl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-8 membered heterocycloalkyl or 5-8 membered heterocycloalkenyl are optionally substituted with one or more R b replace.

[0235] In some embodiments, R 1 Each is independently selected from -CN, -CON(CH3)2, oxo, -OSO2CH3, halogen, -NH2, -NHCH3, -N(CH3)2, -OH, C 1-4 Alkyl, -OC 1-4 Alkyl, -COOCH3, -OCOCH3, -N(CH3)C(O)(CH3), -CONH(CH3), -NHSO2(CH3), -NS(O)(CH3)2, -SO2NH(CH3), -SO2N(CH3)2, -SO2CH3, -PO(C 1-4 Alkyl)2, 5-8 membered cycloalkyl, 5-8 membered cycloalkenyl, 5-8 membered heterocycloalkyl or 5-6 membered heterocycloalkenyl, wherein the C 1-4 Alkyl, 5-8 membered heterocyclyl, 5-8 membered cycloalkyl, 5-8 membered cycloalkenyl or 5-6 membered heterocycloalkenyl are optionally substituted with one or more R b replace.

[0236] In some embodiments, R 1 Each is independently selected from -CN, -CON(CH3)2, oxo, -OSO2CH3, halogen, -NH2, -NHCH3, -N(CH3)2, -OH, C 1-4 Alkyl, -OC 1-4 Alkyl, -COOCH3, -OCOCH3, -N(CH3)C(O)(CH3), -CONH(CH3), -NHSO2(CH3), -NS(O)(CH3)2, -SO2NH(CH3), -SO2N(CH3)2, -SO2CH3, -PO(C 1-4 Alkyl)2, 5-8 membered cycloalkyl, 5-8 membered cycloalkenyl, 5-8 membered heterocycloalkyl, 5-6 membered heterocycloalkenyl, or two adjacent R 1 Connected to form a 5-8 membered heterocyclic group or C 5-8 Cycloalkenyl, wherein the C 1-4 Alkyl, 5-8 membered heterocyclyl, 5-8 membered cycloalkyl, 5-8 membered cycloalkenyl or 5-6 membered heterocycloalkenyl are optionally substituted with one or more R b replace.

[0237] In some embodiments, R 1 are independently selected from halogen, oxo, -N(C 1-2 alkyl)C(O)C1-2 Alkyl, C 1-4 Alkyl, -OC 1-4 Alkyl, -C(O)-C 1-4 Alkyl, -C(O)-4-10 membered heterocycloalkyl, -PO(C 1-4 alkyl) 2, 4-10 membered heterocycloalkyl, 5-8 membered heterocycloalkenyl or C 2-4 Alkynyl, wherein the C 1-4 Alkyl, 4-10 membered heterocycloalkyl, 5-8 membered heterocycloalkenyl or C 2-4 Alkynyl is optionally substituted by 1, 2 or 3 R b replace.

[0238] In some embodiments, R 1 are independently selected from halogen, oxo, -N(C 1-2 alkyl)C(O)C 1-2 Alkyl, C 1-4 Alkyl, -OC 1-4 Alkyl, -PO(C 1-4 alkyl) 2, 4-10 membered heterocycloalkyl, 5-8 membered heterocycloalkenyl or C 2-4 Alkynyl, wherein the C 1-4 Alkyl, 4-10 membered heterocycloalkyl, 5-8 membered heterocycloalkenyl or C 2-4 Alkynyl is optionally substituted by 1, 2 or 3 R b replace.

[0239] In some embodiments, R 1 are independently selected from halogen, oxo, -N(C 1-2 alkyl)C(O)C 1-2 Alkyl, C 1-4 Alkyl, -OC 1-4 Alkyl, -PO(C 1-4 alkyl) 2, 4-8 membered heterocycloalkyl, wherein the C 1-4 The alkyl or 4-8 membered heterocycloalkyl group is optionally substituted by 1, 2 or 3 R b replace.

[0240] In some embodiments, R 1 are each independently selected from halogen, C 1-4 Alkyl, -OC 1-4 Alkyl, -PO(C 1-4 alkyl) 2, 5-7 membered heterocycloalkyl, wherein the C 1-4 Alkyl, or 5-7 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R b replace.

[0241] In some embodiments, R 1Each is independently selected from F, Cl, Br, oxo, -N(CH3)COCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -OC 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-morpholinyl, -PO(C 1-3 alkyl) 2, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, tetrahydrothiophenyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, azaoxanyl, azaspirocycloheptyl, diazaspirocyclooctanyl, azetidinyl, diazaspirocycloheptyl, oxetanyl, azacyclopentanyl, azacyclohexenyl, diazaspirocyclononanyl, cyclopropanyl, cyclobutanyl, cyclopentanyl, diazabicyclooctanyl or ethynyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, tetrahydrothiophenyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, azaoxanyl, azaspirocycloheptyl, diazaspirocyclooctanyl, azetidinyl, diazaspirocycloheptyl, oxetanyl, azacyclopentanyl, azacyclohexenyl, diazaspirocyclononanyl, cyclopropyl, cyclobutyl, cyclopentanyl, diazabicyclooctanyl or ethynyl is optionally substituted by 1, 2 or 3 R b replace.

[0242] In some embodiments, R 1 Each is independently selected from F, Cl, Br, oxo, -N(CH3)COCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -OC 1-3 Alkyl, -PO(C 1-3 alkyl) 2, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, tetrahydrothiophenyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, azaoxanyl, azaspirocycloheptyl, diazaspirocyclooctanyl, azetidinyl, diazaspirocycloheptyl, oxetanyl, azacyclopentanyl, azacyclohexenyl, diazaspirocyclononanyl, cyclopropanyl, cyclobutanyl, diazabicyclooctanyl or ethynyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-Butyl, isobutyl, tert-butyl, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, tetrahydrothiophenyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, azaoxanyl, azaspirocycloheptyl, diazaspirocyclooctanyl, azetidinyl, diazaspirocycloheptyl, oxetanyl, azacyclopentanyl, azacyclohexenyl, diazaspirocyclononanyl, cyclopropanyl, cyclobutanyl, diazabicyclooctanyl or ethynyl is optionally substituted by 1, 2 or 3 R breplace.

[0243] In some embodiments, R 1 Each is independently selected from F, Cl, Br, oxo, -N(CH3)COCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -OC 1-3 Alkyl, -PO(C 1-3 R 2, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, tetrahydrothiophenyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, azaoxanyl, azaspiroheptane, diazaspirooctanyl, azetidinyl, diazaspiroheptane or oxetanyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, tetrahydrothiophenyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, azaoxanyl, azaspiroheptane, diazaspirooctanyl, azetidinyl, diazaspiroheptane or oxetanyl is optionally replaced by 1, 2 or 3 R b replace.

[0244] In some embodiments, R 1 Each independently selected from F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -OC 1-3 Alkyl, -PO(C 1-3 R alkyl) 2, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazene, piperidinyl, tetrahydrothienyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, nitrile, nitrile or nitrile spirocycloheptanyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazene, piperidinyl, tetrahydrothienyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, nitrile, nitrile or spirocycloheptanyl is optionally replaced by 1, 2 or 3 R b replace.

[0245] In some embodiments, R 1Each is independently selected from F, methyl, ethyl, n-propyl, -OCH3, -PO(CH3)2, oxo, -PO(CH2CH3)2, -N(CH3)COCH3, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazene, piperidinyl, aza-oxaspiro-heptane, diaza-spiro-octanyl, piperazinyl, azetidinyl, diaza-spiro-heptane, oxetanyl, aza-cyclopentane, aza-cyclohexenyl, diaza-spiro-nonane, cyclopropyl wherein the methyl, ethyl, n-propyl, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, azaspirocycloheptane, diazaspirocyclooctanyl, piperazinyl, azetidinyl, diazaspirocycloheptane, oxetanyl, azacyclopentane, azacyclohexenyl, diazaspirocyclononane, cyclopropane, cyclobutane, diazabicyclooctanyl or ethynyl is optionally replaced by 1 or 2 R b replace.

[0246] In some embodiments, R 1 R is each independently selected from F, methyl, ethyl, -OCH3, -PO(CH3)2, oxo, -PO(CH2CH3)2, -N(CH3)COCH3, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazene, piperidinyl, azaspiroheptanyl, diazaspirooctanyl, piperazinyl, azetidinyl, diazaspiroheptanyl or oxetanyl, wherein the methyl, ethyl, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazene, piperidinyl, azaspiroheptanyl, diazaspirooctanyl, piperazinyl, azetidinyl, diazaspiroheptanyl or oxetanyl is optionally replaced by 1 or 2 R b replace.

[0247] In some embodiments, R 1 Each independently selected from F, oxo, -N(CH3)COCH3, methyl, ethyl, -OC 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-morpholinyl, -PO(C 1-3alkyl) 2, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, piperazinyl, tetrahydropyrrolyl, azaoxanyl, azaspirocycloheptyl, diazaspirocyclooctanyl, azetidinyl, diazaspirocycloheptyl, oxetanyl, azacyclopentanyl, azacyclohexenyl, diazaspirocyclononanyl, cyclobutanyl, cyclopentanyl, diazabicyclooctanyl or ethynyl, wherein the ... alkyl, cyclopentyl, cyclopentyl, diazabicyclooctanyl, cyclobutyl, cyclopentyl, diazabicyclooctanyl, or ethynyl is optionally substituted by 1, 2, or 3 R b replace.

[0248] In some embodiments, R 1 Each is independently selected from F, -C(O)-CH2CH3, methyl, ethyl, n-propyl, oxo, -OCH3, -PO(CH3)2, wherein the methyl, ethyl, n-propyl, Optionally 1 or 2 R b replace.

[0249] In some embodiments, R 1 Each independently selected from F, methyl, ethyl, n-propyl, -OCH3, -PO(CH3)2, oxo, wherein the methyl, ethyl, n-propyl, Optionally 1 or 2 R b replace.

[0250] In some embodiments, R 1 Each independently selected from F, methyl, ethyl, oxo, -OCH3, -PO(CH3)2, wherein the methyl, ethyl, Optionally 1 or 2 R b replace.

[0251] In some embodiments, R 1Each is independently selected from F, methyl, ethyl, -OCH3, -PO(CH3)2, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazene heterocyclohexyl or piperidinyl, wherein the methyl, ethyl, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazene heterocyclohexyl or piperidinyl is optionally substituted by 1 or 2 R b replace.

[0252] In some embodiments, R 1 Each independently selected from F, methyl, ethyl, n-propyl, -OCH3, -PO(CH3)2, oxo, wherein the methyl, ethyl, n-propyl, Optionally 1 or 2 R b In some embodiments, R 1 Each independently selected from F, methyl, ethyl, oxo, -OCH3, -PO(CH3)2, wherein the methyl, ethyl, Optionally 1 or 2 R b replace.

[0253] In some embodiments, R 1 Each independently selected from F, methyl, ethyl, -OCH3, -PO(CH3)2, wherein the methyl, ethyl, Optionally 1 or 2 R b replace.

[0254] In some embodiments, R 1 Each independently selected from F, -CH3, -OCH3, -PO(CH3)2, oxo,

[0255] In some embodiments, R 1 Each independently selected from F, -CH3, -OCH3, -PO(CH3)2, oxo,

[0256] In some embodiments, R 1 Each independently selected from F, -CH3, -OCH3, -PO(CH3)2, oxo,

[0257] In some embodiments, R 1 Each independently selected from F, -CH3, -OCH3, -PO(CH3)2,

[0258] In some embodiments, the structural unit Selected from where R 1 and m are as defined in this disclosure.

[0259] In some embodiments, the structural unit Selected from where R 1 and m are as defined in this disclosure.

[0260] In some embodiments, the structural unit Selected from where R 1 and m are as defined in this disclosure.

[0261] In some embodiments, the structural unit Selected from where R 1 and m are as defined in this disclosure.

[0262] In some embodiments, the structural unit Selected from where R 1 and m are as defined in this disclosure.

[0263] In some embodiments, the structural unit Selected from where R 1 The definition of is as described in this disclosure.

[0264] In some embodiments, the structural unit Selected from where R 1 The definition of is as described in this disclosure.

[0265] In some embodiments, the structural unit Selected from where R 1 The definition of is as described in this disclosure.

[0266] In some embodiments, the structural unit Selected from where R 1 The definition of is as described in this disclosure.

[0267] In some embodiments, the structural unit Selected from where R 1 The definition of is as described in this disclosure.

[0268] In some embodiments, the structural unit Selected from where R 1 The definition of is as described in this disclosure.

[0269] In some embodiments, the structural unit Selected from where R 1 The definition of is as described in this disclosure.

[0270] In some embodiments, the moiety Selected from

[0271] In some embodiments, the moiety Selected from

[0272] In some embodiments, the moiety Selected from

[0273] In some embodiments, the moiety Selected from

[0274] In some embodiments, the structural unit Selected from

[0275] In some embodiments, the structural unit Selected from where X 1 、X 2 、X 3 、R 2 and R a ' is as defined in this disclosure.

[0276] In some embodiments, R 2 is selected from a 5-6 membered monocyclic heteroaryl containing 1 or 2 N atoms, a 5-6 membered monocyclic heterocycloalkenyl containing 1 or 2 N atoms, an 8-10 membered partially saturated or aromatic bicyclic group, a 9-14 membered partially saturated or aromatic tricyclic group, wherein the bicyclic group contains 1-4 heteroatoms independently selected from N, O or S, the tricyclic group contains 1-6 heteroatoms independently selected from N, O or S, and the R 2 Optionally, one or more R c replace.

[0277] In some embodiments, R 2 is selected from a 5-6 membered monocyclic heteroaryl containing 1 N atom, a 5-6 membered monocyclic heterocycloalkenyl containing 1 N atom, a 9-10 membered partially saturated or aromatic bicyclic group, a 10-12 membered partially saturated or aromatic tricyclic group, wherein the bicyclic group contains 1-3 heteroatoms independently selected from N, O or S, the tricyclic group contains 1-4 heteroatoms independently selected from N, O or S, and the R 2 Optionally, one or more R c replace.

[0278] In some embodiments, R 2 is selected from a 6-membered monocyclic heteroaryl containing 1 N atom, a 6-membered monocyclic heterocycloalkenyl containing 1 N atom, a 9- or 10-membered partially saturated or aromatic bicyclic group, a 10- or 12-membered partially saturated or aromatic tricyclic group, wherein the bicyclic group contains 1-3 heteroatoms independently selected from N, O or S, the tricyclic group contains 2-3 heteroatoms independently selected from N or O, and the R 2 Optionally, one or more R c replace.

[0279] In some embodiments, R 2is selected from a 6-membered monocyclic heteroaryl containing 1 N atom, a 6-membered monocyclic heterocycloalkenyl containing 1 N atom, a 9-membered partially saturated or aromatic bicyclic group, a 10- or 12-membered partially saturated or aromatic tricyclic group, wherein the bicyclic group contains 1-3 heteroatoms independently selected from N, O or S, the tricyclic group contains 2-3 heteroatoms independently selected from N or O, and the R 2 Optionally, one or more R c replace.

[0280] In some embodiments, R 2 Selected from wherein R 2 Optionally, one or more R c replace.

[0281] In some embodiments, R 2 Selected from wherein R 2 Optionally, one or more R c replace.

[0282] In some embodiments, R 2 Selected from wherein R 2 Optionally, one or more R c replace.

[0283] In some embodiments, R 2 Selected from wherein R 2 Optionally, one or more R c replace.

[0284] In some embodiments, R 2 Selected from

[0285] In some embodiments, R 2 Selected from

[0286] In some embodiments, each R a’ Each is independently selected from hydrogen, halogen, -CN, -NH2, -OH, -NO2 or the following groups optionally substituted by one or more substituents: -OC 1-6Alkyl, C 1-6 Alkyl, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, -NH-3-8 membered cycloalkyl, -SO2C 1-6 Alkyl, -OSO2C 1-6 Alkyl, -OC 1-6 Alkyl-SO2C 1-6 Alkyl, -(C 1-6 alkyl)sulfonimide, -OSO2C 1-6 Alkyl, -C(C 1-6 Alkyl)2SO2C 1-6 Alkyl, -SO2NHC 1-6 Alkyl, -SO2N(C 1-6 Alkyl)2, -OC 1-6 Alkyl-N(C 1-6 Alkyl)2, -C 1-6 Alkyl (3-14 membered heterocycloalkyl), -C(O)(C 1-6 alkyl), -C(O)NH(C 1-6 alkyl), -CH2C(O)NH(C 1-6 alkyl), -C(O)(3-8 membered heterocycloalkyl), -NH-3-8 membered heterocycloalkyl, -C(O)(3-8 membered cycloalkyl), -C(O)NH(3-8 membered cycloalkyl) or -C(O)NH(3-8 membered heterocycloalkyl).

[0287] In some embodiments, each R a’ Each independently selected from hydrogen, halogen, -CN, or the following groups optionally substituted by one or more substituents: -NH2, -OH, -OC 1-6 Alkyl, C 1-6 Alkyl, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, -NH-3-8 membered cycloalkyl, -SO2C 1-6 Alkyl, -OSO2C 1-6 Alkyl, -OC 1-6 Alkyl-SO2C 1-6 Alkyl, (C 1-6 alkyl)sulfonimide, -OSO2C 1-6 Alkyl, -C(C 1-6 Alkyl)2SO2C 1-6 Alkyl, -SO2NHC 1-6 Alkyl, -SO2N(C 1-6 Alkyl)2, -OC 1-6 Alkyl-N(C 1-6Alkyl)2, -C 1-6 Alkyl (3-14 membered heterocycloalkyl), -C(O)(C 1-6 alkyl), -C(O)NH(C 1-6 alkyl), -CH2C(O)NH(C 1-6 alkyl) or -C(O)(3-8 membered heterocycloalkyl).

[0288] In some embodiments, each R a’ are each independently selected from hydrogen, halogen, -CN, -NH2, -OH or optionally substituted by one or more R a’a’ Substituted with the following groups: -OC 1-6 Alkyl, C 1-6 Alkyl, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, -NH-3-8 membered cycloalkyl or -NH-3-8 membered heterocycloalkyl; and each R a’a’ are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0289] In some embodiments, each R a’ are each independently selected from hydrogen, halogen, -CN, or optionally substituted by one or more R a’a’ Substituted with the following groups: -NH2, -OH, -OC 1-6 Alkyl, C 1-6 Alkyl, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl or -NH-3-8 membered cycloalkyl; and each R a’a’ are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0290] In some embodiments, each Ra’ Each independently selected from hydrogen, halogen, -NH2, -OH, -OC 1-4 Alkyl, -CN, C 1-4 Alkyl, -NH(C 1-4 Alkyl), -N(C 1-4 alkyl) 2, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, -NH-3-8 membered cycloalkyl or -NH-3-8 membered heterocycloalkyl, the -OC 1-4 Alkyl, C 1-4 Alkyl, -NH(C 1-4 Alkyl), -N(C 1-4 alkyl) 2, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, -NH-3-8 membered cycloalkyl or -NH-3-8 membered heterocycloalkyl are optionally substituted with one or more halogens.

[0291] In some embodiments, each R a’ Each independently selected from hydrogen, halogen, -NH2, -OH, -OC 1-4 Alkyl, -CN, C 1-4 Alkyl, -NH(C 1-4 Alkyl), -N(C 1-4 alkyl) 2, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl or -NH-3-8 membered cycloalkyl, the C 1-4 The alkyl, cycloalkyl or heterocycloalkyl group is optionally substituted with one or more halogens.

[0292] In some embodiments, each R a’ are each independently selected from H, halogen, -OC 1-4 Alkyl, C 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 alkyl) 2, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, -NH-3-6 membered cycloalkyl or -NH-3-6 membered heterocycloalkyl, the -OC 1-4 Alkyl, C 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 alkyl) 2, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, -NH-3-6 membered cycloalkyl or -NH-3-6 membered heterocycloalkyl are optionally substituted with one or more halogens.

[0293] In some embodiments, each R a’ are each independently selected from H, halogen, -OC 1-4 Alkyl, C 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4alkyl) 2, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl or -NH-3-6 membered cycloalkyl, the C 1-4 The alkyl, cycloalkyl or heterocycloalkyl group is optionally substituted with one or more halogens.

[0294] In some embodiments, each R a’ Each independently selected from H, F, Cl, C 1-3 Alkyl, -NHC 1-3 Alkyl, 3-5 membered cycloalkyl, -NH-3-5 membered cycloalkyl, 3-5 membered heterocycloalkyl or -NH-3-5 membered heterocycloalkyl, the C 1-3 Alkyl, -NHC 1-3 The alkyl, 3-5 membered cycloalkyl, -NH-3-5 membered cycloalkyl, 3-5 membered heterocycloalkyl or -NH-3-5 membered heterocycloalkyl is optionally substituted with one or more halogens.

[0295] In some embodiments, each R a’ Each independently selected from H, F, Cl, -NHC 1-3 Alkyl, 3-5 membered cycloalkyl, -NH-3-5 membered cycloalkyl, 3-5 membered heterocycloalkyl or -NH-3-5 membered heterocycloalkyl, the -NHC 1-3 The alkyl, 3-5 membered cycloalkyl, -NH-3-5 membered cycloalkyl, 3-5 membered heterocycloalkyl or -NH-3-5 membered heterocycloalkyl is optionally substituted with one or more halogens.

[0296] In some embodiments, each R a’ Each independently selected from H, F, Cl, C 1-3 Alkyl, -NHC 1-3 Alkyl, 3-5 membered cycloalkyl or -NH-3-5 membered cycloalkyl, the C 1-3 Alkyl, -NHC 1-3 The alkyl, 3-5 membered cycloalkyl or -NH-3-5 membered cycloalkyl is optionally substituted with one or more halogens.

[0297] In some embodiments, each R a’ Each independently selected from H, F, Cl, -NHC 1-3 Alkyl, 3-5 membered cycloalkyl or -NH-3-5 membered cycloalkyl, the -NHC 1-3 The alkyl, 3-5 membered cycloalkyl or -NH-3-5 membered cycloalkyl is optionally substituted with one or more halogens.

[0298] In some embodiments, each R a’ Each independently selected from H, F, ethyl, -NHC 1-3 Alkyl, 3-5 membered cycloalkyl, 3-5 membered heterocycloalkyl or -NH-3-5 membered cycloalkyl, the ethyl or -NHC1-3 The alkyl group is optionally substituted with 1, 2 or 3 F groups.

[0299] In some embodiments, each R a’ Each independently selected from H, F, -NHC 1-3 Alkyl, 3-5 membered cycloalkyl, 3-5 membered heterocycloalkyl or NH-3-5 membered cycloalkyl, the -NHC 1-3 The alkyl group is optionally substituted with 1, 2 or 3 F groups.

[0300] In some embodiments, each R a’ Each independently selected from H, F, -NHC 1-3 Alkyl or 3-5 membered cycloalkyl.

[0301] In some embodiments, each R a’ Each independently selected from H, F, -NHCH3, cyclopropyl, -NHCH2CF3,

[0302] In some embodiments, each R a’ Each independently selected from H, F, -NHCH3, cyclopropyl, -NHCH2CF3,

[0303] In some embodiments, each R a’ Each is independently selected from H, F, -NHCH3, or cyclopropyl.

[0304] In some embodiments, each R a are each independently selected from hydrogen, or the following groups optionally substituted by one or more substituents: C 1-12 Alkyl or C 3-8 Cycloalkyl.

[0305] In some embodiments, each R a are each independently selected from hydrogen, or optionally replaced by one or more R aa Substituted C 1-6 alkyl, and each R aa Each independently selected from deuterium, halogen, -OH, -NH2, -CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 5-8 Cycloalkyl, C 5-6 aryl, 5-6 membered heteroaryl or 3-8 membered heterocyclic group.

[0306] In some embodiments, each R a Each independently selected from hydrogen or C1-4 alkyl.

[0307] In some embodiments, each R a In some embodiments, R a Selected from hydrogen.

[0308] In some embodiments, each R b Each independently selected from deuterium, halogen, -OH, -NH2, -CN, or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, -SC 1-12 Alkyl, C 1-12 Alkyl, -C(O)C 1-12 Alkyl, -NHC(O)(C 1-12 alkyl), -C(O)N(C 1-12 Alkyl)2, -C(O)NH(C 1-12 alkyl), 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl, 3-14 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)-3-14 membered cycloalkyl, -C(O)-3-14 membered heterocycloalkyl, -C(O)-3-14 membered heterocycloalkenyl, -NH-3-14 membered cycloalkyl, -NH-3-14 membered heterocycloalkyl or -NH-3-14 membered heterocycloalkenyl.

[0309] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2 or the following groups optionally substituted by one or more substituents: -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl, C 1-6 Alkyl, -C(O)C 1-6 Alkyl, -C(O)N(C 1-6 Alkyl)2, -C(O)NH(C 1-6 alkyl), -NHC(O)(C 1-6 alkyl), 3-8 membered cycloalkyl, 3-8 membered cycloalkenyl, 3-8 membered heterocyclyl, C6 aryl, 5-6 membered heteroaryl, -C(O)-3-8 membered cycloalkyl, -C(O)-4-8 membered heterocycloalkyl, -C(O)-4-8 membered heterocycloalkenyl, -NH-3-8 membered cycloalkyl, -NH-4-8 membered heterocycloalkyl or -NH-4-8 membered heterocycloalkenyl.

[0310] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2 or the following groups optionally substituted by one or more substituents: -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl, C 1-6 Alkyl, -C(O)C 1-6 Alkyl, -C(O)N(C 1-6 Alkyl)2, -C(O)NH(C 1-6 alkyl), 3-8 membered cycloalkyl, 3-8 membered cycloalkenyl, 3-8 membered heterocycloalkyl, -C(O)-3-8 membered cycloalkyl, -C(O)-4-8 membered heterocycloalkyl or -C(O)-4-8 membered heterocycloalkenyl.

[0311] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2 or the following groups optionally substituted by one or more substituents: -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl, C 1-6 Alkyl, -C(O)C 1-6 Alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl.

[0312] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, Or the following groups optionally substituted by one or more substituents: -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl, C 1-6 alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl.

[0313] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2 or optionally one or more R bb Substituted with the following groups: -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl, C 1-6 Alkyl, -C(O)C 1-6 Alkyl, -C(O)N(C 1-6Alkyl)2, -C(O)NH(C 1-6 alkyl), 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, -C(O)-3-6 membered cycloalkyl or -C(O)-4-6 membered heterocycloalkyl, and each R bb are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, -C(O)C 1-12 Alkyl, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0314] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2 or optionally one or more R bb Substituted with the following groups: -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl, C 1-6 Alkyl or -C(O)C 1-4 alkyl, and each R bb are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0315] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, or optionally one or more R bb Substituted with the following groups: -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl or C 1-6 alkyl, and each R bb are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0316] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl, C 1-4 Alkyl, -C(O)C 1-4 Alkyl, -C(O)N(C 1-4 Alkyl)2, -C(O)NH(C 1-4 alkyl), 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, -C(O)-3-6 membered cycloalkyl or -C(O)-4-6 membered heterocycloalkyl, wherein the -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl, C 1-4 Alkyl, -C(O)C 1-4 Alkyl, -C(O)N(C 1-4 Alkyl)2, -C(O)NH(C 1-4 alkyl), 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, -C(O)-3-6 membered cycloalkyl or -C(O)-4-6 membered heterocycloalkyl, optionally substituted by one or more selected from deuterium, halogen, -OH, -NH2, -CN, -C(O)C 1-4 Alkyl or -N(C 1-4 alkyl)2 is substituted with a substituent.

[0317] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl, C 1-4 Alkyl or -C(O)C 1-4 Alkyl, wherein the -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl, C 1-4 Alkyl or -C(O)C 1-4The alkyl group is optionally substituted with one or more deuterium, halogen, -NH2 or Substituent substitution.

[0318] In some embodiments, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl or C 1-4 Alkyl, wherein the -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OC 1-4 Alkyl and C 1-4 The alkyl group is optionally substituted with one or more deuterium, halogen or Substituent substitution.

[0319] In some embodiments, each R b Each independently selected from deuterium, halogen, -OH, -NH2, -CN, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -OC 1-3 Alkyl, C 1-3 Alkyl, -C(O)C 1-3 Alkyl, -C(O)N(C 1-3 -C(O)-3-5 membered cycloalkyl or -C(O)-4-6 membered heterocycloalkyl, wherein the -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -OC 1-3 Alkyl, C 1-3 Alkyl, -C(O)C 1-3 Alkyl, -C(O)N(C 1-3 -C(O)-3-5 membered cycloalkyl or -C(O)-4-6 membered heterocycloalkyl are optionally substituted with one or more selected from deuterium, halogen, -NH2, -C(O)C 1-3 Alkyl or -N(C 1-3 alkyl)2 is substituted with a substituent.

[0320] In some embodiments, each R b Each independently selected from deuterium, halogen, -OH, -NH2, -CN, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -OC1-3 Alkyl, C 1-3 Alkyl or -C(O)C 1-3 Alkyl, wherein the -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -OC 1-3 Alkyl, C 1-3 Alkyl or -C(O)C 1-3 The alkyl group is optionally substituted with one or more deuterium, halogen, NH2 or Substituent substitution.

[0321] In some embodiments, each R b Each independently selected from deuterium, halogen, -OH, -NH2, -CN, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -OC 1-3 Alkyl or C 1-3 Alkyl, wherein the -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -OC 1-3 Alkyl and C 1-3 The alkyl group is optionally substituted with one or more deuterium, halogen or Substituent substitution.

[0322] In some embodiments, each R b Each independently selected from F, Cl, Br, C 1-3 Alkyl, -N(C 1-3 Alkyl)2, -NHC 1-3 Alkyl, -C(O)C 1-3 Alkyl, -C(O)N(C 1-3 alkyl) 2, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl or -C(O)-3-5 membered cycloalkyl, wherein the C 1-3 Alkyl, -N(C 1-3 Alkyl)2, -NHC 1-3 Alkyl, -C(O)C 1-3 Alkyl, -C(O)N(C 1-3 alkyl)2, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl or -C(O)-3-5 membered cycloalkyl are optionally substituted with one or more substituents selected from halogen, -NH2, -C(O)CH2CH3 or -N(CH3)2.

[0323] In some embodiments, each R b Each independently selected from halogen, -OH, -CN, or optionally one or more R bbSubstituted with the following groups: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, -SC 1-12 Alkyl, C 1-12 Alkyl, -C(O)C 1-12 Alkyl, -C(O)N(C 1-12 Alkyl)2, -C(O)NH(C 1-12 alkyl), 3-14 membered cycloalkyl, 3-14 membered heterocyclyl, -C(O)-3-14 membered cycloalkyl or -C(O)-3-14 membered heterocycloalkyl, and each R bb are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, -C(O)C 1-12 Alkyl, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0324] In some embodiments, each R b Each independently selected from halogen, -OH, -CN, or optionally one or more R bb Substituted with the following groups: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, -SC 1-12 Alkyl, C 1-12 Alkyl, -C(O)C 1-12 Alkyl, -C(O)N(C 1-12 Alkyl)2, -C(O)NH(C 1-12 alkyl), 3-14 membered cycloalkyl, 3-14 membered heterocyclyl, -C(O)-3-14 membered cycloalkyl or -C(O)-3-14 membered heterocycloalkyl, and each R bb are independently selected from halogen, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 Alkyl), C 1-12 Alkoxy, -C(O)C 1-12 alkyl.

[0325] In some embodiments, each R b Each independently selected from F, Cl, Br, C 1-3 Alkyl, -N(C1-3 Alkyl)2, -NHC 1-3 Alkyl or -C(O)C 1-3 Alkyl, wherein the C 1-3 Alkyl, -N(C 1-3 Alkyl)2, -NHC 1-3 Alkyl or -C(O)C 1-3 The alkyl group is optionally substituted with one or more halogen or NH2.

[0326] In some embodiments, each R b Each independently selected from F, Cl, Br, C 1-3 Alkyl, -N(C 1-3 Alkyl)2 or NHC 1-3 Alkyl, wherein the C 1-3 Alkyl, -N(C 1-3 Alkyl)2 or -NHC 1-3 The alkyl group is optionally substituted with one or more halogens.

[0327] In some embodiments, each R b Each independently selected from F, Cl, C 1-3 Alkyl, -N(C 1-3 Alkyl)2, -NHC 1-3 Alkyl, -C(O)C 1-3 Alkyl, -C(O)N(C 1-3 alkyl) 2, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl or -C(O)-3-5 membered cycloalkyl, the C 1-3 Alkyl, -C(O)C 1-3 The alkyl or 3-6 membered heterocycloalkyl is optionally substituted with 1, 2 or 3 substituents selected from F, Cl, -NH2, -C(O)CH2CH3 or -N(CH3)2.

[0328] In some embodiments, each R b Each independently selected from F, Cl, C 1-3 Alkyl, -N(C 1-3 Alkyl)2, NHC 1-3 Alkyl or -C(O)C 1-3 Alkyl, the C 1-3 Alkyl or -C(O)C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 substituents selected from F, Cl or NH2.

[0329] In some embodiments, each R b Each independently selected from F, Cl, C1-3 Alkyl, -N(C 1-3 Alkyl)2 or NHC 1-3 alkyl.

[0330] In some embodiments, each R bb are independently selected from halogen, -NH2, -N(C 1-6 Alkyl)2, -NH(C 1-6 Alkyl), C 1-6 Alkoxy, -C(O)C 1-6 alkyl.

[0331] In some embodiments, each R bb are independently selected from halogen, -NH2, -N(C 1-4 Alkyl)2, -NH(C 1-4 Alkyl), C 1-4 Alkoxy, -C(O)C 1-4 alkyl.

[0332] In some embodiments, each R bb Each is independently selected from F, Cl, -NH2, -C(O)CH2CH3, -N(CH3)2 or -OCH3.

[0333] In some embodiments, each R b Each independently selected from F, methyl, -N(CH3)2、-NHCH3、-CF3、-CH2Cl、

[0334] -CH2NH2, -C(O)CHF2, -C(O)CH2CH3, -C(O)CH2F, -CH2N(CH3)2, -SCH3, -OCH3, -N(CH3)(CH2CF3), -OH, -C(CH3)2OH or -CN.

[0335] In some embodiments, each R b Each independently selected from F, methyl, -N(CH3)2, -NHCH3, -CF3, -CH2Cl, -CH2NH2, -C(O)CHF2, -C(O)CH2CH3, -C(O)CH2F, -CH2N(CH3)2, -SCH3, -OCH3, -N(CH3)(CH2CF3), -OH, -C(CH3)2OH or -CN.

[0336] In some embodiments, each R b Each independently selected from F, methyl, -N(CH3)2, -NHCH3, -CF3, -CH2Cl, -CH2NH2, -C(O)CHF2, -C(O)CH2CH3, -C(O)CH2F,

[0337] In some embodiments, each R b Each independently selected from F, methyl, -N(CH3)2, -NHCH3, -CF3, ethyl, -C(O)CHF2, -C(O)CH2F, -C(O)CH2CH3, -CH2Cl, or -CH2NH2. In some embodiments, each R b Each independently selected from F, methyl, -N(CH3)2 or -NHCH3.

[0338] In some embodiments, each R c are each independently selected from deuterium, halogen, -NH2, -OH or the following groups optionally substituted by one or more substituents: -NH(C 1-8 Alkyl), -N(C 1-8 Alkyl)2, -OC 1-8 Alkyl, C 1-8 Alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl.

[0339] In some embodiments, each R c are each independently selected from deuterium, halogen, Or the following groups optionally substituted by one or more substituents: -NH2, -NH(C 1-8 Alkyl), -N(C 1-8 Alkyl)2, -OH, -OC 1-8 Alkyl, C 1-8 Alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl.

[0340] In some embodiments, each R c are each independently selected from deuterium, halogen, -NH2, -OH or optionally one or more R cc Substituted with the following groups: -NH(C 1-8 Alkyl), -N(C 1-8 Alkyl)2, OC1-8 Alkyl, C 1-8 alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl; and each R cc are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0341] In some embodiments, each R c are each independently selected from deuterium, halogen, Or the following groups optionally substituted by one or more substituents: -NH2, -NH(C 1-8 Alkyl), -N(C 1-8 Alkyl)2, -OH, -OC 1-8 Alkyl, C 1-8 alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl; and each R cc are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0342] In some embodiments, each R c Each independently selected from -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OH, -OC 1-4 Alkyl, halogen, 3-6 membered cycloalkyl or C optionally substituted by one or more deuterium 1-6 alkyl.

[0343] In some embodiments, each R c Each independently selected from -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OH, -OC 1-4 Alkyl, halogen, or C optionally substituted by one or more deuteriums 1-6 alkyl.

[0344] In some embodiments, each R c Each independently selected from F, Cl, -NH2、-NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -OH, -OC 1-3 alkyl, or C optionally substituted by one or more deuterium 1-3 alkyl.

[0345] In some embodiments, each R c Each independently selected from F, Cl, or C 1-3 alkyl.

[0346] In some embodiments, each R c Each independently selected from F, Or -CH3.

[0347] In some embodiments, each R d Each is independently selected from optionally substituted with one or more substituents (e.g., R dd ) substituted by the following groups: C 1-12 Alkyl or 3-14 membered heterocycloalkyl;

[0348] In some embodiments, each R d Each is independently selected from optionally substituted with one or more substituents (e.g., R dd ) substituted by the following groups: C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-8 membered heterocycloalkyl.

[0349] In some embodiments, each R d Each is independently selected from optionally substituted with one or more substituents (e.g., R dd ) substituted by the following groups: C 1-6 Alkyl or 3-8 membered heterocycloalkyl.

[0350] In some embodiments, each R d Each is independently selected from optionally substituted with one or more substituents (e.g., R dd ) substituted 3-8 membered heterocycloalkyl.

[0351] In some embodiments, each R d are each independently selected from the following groups optionally substituted by one or more substituents: C 1-6 Alkyl or C 3-8 Cycloalkyl.

[0352] In some embodiments, each R d Each independently selected from optionally one or more R dd Substituted with the following groups: C 1-6 Alkyl or C 3-8 cycloalkyl; and each R dd are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-12 Alkyl)2, -NH(C 1-12 alkyl), -CN, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-14 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-14 membered heterocyclyl.

[0353] In some embodiments, each R d Each independently selected from C 1-4 Alkyl or C 3-6 Cycloalkyl.

[0354] In some embodiments, each R d Each independently selected from C 1-2 Alkyl or C 3-4 Cycloalkyl.

[0355] In some embodiments, each R d Each independently selected from C 1-2 alkyl.

[0356] In some embodiments, R d Each independently selected from C 3-4 Cycloalkyl.

[0357] In some embodiments, each R d Each independently selected from C 1-4 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl.

[0358] In some embodiments, each R d Each is independently selected from methyl, ethyl or morpholinyl.

[0359] In some embodiments, each R a’a’ 、R aa 、R bb 、R cc or R dd are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-6 Alkyl)2, -NH(C 1-6 alkyl), -CN, C 1-6 Alkyl, C 1-6 Alkoxy, -C(O)C 1-6 Alkyl, C 5-10 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-10 membered heterocyclyl.

[0360] In some embodiments, each R a’a’ 、R aa 、R bb 、R cc or R dd are each independently selected from deuterium, halogen, -OH, -NH2, -N(C 1-6 Alkyl)2, -NH(C 1-6 alkyl), -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 5-10 Cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl or 3-10 membered heterocyclyl.

[0361] In some embodiments, each R a’a’ 、R aa 、R bb 、R cc or R dd Each independently selected from deuterium, halogen, -OH, -NH2, -CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 5-8 Cycloalkyl, C 5-6 aryl, 5-6 membered heteroaryl or 3-8 membered heterocyclic group.

[0362] In some embodiments, each R a’a’ 、R aa 、R bb 、R cc or R dd Each independently selected from F, Cl, -NH2, C 1-6 Alkyl or -N(CH3)2.

[0363] In some embodiments, each R a’a’ 、R aa 、R bb 、R cc or R dd are each independently selected from deuterium, halogen, or C 1-6 alkyl.

[0364] In some embodiments, m is selected from 1, 2, 3, 4, 5, or 6.

[0365] In some embodiments, m is selected from 0, 1, 2, 3, or 4.

[0366] In some embodiments, m is selected from 1, 2, 3, or 4.

[0367] In some embodiments, m is selected from 1, 2, or 3.

[0368] In some embodiments, m is selected from 1 or 2.

[0369] In some embodiments, m is 0.

[0370] In some embodiments, one or both of the bicyclic rings are aromatic.

[0371] In some embodiments, one, two, or three rings in the tricyclic group are aromatic.

[0372] In some embodiments, the bicyclic or tricyclic group is Some of the connected monocyclic rings are aromatic rings.

[0373] In some embodiments, the bicyclic or tricyclic group is Some of the connected monocyclic rings are benzene rings or aromatic rings containing a nitrogen atom.

[0374] In some embodiments, the bicyclic or tricyclic group is Some of the connected monocyclic rings are benzene rings, or 5-membered or 6-membered aromatic rings containing a nitrogen atom.

[0375] In some embodiments, any two adjacent rings in the tricyclic group are optionally fused, bridged, or spiro rings.

[0376] In some embodiments, the tricyclic group is A partially connected monocyclic ring and its adjacent ring are a fused ring.

[0377] In some embodiments, the tricyclic group is Partially connected monocyclic rings are aromatic rings, and the monocyclic ring and the adjacent ring are fused rings.

[0378] In some embodiments, the compound of formula (I) of the present disclosure or a pharmaceutically acceptable salt thereof is selected from the following formula (II), formula (II-1), formula (II-2), formula (II-3), formula (II-4), formula (II-1a), formula (II-1b), formula (II-1c), formula (II-1d) or formula (II-1e) compounds or pharmaceutically acceptable salts thereof:

[0379] Among them, X 1 、X 2 、X 3 、R a ', Ring A, R 1 、R 2 and m are as defined in this disclosure.

[0380] In some embodiments, the compound of formula (I) of the present disclosure or a pharmaceutically acceptable salt thereof is selected from the following formula (II), formula (II-1), formula (II-2), formula (II-3), formula (II-4), formula (II-1a), formula (II-1a-1), formula (II-1b), formula (II-1b-1), formula (II-1b-2), formula (II-1b-3), formula (II-1b-4), formula (II-2a), formula (II-3a), formula (II-3a-1) or formula (II-4a) compounds or pharmaceutically acceptable salts thereof:

[0381] Among them, X 1 、X 2 、X 3 、R a ', Ring A, R 1 、R 2 and m are as defined in this disclosure.

[0382] In some embodiments, the ring of the "aryl" group described herein that is directly attached to the parent structure is a benzene ring.

[0383] In some embodiments, the ring of the "heteroaryl" group described herein that is directly attached to the parent structure is an aromatic ring.

[0384] In some embodiments, the present disclosure encompasses the above-defined variables and embodiments thereof, and any combination thereof.

[0385] It is to be understood that any of the embodiments of the compounds of the present disclosure as described above and the descriptions herein with respect to a particular X in the compounds of the present disclosure as described above 1 、X 2 、X 3 , Y, Ring A, R 1 、R 2 、Y 1 、Y 2 、Y 3 、R 3 、R a 、R a’ 、R b 、R c 、R dAny specific substituent described can be independently combined with other embodiments of the present disclosure and / or substituents of compounds to form embodiments of the present disclosure not specifically described above. In addition, any specific substituents described in the specific embodiments and / or claims with respect to any particular X 1 、X 2 、X 3 , Y, Ring A, R 1 、R 2 、Y 1 、Y 2 、Y 3 、R 3 、R a 、R a’ 、R b 、R c 、R d Where a substituent range is disclosed, it is understood that one or more substituents may be deleted from the range and the remaining substituent range shall also be considered an embodiment of the present disclosure. In some embodiments, the heteroatoms in the heterocycloalkenyl, heterocycloalkyl, heterocyclyl or heteroaryl are selected from N, O, NH, S or P, and the number of heteroatoms is selected from 1, 2, 3, 4 or 5; or, the number of heteroatoms is selected from 1, 2, 3 or 4; or, the number of heteroatoms is selected from 1, 2 or 3; or, the number of heteroatoms is selected from 1 or 2.

[0386] In some embodiments, the present disclosure is the following compound or a pharmaceutically acceptable salt thereof:

[0387] In another aspect, the present disclosure provides a pharmaceutical composition comprising the above-mentioned compound of the present disclosure or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition of the present disclosure further comprises a pharmaceutically acceptable excipient.

[0388] In another aspect, the present disclosure provides a method for treating a disease in an individual (eg, a mammal), comprising administering a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to a mammal, preferably a human, in need of such treatment.

[0389] In another aspect, the present disclosure provides use of the aforementioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for treating a disease.

[0390] In another aspect, the present disclosure provides use of the aforementioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in treating a disease.

[0391] In another aspect, the present disclosure provides the above-mentioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for use in treating a disease.

[0392] In some embodiments, the disease is selected from a disease associated with HPK1 kinase.

[0393] In some embodiments, the disease associated with HPK1 kinase is selected from cancer (eg, leukemia, colon cancer, etc.).

[0394] The compounds disclosed herein have good HPK1 kinase inhibitory activity and cell proliferation inhibitory activity, are stable in vitro in liver microsome metabolism, and have good in vivo efficacy and pharmacokinetic properties.

[0395] definition

[0396] Unless otherwise indicated, the following terms used in this disclosure have the following meanings. A particular term should not be construed as undefined or unclear unless specifically defined, but rather should be understood according to its ordinary meaning in the art. When a trade name appears herein, it is intended to refer to the corresponding commercial product or its active ingredient.

[0397] The term "substituted" refers to the replacement of any one or more hydrogen atoms on a particular atom by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is an oxo (i.e., =O), it means that two hydrogen atoms are replaced. Oxo does not occur on aromatic groups.

[0398] The term "optionally" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes both the occurrence of the event or situation and the non-occurrence of the event or situation. For example, an ethyl group is "optionally" substituted with a halogen, meaning that the ethyl group may be unsubstituted (-CH2CH3), monosubstituted (e.g., -CH2CH2F), polysubstituted (e.g., -CHFCH2F, -CH2CHF2, etc.), or fully substituted (-CF2CF3). It will be understood by those skilled in the art that for any group containing one or more substituents, no substitution or substitution pattern that would be sterically impossible and / or incomposable to synthesize will be introduced.

[0399] As used herein, "one or more" refers to an integer from one to ten. For example, "one or more" refers to one, two, three, four, five, six, seven, eight, nine, or ten; or, "one or more" refers to one, two, three, four, five, or six; or, "one or more" refers to one, two, or three.

[0400] The "substituents" described herein include, but are not limited to, the terms "alkyl", "alkenyl", "alkynyl", "bicyclic", "tricyclic", "cycloalkyl", "cycloalkenyl", "heterocyclic", "alkoxy", "cycloalkyl", "heterocycloalkyl", "heteroaryl", "spirocycloalkyl", "spiroheterocycloalkyl", "bridged ring", "heterocycloalkenyl", "fused ring", etc., and corresponding non-limiting or exemplary groups, wherein some non-limiting examples of the "substituents" include deuterium, tritium, -OH, -SH, halogen, -NH2, nitro a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a halo-alkyl group, a cycloalkyl group, a halo-cycloalkyl group, an alkenyl group, a halo-alkenyl group, a cycloalkenyl group, a halo-cycloalkenyl group, an alkynyl group, a halo-alkynyl group, a cycloalkynyl group, a halo-cycloalkynyl group, a heteroalkyl group, a halo-heteroalkyl group, an alkoxy group, an alkylthio group, an aryl group, an aryloxy group, an arylthio group, an aralkyl group, an arylalkoxy group, an arylalkylthio group, a heteroaryl group, a heteroaryloxy group, a heteroarylthio group, a heteroaralkyl group, a heteroarylalkoxy group, a heteroarylalkylthio group The present invention also includes but is not limited to: alkyl, heterocyclic, heterocyclic, heterocyclicoxy, heterocyclicthio, heterocyclicalkyl, heterocyclicalkoxy, heterocyclicalkylthio, acyl, acyloxy, carbamate group, amide group, urea group, epoxy group and ester group, etc., which are optionally substituted by one or more substituents selected from the following: oxo, hydroxyl, amino, nitro, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, carboxyl, -C(O)O-alkyl, -OC(O)-alkyl, -C (O)NH2, -C(O)NH-alkyl, -C(O)N(alkyl)2, -NHC(O)-alkyl, -C(O)-alkyl, -S(O)-alkyl, -S(O)2-alkyl, -S(O)2NH2, -S(O)2NH-alkyl, -S(O)2N(alkyl)2, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkyl, heterocyclyloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, aryl, arylalkyl or aryloxy.

[0401] In some embodiments herein, the “substituent” is selected from deuterium, tritium, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azide, sulfoxide, sulfone, sulfonamide, carboxyl, aldehyde, imine, C 1-12 Alkyl, halo-C 1-12 Alkyl, 3-12 membered cycloalkyl, halogenated 3-12 membered cycloalkyl, C 2-12 Alkenyl, halo-C 2-12 Alkenyl, 3-12 membered cycloalkenyl, halogenated 3-12 membered cycloalkenyl, C 2-12 Alkynyl, halo-C 2-12Alkynyl, 8-12 membered cycloalkynyl, halogenated 8-12 membered cycloalkynyl, C 1-12 Heteroalkyl, halo-C 1-12 Heteroalkyl, C 1-12 Alkoxy, C 1-12 Alkylthio, 6-10 membered aryl, 6-10 membered aryloxy, 6-10 membered arylthio, 6-10 membered arylC 1-12 Alkylene, 6-10 membered aryl C 1-12 Alkoxy, 6-10 membered aryl C 1-12 alkylthio, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, 5-10 membered heteroarylthio, 5-10 membered heteroarylalkylene, 5-10 membered heteroarylalkoxy, 5-10 membered heteroarylalkylthio, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, 3-12 membered heterocyclylthio, 3-12 membered heterocyclylC 1-12 Alkylene, 3-12 membered heterocyclic group C 1-12 Alkoxy, 3-12 membered heterocyclic group C 1-12 Alkylthio, C 1-12 Acyl, C 1-12 Acyloxy, carbamate group, C 1-12 Amide group, urea group, epoxy group, C 2-12 Ester group and oxo, said substituent being optionally substituted by one or more substituents selected from the group consisting of oxo, hydroxy, amino, nitro, halogen, cyano, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, C 1-12 Alkylamino, di-C 1-12 Alkylamino, halogenated C 1-12 Alkylamino, halogenated di-C 1-12 Alkylamino, carboxyl, -C(O)OC 1-12 Alkyl, -OC(O)-C 1-12 Alkyl, -C(O)NH2, -C(O)NH-C 1-12 Alkyl, -C(O)N(C 1-12 Alkyl)2, -NHC(O)-C 1-12 Alkyl, -C(O)-C 1-12 Alkyl, -S(O)-C 1-12 Alkyl, -S(O)2-C 1-12 Alkyl, -S(O)2NH2, -S(O)2NH-C 1-12 Alkyl, -S(O)2N(C 1-12 alkyl) 2, 3-12 membered cycloalkyl, 3-12 membered cycloalkyl C 1-12Alkylene, 3-12 membered cycloalkyloxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group C 1-12 Alkylene, 3-12 membered heterocyclyloxy, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkylC 1-12 Alkylene, 3-12 membered heterocycloalkyloxy, 5-10 membered heteroaryl, 5-10 membered heteroarylC 1-12 Alkylene, 5-10 membered heteroaryloxy, 6-10 membered aryl, 6-10 membered arylC 1-12 an alkylene group or a 6- to 10-membered aryloxy group.

[0402] In this article, C m-n , means that the moiety has an integer number of carbon atoms in a given range. For example, "C 1-6 " means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms. For example, C 1-3 It means that the group may have 1 carbon atom, 2 carbon atoms, or 3 carbon atoms.

[0403] As used herein, m and n are integers within a given range. For example, "3-14 membered" means that the group may have a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered moiety. For example, "3-12 membered" means that the group may have a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered moiety. For example, "5-10 membered" means that the group may have a 5-, 6-, 7-, 8-, 9-, or 10-membered moiety.

[0404] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition on each occurrence is independent. Thus, for example, if a group is substituted with two R's, each R has an independent alternative.

[0405] When a substituent's bond crosses between two atoms in a ring, the substituent may be bonded to any atom in the ring. It means that it can be substituted at any position on the cyclohexyl group or cyclohexadiene.

[0406] The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.

[0407] The term "hydroxy" refers to an -OH group.

[0408] The term "amino" refers to a -NH2 group.

[0409] The term "nitro" refers to a -NO2 group.

[0410] The term "cyano" refers to a -CN group.

[0411] The term "alkyl" refers to a group of the formula C n H 2n+1 The alkyl group may be straight chain or branched. For example, the term "C 1-6 The term "alkyl" refers to an alkyl group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc.). Similarly, the alkyl portion (i.e., alkyl) of alkoxy, alkylamino, dialkylamino, alkylsulfonyl, and alkylthio has the same definition as above.

[0412] The term "alkenyl" refers to a linear or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond. Non-limiting examples of alkenyl include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, and the like.

[0413] The term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond. Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), 1-propynyl (-C≡C-CH3), 2-propynyl (-CH2-C≡CH), 1,3-butadiynyl (-C≡C≡CH), and the like.

[0414] The term "alkoxy" refers to an -O-alkyl group.

[0415] The term "monocyclic" refers to a cyclic group containing one ring, which may be fully saturated, partially saturated or aromatic. The monocyclic ring may be composed entirely of C atoms and may contain one or more heteroatoms selected from, for example, N, O, S or P.

[0416] The term "bicyclic" or "bicyclyl" refers to a cyclic group containing two rings, which may be fully saturated, partially saturated or aromatic. The bicyclic ring may be composed entirely of carbon atoms and may contain one or more heteroatoms selected from, for example, N, O, S or P. The bicyclic ring may be a fused ring, a bridged ring or a spiro ring.

[0417] The term "tricyclic" or "tricyclyl" refers to a cyclic group containing three rings, which may be fully saturated, partially saturated, or aromatic. The tricyclic ring may be composed entirely of carbon atoms and may contain one or more heteroatoms selected from, for example, nitrogen, oxygen, sulfur, or phosphorus. Any two adjacent monocyclic rings in the tricyclic ring may be fused, bridged, or spirocyclic.

[0418] The term "cycloalkyl" refers to a fully saturated carbocyclic ring. Unless otherwise indicated, the carbocyclic ring is typically 3 to 14-membered; preferably 3-10-membered. Unless otherwise indicated, the cycloalkyl group may be monocyclic, bicyclic, or tricyclic. Non-limiting examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, and the like.

[0419] The term "heterocyclyl" refers to a non-aromatic ring that is fully saturated or partially unsaturated (but not fully unsaturated heteroaromatic) and can exist as a monocyclic, bridged, fused or spirocyclic ring. Unless otherwise indicated, the heterocycle is typically a 3 to 20-membered ring, a 3 to 15-membered ring, a 3 to 12-membered ring, or a 3 to 10-membered ring (e.g., a 3-membered, 4-membered, 5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered ring), a 4 to 8-membered ring, a 5 to 8-membered ring, or a 5 to 6-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, nitrogen, phosphorus, silicon and / or boron. Non-limiting examples of heterocyclyl groups include, but are not limited to, oxiranyl, tetrahydrofuranyl, dihydrofuranyl, dihydropyridinyl, pyrrolidinyl, N-methylpyrrolidinyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyrazolidinyl, 4H-pyranyl, morpholinyl, thiomorpholinyl, tetrahydrothiophenyl, and the like.

[0420] The term "cycloalkenyl" refers to an incompletely saturated, non-aromatic carbocyclic ring that can exist as a monocycle, a bicyclic bridged ring or a spirocycle. Unless otherwise indicated, the carbocyclic ring is typically 4 to 16 rings, 4 to 12 rings, 4 to 10 rings or 4 to 8 rings (specifically, for example, 5, 6, 7, 8, 9, 10 or 11 rings). Non-limiting examples of cycloalkenyl include, but are not limited to, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl etc.

[0421] The term "spirocycle" refers to a fully saturated or partially unsaturated polycyclic system in which the monocyclic rings share a carbon atom (called a spiro atom), including carbocycles and heterocycles. Unless otherwise indicated, the spirocycle is 5 to 20 members, preferably 6 to 14 members, and more preferably 9 to 14 members. When the spirocycle is a heterocycle, one or more ring atoms in the polycyclic ring are selected from N, O, S(O) n 、P(O) n (wherein n is 0, 1 or 2) heteroatoms (preferably 1 or 2 heteroatoms), and the remaining ring atoms are carbon atoms.

[0422] The term "spiroalkyl" refers to a fully saturated, all-carbon polycyclic ring that shares a carbon atom (called a spiro atom) between monocyclic rings. Unless otherwise indicated, the spiroalkyl is 5 to 20 yuan, preferably 6 to 14 yuan, and more preferably 9 to 14 yuan. According to the number of spiro atoms shared between rings, spiroalkyl is divided into single spiroalkyl, double spiroalkyl or multiple spiroalkyl, preferably single spiroalkyl and double spiroalkyl, more preferably 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiroalkyl. Non-limiting examples of spiroalkyl include

[0423] The term "spiroheterocycloalkyl" refers to a fully saturated polycyclic ring in which the monocyclic rings share a carbon atom (called a spiro atom), and one or more ring atoms in the polycyclic ring are selected from N, O, S(O) n 、P(O) n (wherein n is 0, 1 or 2) heteroatoms (preferably 1 or 2 heteroatoms), and the remaining ring atoms are carbon atoms. Unless otherwise indicated, the spiro heterocycloalkyl is 5 to 20 yuan, preferably 6 to 14 yuan, more preferably 6 to 10 yuan. According to the number of shared spiro atoms between the rings, the spiro heterocycle is divided into a monospiro heterocycle, a dispiro heterocycle or a polyspiro heterocycle, preferably a monospiro heterocycle or a dispiro heterocycle, more preferably a 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or a 5 yuan / 6 yuan monospiro heterocycle. Non-limiting examples of spiro heterocycloalkyl include wait.

[0424] The term "bridged ring" refers to a fully saturated or partially unsaturated polycyclic ring system in which two rings share three or more atoms, including carbocyclic and heterocyclic rings. Unless otherwise indicated, the bridged ring is 5 to 14 members, preferably 6 to 14 members, more preferably 6 to 10 members. Depending on the number of rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged rings, preferably bicyclic or tricyclic, more preferably bicyclic. When the bridged ring is a heterocyclic ring, one or more ring atoms in the polycyclic ring are selected from N, O, S(O) n 、P(O) n (wherein n is 0, 1 or 2) heteroatoms (preferably 1 or 2 heteroatoms), and the remaining ring atoms are carbon atoms.

[0425] The term "heterocycloalkyl" refers to a fully saturated cyclic group containing heteroatoms. Unless otherwise indicated, the heterocycloalkyl group is typically a cyclic group containing 1 to 3 atoms independently selected from N, O, S(O), n 、P(O) n(wherein n is 0, 1 or 2) a heteroatom (preferably 1 or 2 heteroatoms). Unless otherwise indicated, the heterocycloalkyl group may be a monocyclic, bicyclic or tricyclic group. Unless otherwise indicated, the heterocycloalkyl group includes but is not limited to a 3 to 12-membered ring, a 3 to 8-membered ring or a 5 to 8-membered ring. Examples of 3-membered heterocycloalkyl groups include, but are not limited to, oxirane, thioethane, and aziridine groups; non-limiting examples of 4-membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, and thietanyl groups; examples of 5-membered heterocycloalkyl groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl, and tetrahydropyrazolyl groups; examples of 6-membered heterocycloalkyl groups include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, piperazinyl, 1,4-thioxanyl, 1,4-dioxanyl, thiomorpholinyl, 1,3-dithianyl, or 1,4-dithianyl groups; examples of 7-membered heterocycloalkyl groups include, but are not limited to, azepanyl, oxetanyl, and thiepanyl groups. Preferably, the heterocycloalkyl group is a monocyclic group having 5 or 6 ring atoms.

[0426] The term "monocyclic heterocycloalkyl" refers to a heterocycloalkyl group existing as a single ring.

[0427] The term "heterocyclenyl" includes cycloalkenyl groups in which one or more carbon atoms are replaced by heteroatoms, specifically cycloalkenyl groups in which up to 3 carbon atoms, up to 2 carbon atoms, in one embodiment 1 carbon atom is independently replaced by N, O or S (O), with the condition that at least one cycloalkenyl carbon-carbon double bond is retained. Heterocyclenyl can be a cyclic group existing with a monocycle, a bridged ring or a spirocycle, and can be a 3 to 16-membered ring (e.g., 3 to 12 members, 5 to 8-membered ring, specifically 5 members, 6 members, 7 members, 8 members, 9 members, 10 members or 11-membered ring). Examples of heterocyclenyl include, but are not limited to, dihydropyridyl, dihydropyrrolyl, tetrahydropyridyl, tetrahydroazepine or azaspirooctene.

[0428] The term "monocyclic heterocycloalkenyl" refers to a heterocycloalkenyl group existing as a single ring.

[0429] The term "fused ring" refers to a polycyclic compound formed by two or more carbon rings or heterocyclic rings joined together with two atoms in common, including fully saturated, partially saturated and aromatic rings. Unless otherwise indicated, the fused ring is 5 to 20 members, preferably 6 to 14 members, more preferably 9 to 14 members. Non-limiting examples of fused rings include, but are not limited to, naphthalene, anthracene, phenanthrene, wait.

[0430] It should be understood that R 2 Selected from For example, the "bicyclic group or tricyclic group in the present disclosure and the group of formula (I) "Part of the connected monocyclic rings are aromatic rings" means that the structure of the compound of formula (I) can be instead of wait.

[0431] It should be understood that R 2 Selected from For example, the "tricyclic group with formula (I)" in the present disclosure The partially connected single ring and its adjacent ring are fused rings" means that the structure of the compound of formula (I) can be Wait, instead of

[0432] The term "aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated π electron system. Unless otherwise indicated, an aryl group may have 6-20 carbon atoms, 6-14 carbon atoms, 6-12 carbon atoms or 6-10 carbon atoms. Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl and 1,2,3,4-tetrahydronaphthalene, etc., preferably phenyl. In some embodiments, the ring directly connected to the parent structure of the aryl group is a benzene ring; in some preferred embodiments, the aryl group may be a phenyl group fused with a heterocyclic group or a cycloalkyl group to form 2 or more rings (e.g., 2, 3, 4 rings, etc.), wherein the ring directly connected to the parent structure is a benzene ring, and non-limiting examples include, but are not limited to. wait.

[0433] The term "heteroaryl" refers to a monocyclic or polycyclic ring system containing at least one ring selected from N, O, S(O) n 、P(O) n (wherein n is 0,1 or 2) ring atoms, the remaining ring atoms are C, and there is an aromatic ring of at least one heteroaromatic ring. Unless otherwise indicated, the heteroaryl can be a monocyclic, bicyclic or tricyclic radical. Unless otherwise indicated, the heteroaryl can have a single 5 to 8-membered ring, or comprise 6 to 14, especially multiple fused rings of 6 to 10 ring atoms. The limiting examples of heteroaryl include but are not limited to pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl etc. In some embodiments, the ring to which the heteroaryl is directly connected to the parent structure is a heteroaromatic ring.

[0434] The term "treating" means administering a compound or formulation of the present disclosure to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:

[0435] (i) inhibiting a disease or disease state, i.e., arresting its development;

[0436] (ii) ameliorating the disease or condition, i.e., causing regression of the disease or condition.

[0437] The term "therapeutically effective amount" means (i) treating a specific disease, condition, or disorder described herein, and (ii) alleviating, ameliorating, or eliminating one or more symptoms of a specific disease, condition, or disorder described herein. The amount of a compound of the present disclosure that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by one skilled in the art based on their knowledge and this disclosure.

[0438] The term "prophylactically effective amount" means an amount of a compound of the present disclosure that prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of a compound of the present disclosure that constitutes a "prophylactically effective amount" will vary depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by one skilled in the art based on their knowledge and this disclosure.

[0439] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0440] As the pharmaceutically acceptable salt, for example, metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids and the like can be mentioned.

[0441] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present disclosure or their salts and a pharmaceutically acceptable excipient. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present disclosure to an organism.

[0442] The term "pharmaceutically acceptable excipient" refers to an excipient that is non-irritating to organisms and does not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art and include, for example, carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.

[0443] The term "subject" includes mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates (e.g., chimpanzees and other apes and monkeys); livestock, such as cattle, horses, sheep, goats, and pigs; domestic animals, such as rabbits, dogs, and cats; and laboratory animals, including rodents, such as rats, mice, and guinea pigs. Examples of non-human mammals include, but are not limited to, birds and fish. In one embodiment of the methods and compositions provided herein, the mammal is a human.

[0444] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be understood as having an open and non-exclusive meaning, ie, "including but not limited to".

[0445] Unless otherwise specifically stated, singular terms encompass plural terms and plural terms encompass the singular. Unless otherwise specifically stated, the words "a" or "an" mean "at least one" or "at least one." Unless otherwise specified, the use of "or" means "and / or."

[0446] The compounds of the present disclosure may exist in specific geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures thereof and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present disclosure. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All of these isomers and their mixtures are included within the scope of the present disclosure.

[0447] Unless otherwise indicated, "(D)" or "(+)" indicates dextrorotatory, "(L)" or "(-)" indicates levorotatory, and "(DL)" or "(±)" indicates racemic.

[0448] Unless otherwise specified, use a solid wedge key. and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond and straight dashed key Indicates the relative configuration of a stereocenter.

[0449] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary groups are cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and then the pure enantiomers are recovered. In addition, separation of enantiomers and diastereoisomers is typically accomplished using chromatography using a chiral stationary phase, optionally combined with chemical derivatization (e.g., to form carbamates from amines).

[0450] The present disclosure also includes isotopically labeled compounds of the present disclosure that are identical to those described herein, but where one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 For example, it should be understood that compounds in which one or more hydrogen atoms in the compounds of formula (I) of the present disclosure are replaced by deuterium atoms are still within the scope of the compounds of formula (I) of the present disclosure.

[0451] Certain isotopically labeled compounds of the present disclosure (e.g., 3 H and 14 C-labeled) can be used in compound and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. Positron emitting isotopes such as 15 O. 13 N. 11 C and 18F can be used in positron emission tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the disclosure can generally be prepared by following procedures analogous to those disclosed in the Schemes and / or Examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0452] In addition, the use of heavier isotopes such as deuterium (i.e. 2 H or D)) substitution can provide certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and may therefore be preferred in certain circumstances, wherein deuterium substitution may be partial or complete, partial deuterium substitution means that at least one hydrogen is replaced by at least one deuterium, and complete deuterium substitution means that all hydrogens on the group are replaced by deuterium, for example, complete replacement of a methyl group (-CH3) by deuterium yields -CD3.

[0453] The compounds of the present disclosure may exist in their tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. A specific example of a proton tautomer can be an imidazole moiety, in which a proton can migrate between two ring nitrogens.

[0454] The pharmaceutical compositions of the present disclosure can be prepared by combining the compounds of the present disclosure with suitable pharmaceutically acceptable excipients.

[0455] Typical routes of administration of the disclosed compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof include, but are not limited to, oral, topical, inhalation, parenteral, intranasal, intraocular, intramuscular, subcutaneous, and intravenous administration.

[0456] The pharmaceutical composition of the present disclosure can be manufactured by methods well known in the art, such as conventional mixing methods, dissolving methods, granulating methods, making dragees, grinding methods, emulsifying methods, freeze-drying methods, and the like.

[0457] In all methods of administration of the compounds of (I) disclosed herein, the dosage administered per day is 0.001 to 2000 mg / kg body weight, in single or divided doses.

[0458] The compounds disclosed herein can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining the same with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include, but are not limited to, the examples disclosed herein.

[0459] The chemical reactions of the embodiments of the present disclosure are carried out in a suitable solvent that is compatible with the chemical transformations of the present disclosure and the reagents and materials required. In order to obtain the compounds of the present disclosure, it is sometimes necessary for those skilled in the art to modify or select synthetic steps or reaction schemes based on existing embodiments.

[0460] An important consideration in synthetic route planning in the art is the selection of a suitable protecting group for a reactive functional group (such as the amino group in the present disclosure). For example, reference may be made to Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc., all references cited in the present disclosure are hereby incorporated into the present disclosure in their entirety.

[0461] For the purposes of description and disclosure, all patents, patent applications, and other identified publications are expressly incorporated herein by reference. These publications are provided solely because their disclosure predates the filing date of the present disclosure. All statements regarding the dates of these documents or representations of the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any citation of these publications herein does not constitute an admission that such publications are part of the common general knowledge in the art in any country.

[0462] In some embodiments, the compounds of the present disclosure can be prepared by those skilled in the art of organic synthesis by referring to the following routes:

[0463] Preparation route 1:

[0464] Preparation route 2:

[0465] Among them, the Z 1 Selected from halogen, -OH, -NH2 or -NH(C 1-6 alkyl) and other groups; Z 2 is selected from halogen, -NH2, boronic acid or boronic ester groups; Z 3 is selected from the group consisting of halogen, boronic acid, borate, OTf, ONf or tin reagent; Z 4 Selected from halogen, hydroxyl, -O(C 1-6 alkyl), -NH2 or -NH(C 1-6 alkyl) and other groups; Z 5 is selected from halogen, OTf, ONf, boronic acid, boronic ester, tin reagent or boron trifluoride derivative. 1 、X 1 、X2 、X 3 , Y, R 2 , m are defined as described in this disclosure.

[0466] This disclosure uses the following abbreviations:

[0467] DMSO represents dimethyl sulfoxide; THF represents tetrahydrofuran; MeOH represents methanol; DCM represents dichloromethane; NBS represents N-bromosuccinimide; DMF represents N,N-dimethylformamide; Boc represents tert-butyloxycarbonyl; Ms represents methanesulfonyl; OTf represents trifluoromethanesulfonate; and ONf represents nonafluorobutanesulfonate. DETAILED DESCRIPTION

[0468] For the sake of clarity, the present disclosure is further illustrated by examples, but the examples are not intended to limit the scope of the present disclosure. It will be apparent to those skilled in the art that various changes and modifications can be made to the embodiments of the present disclosure without departing from the spirit and scope of the present disclosure. All reagents used in the present disclosure are commercially available and can be used without further purification.

[0469] The compounds of the present invention can be prepared by similar preparation methods as those described in the examples, including but not limited to adjusting structurally similar raw materials, reagents, or process parameters. The compounds of the present invention can be confirmed by MS or HNMR. The compounds of the present invention can also be tested using the same efficacy test methods to obtain results.

[0470] Preparation of intermediates

[0471] Intermediate Example 1: Preparation of Intermediate 1A

[0472] Step A: Preparation of Intermediate 1A-1

[0473] To a reaction flask, methyl 3-amino-5,6-dichloro-2-pyrazinecarboxylate (5.0 g), methanol (50.0 mL), and a 30 wt% ethanolic solution of methylamine (11.66 g) were added sequentially. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was filtered, and the filter cake was washed and dried to obtain Intermediate 1A-1 (3.3 g).

[0474] MS (ESI, [M+H] + )m / z:217.3.

[0475] Step B: Preparation of Intermediate 1A-2

[0476] To a reaction flask at 0°C, intermediate 1A-1 (3.2 g), 28 wt% dilute sulfuric acid solution (40.0 mL), and water (40.0 mL) were added sequentially. A solution of sodium nitrite (1.22 g) dissolved in water (10.0 mL) was then added dropwise. After the addition was complete, the mixture was stirred at room temperature. The reaction was monitored by TLC until completion. The reaction mixture was filtered, and the filter cake was washed and dried to yield intermediate 1A-2 (2.6 g).

[0477] MS (ESI, [M+H] + )m / z:218.2.

[0478] Step C: Preparation of Intermediate 1A-3

[0479] To the reaction flask, add Intermediate 1A-2 (2.6 g), dichloromethane (26 mL), N,N-diisopropylethylamine (3.09 g), and trifluoromethanesulfonic anhydride (6.07 g) in sequence at 0°C. After addition, stir the mixture at 0°C. Monitor the reaction by TLC until completion. The solvent is removed under reduced pressure to afford Intermediate 1A-3 (6.9 g), which is used directly in the next step without purification.

[0480] MS (ESI, [M+H] + )m / z:350.0.

[0481] Step D: Preparation of Intermediate 1A

[0482] To a reaction flask, add Intermediate 1A-3 (6.9 g), N,N-diisopropylethylamine (15.4 g), and 4-(4-morpholinyl)aniline (2.5 g) in sequence. After addition, stir the reaction at 100°C. Monitor the reaction by TLC until completion. The reaction solution is concentrated, and the residue is purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford Intermediate 1A (2.0 g).

[0483] MS (ESI, [M+H] + )m / z:378.4.

[0484] Intermediate Example 2: Preparation of Intermediate 2A

[0485] Step A: Preparation of Intermediate 2A-1

[0486] To a reaction flask, methyl 3-amino-5,6-dichloro-2-pyrazinecarboxylate (10 g), toluene (150.0 mL), water (5.0 mL), cesium carbonate (29.3 g), palladium acetate (1.52 g), n-butyldi(1-adamantyl)phosphine (4.84 g), and potassium tetrafluorocyclopropane (7.33 g) were added sequentially. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was filtered, and the filter cake was washed and dried to obtain Intermediate 2A-1 (6.8 g).

[0487] MS (ESI, [M+H] + )m / z:228.4.

[0488] Step B: Preparation of Intermediate 2A-2

[0489] To a reaction flask, intermediate 2A-1 (6.8 g) and a 65-80 wt% hydrogen fluoride pyridine complex solution (100.0 mL) were added sequentially. After addition, sodium nitrite (2.2 g) was slowly added at 0°C. After addition, the mixture was slowly warmed to room temperature and stirred. The reaction was monitored by TLC until completion. Ethyl acetate was added for extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to afford intermediate 2A-2 (5.1 g).

[0490] MS (ESI, [M+H] + )m / z:231.0.

[0491] Step C: Preparation of Intermediate 2A-3

[0492] To a reaction flask, 3-methyl-4-nitropyrazole (10 g), N,N-dimethylformamide (80.0 mL), 2-iodo-1,1,1-trifluoroethane (24.8 g), and potassium carbonate (21.7 g) were added sequentially. After addition, the mixture was stirred at 100°C. The reaction was monitored by TLC until completion, and ethyl acetate was added for extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to obtain intermediate 2A-3 (6.2 g).

[0493] 1 H NMR (500MHz, DMSO-d6) δ8.93 (s, 1H), 5.19 (q, J = 8.9Hz, 2H), 2.46 (s, 3H).

[0494] Step D: Preparation of Intermediate 2A-4

[0495] To the reaction flask, add Intermediate 2A-3 (6.2 g), 10% palladium on carbon (3.1 g), and methanol (10 mL) in sequence. After the addition, replace the hydrogen atmosphere, and then stir the reaction at room temperature under a hydrogen atmosphere. Monitor the reaction by TLC until complete, filter, and concentrate to obtain Intermediate 2A-4 (5.2 g).

[0496] MS (ESI, [M+H] + )m / z:180.0.

[0497] Step E: Preparation of Intermediate 2A

[0498] To a reaction flask, add Intermediate 2A-2 (5.0 g), N,N-diisopropylethylamine (4.2 g), N,N-dimethylformamide (30 mL), and Intermediate 2A-4 (4.3 g) in sequence. After addition, stir the reaction at 100°C. Monitor the reaction by TLC until completion. The reaction solution is concentrated, and the residue is purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford Intermediate 2A (7.7 g).

[0499] MS (ESI, [M+H] + )m / z:390.2.

[0500] Intermediate Example 3: Preparation of Intermediate 3A

[0501] Step A: Preparation of Intermediate 3A

[0502] To a reaction flask, 7-bromo-3-methyl-3H-imidazo[4,5-c]pyridine (0.50 g), neopentyl glycol diboron (0.80 g), bistriphenylphosphine palladium dichloride (0.17 g), potassium acetate (0.70 g), and 1,4-dioxane (15 mL) were added sequentially. The reaction was stirred at 130°C under nitrogen. TLC was used to monitor the reaction until completion. The reaction solution was filtered to obtain Intermediate 3A, which was used directly in the next step without purification.

[0503] MS (ESI, [M+H] + )m / z:178.0.

[0504] Intermediate Example 4: Preparation of Intermediate 4A

[0505] Step A: Preparation of Intermediate 4A-1

[0506] To a reaction flask, methyl 3-amino-5,6-dichloro-2-pyrazinecarboxylate (5.0 g), methanol (50.0 mL), and a 30 wt% cyclopropylamine ethanol solution (14.0 g) were added sequentially. The mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was filtered, and the filter cake was washed and dried to obtain intermediate 4A-1 (4.3 g).

[0507] MS (ESI, [M+H] + )m / z:243.3.

[0508] Step B: Preparation of Intermediate 4A-2

[0509] To a reaction flask at 0°C, intermediate 4A-1 (2.2 g), 28 wt% dilute sulfuric acid solution (30.0 mL), and water (30.0 mL) were added sequentially. A solution of sodium nitrite (1.5 g) dissolved in water (20.0 mL) was then added dropwise. After addition, the mixture was allowed to warm to room temperature and stirred. The reaction was monitored by TLC until completion. The reaction mixture was filtered, and the filter cake was washed and dried to yield intermediate 4A-2 (2.0 g).

[0510] MS (ESI, [M+H] + )m / z:244.2.

[0511] Step C: Preparation of Intermediate 4A-3

[0512] To the reaction flask, add intermediate 4A-2 (2.0 g), dichloromethane (26 mL), N,N-diisopropylethylamine (3.0 g), and trifluoromethanesulfonic anhydride (2.07 g) in sequence at 0°C. After addition, stir the mixture at 0°C. Monitor the reaction by TLC until completion. The solvent is removed by rotary evaporation to afford intermediate 4A-3 (2.1 g), which is used directly in the next step without purification.

[0513] MS (ESI, [M+H] + )m / z:376.1.

[0514] Step D: Preparation of Intermediate 4A

[0515] To a reaction flask, add Intermediate 4A-3 (1.9 g), N,N-diisopropylethylamine (2.4 g), 2A-4 (1.5 g), and 1,4-dioxane (10 mL) in sequence. After addition, stir the reaction at 100°C. Monitor the reaction by TLC until completion. The reaction solution is concentrated, and the residue is purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford Intermediate 4A (2.0 g).

[0516] MS (ESI, [M+H] + )m / z:405.2.

[0517] Intermediate Example 5: Preparation of Intermediate 5A

[0518] Step A: Preparation of Intermediate 5A-1

[0519] At 0°C, 4-bromo-1H-pyrrolo[2,3-c]pyridine (5.0 g) and N,N-dimethylformamide (20 mL) were added sequentially to a reaction flask. After the addition was complete, 60 wt% sodium hydride (1.52 g) was slowly added to the reaction solution. The reaction was stirred for 30 min, and then iodomethane (0.216 g) was slowly added to the reaction solution. After the addition was complete, the reaction was stirred at 0°C. TLC was used to monitor the reaction until completion. Water was added to the reaction solution to quench the reaction, and ethyl acetate was added for extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to obtain intermediate 5A-1 (3.9 g).

[0520] MS (ESI, [M+H] + )m / z:211.1.

[0521] Step B: Preparation of Intermediate 5A

[0522] To a reaction flask, add Intermediate 5A-1 (0.5 g), neopentyl glycol diboron (0.81 g), bistriphenylphosphine palladium dichloride (0.17 g), potassium acetate (0.70 g), and 1,4-dioxane (15 mL) sequentially. Stir the reaction at 130°C under nitrogen. Monitor the reaction by TLC until completion. Filter the reaction solution to obtain Intermediate 5A, which is used directly in the next step without purification.

[0523] MS (ESI, [M+H] + )m / z:177.0.

[0524] Intermediate Example 6: Preparation of Intermediate 6A

[0525] Step A: Preparation of Intermediate 6A-1

[0526] To a reaction flask, 4-methyl-1,4-azaphosphane 4-oxide (0.5 g), p-nitrofluorobenzene (1.06 g), potassium carbonate (1.3 g), and N,N-dimethylformamide (10 mL) were added sequentially. After addition, the mixture was stirred at 100°C. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford Intermediate 6A-1 (0.62 g).

[0527] MS (ESI, [M+H] + )m / z:255.1.

[0528] Step B: Preparation of Intermediate 6A-2

[0529] To a reaction flask, intermediate 6A-1 (100 mg), methanol (2 mL), and 10% palladium on carbon (55 mg) were added sequentially. After addition, the mixture was replaced with a hydrogen balloon three times and then stirred at room temperature under a hydrogen atmosphere. The reaction was monitored by TLC until completion, the palladium on carbon was removed by filtration, and the mixture was concentrated under reduced pressure to afford intermediate 6A-2 (75 mg).

[0530] MS (ESI, [M+H] + )m / z:225.1.

[0531] Step C: Preparation of Intermediate 6A

[0532] To a reaction flask, compound 6A-2 (75 mg), intermediate 2A-2 (85 mg), 1,4-dioxane (3 mL), and N,N-diisopropylethylamine (86 mg) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain intermediate 6A (90 mg).

[0533] MS (ESI, [M+H] + )m / z:435.2.

[0534] Intermediate Example 7: Preparation of Intermediate 7A

[0535] Step A: Preparation of Intermediate 7A-1

[0536] To a reaction flask, add the intermediate 2-(4-methyl-1-piperazine)-5-nitrobenzaldehyde (2 g), p-toluenesulfonylhydrazide (1.6 g), and methanol (10 ml) in sequence. After addition, stir the reaction at 60°C. Monitor the reaction by TLC until completion. The reaction solution is concentrated, and the residue is purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford Intermediate 7A-1 (1.9 g).

[0537] MS (ESI, [M+H] + )m / z:418.3.

[0538] Step B: Preparation of Intermediate 7A-2

[0539] To a reaction flask, intermediate 7A-1 (1.9 g), toluene (6 mL), and 60 wt% sodium hydride (0.2 g) were added sequentially. After addition, the mixture was stirred under nitrogen at 140°C. TLC was used to monitor the reaction until completion. The reaction solution was quenched by pouring into water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford intermediate 7A-2 (0.6 g).

[0540] MS (ESI, [M+H]+ )m / z:234.3.

[0541] Step C: Preparation of Intermediate 7A

[0542] To a reaction flask, intermediate 7A-2 (0.5 g), 10% palladium on carbon (0.2 g), and methanol (10 mL) were added sequentially. After the addition, the hydrogen atmosphere was replaced, and the mixture was stirred at room temperature under a hydrogen atmosphere. The reaction was monitored by TLC until completion, filtered, and concentrated to afford intermediate 7A (0.4 g).

[0543] MS (ESI, [M+H] + )m / z:204.1.

[0544] Intermediate Example 8: Preparation of Intermediate 8A

[0545] Step A: Preparation of Intermediate 8A-1

[0546] To a reaction flask, methyl 3-amino-5,6-dichloro-2-pyrazinecarboxylate (10 g), toluene (100.0 mL), bistriphenylphosphine palladium dichloride (3.2 g), and tributyl(1-ethoxyethylene)tin (27.7 g) were added sequentially. After addition, the mixture was stirred at 100°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. Saturated aqueous ammonium chloride and ethyl acetate were added for extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 7 / 3) to afford Intermediate 8A-1 (10 g).

[0547] MS (ESI, [M+H] + )m / z:258.3.

[0548] Step B: Preparation of Intermediate 8A-2

[0549] To a reaction flask, add Intermediate 8A-1 (10 g), p-toluenesulfonic acid monohydrate (14.7 g), and tetrahydrofuran (100.0 mL) sequentially. After addition, stir the mixture at room temperature. Monitor the reaction by TLC until completion. Adjust the reaction mixture to alkaline (pH approximately 10) by adding saturated sodium bicarbonate solution. Extract the mixture with water and dichloromethane. The organic phase is separated, dried, filtered, and concentrated to afford Intermediate 8A-2 (8.7 g).

[0550] MS (ESI, [M+H] + )m / z:230.1.

[0551] Step C: Preparation of Intermediate 8A-3

[0552] At 0°C, intermediate 8A-2 (8.7 g), dichloromethane (60.0 mL), and diethylaminosulfur trifluoride (13.1 g) were added sequentially to a reaction flask. After addition, the reaction was stirred at room temperature. TLC was used to monitor the reaction until completion. Saturated sodium bicarbonate solution was added to the reaction solution to adjust the pH to approximately 10. Water and dichloromethane were added to the reaction solution, and the organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain intermediate 8A-3 (5.5 g).

[0553] MS (ESI, [M+H] + )m / z:252.3.

[0554] Step D: Preparation of Intermediate 8A

[0555] To the reaction flask, intermediate 8A-3 (5.5 g) and a 65-80 wt% hydrogen fluoride pyridine complex solution (74.0 mL) were added sequentially. After addition, sodium nitrite (1.7 g) was slowly added at 0°C. After addition, the mixture was slowly warmed to room temperature and stirred. TLC was monitored until the reaction was complete. Ethyl acetate was added for extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to obtain intermediate 8A (4.1 g).

[0556] MS (ESI, [M+H] + )m / z:255.1.

[0557] Example 1: Preparation of Compound I-1

[0558] Step A: Preparation of compound 1a

[0559] To a reaction flask, 3-bromo-7-fluoroimidazo[1,2-A]pyridine (3.5 g) and tetrahydrofuran (50 mL) were added sequentially. After addition, a solution of isopropylmagnesium chloride in tetrahydrofuran (15 mL, 1.3 M) was slowly added dropwise under nitrogen at -15°C. The reaction was stirred for 0.5 h at -15°C. Then, isopropyl pinacol borate (4.5 g) was slowly added dropwise. After addition, the mixture was slowly warmed to room temperature and stirred. The reaction was monitored by TLC until completion. Saturated ammonium chloride solution was added to quench the reaction, filtered, washed, and dried to yield compound 1a (2.2 g).

[0560] MS (ESI, [M+H] + )m / z:181.2.

[0561] Step B: Preparation of compound 1b

[0562] To a reaction flask, compound 1a (0.09 g), intermediate 1A (0.1 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.02 g), tripotassium phosphate (0.17 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After the addition, the mixture was stirred and heated at 90°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 1b (0.1 g).

[0563] MS (ESI, [M+H] + )m / z:478.2.

[0564] Step C: Preparation of compound 1c

[0565] To a reaction flask, compound 1b (0.1 g), tetrahydrofuran (5 mL), methanol (5 mL), and a solution of potassium hydroxide (0.7 g) dissolved in water (1.5 mL) were added sequentially. The mixture was stirred and heated at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidity (pH approximately 3) by adding 1 M hydrochloric acid. The solvent was removed by drying under reduced pressure to afford compound 1c (1.1 g), which was used directly in the next step.

[0566] MS (ESI, [M+H] + )m / z:464.1.

[0567] Step D: Preparation of Compound I-1

[0568] To the reaction flask, compound 1c (1.1 g), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (0.2 g), ammonium chloride (0.06 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.19 g) were added in sequence. After the addition, the reaction was carried out at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 5 / 1) to obtain compound I-1 (0.08 g).

[0569] HRMS (ESI, [M+H] + )m / z:463.20070.

[0570] 1H NMR(500MHz,DMSO-d6)δ8.65(dd,J=7.6,5.9Hz,1H),8.16(s,2H),7.89(s,1H),7.69–7.60(m,2H),7.55(d,J=2.7Hz,1H),7.38–7.27(m,1H), 7.09(d,J=4.7Hz,1H),7.02(td,J=7.6,2.7Hz,1H),6.98–6.87(m,2H),3.62(pd,J=6.5,3.8Hz,4H),3.14(qd,J=7.4,4.2Hz,4H),2.90(m,3H).

[0571] Example 2: Preparation of Compound I-2

[0572] Step A: Preparation of compound 2a

[0573] To a reaction flask, 2-methyl-4-pyridineboronic acid (0.06 g), intermediate 1A (0.15 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.03 g), tripotassium phosphate (0.17 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After addition, the mixture was stirred under nitrogen at 90°C. The reaction was monitored by TLC until completion, and the reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 2a (0.1 g).

[0574] MS (ESI, [M+H] + )m / z:435.18.

[0575] Step C: Preparation of compound 2b

[0576] To a reaction flask, compound 2a (0.1 g), tetrahydrofuran (5 mL), methanol (5 mL), and a solution of potassium hydroxide (0.7 g) dissolved in water (1.5 mL) were added sequentially. The mixture was stirred and heated at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidic pH (approximately 3) by adding 1 M hydrochloric acid. The solution was dried under reduced pressure and the solvent removed to afford compound 2b (1.0 g), which was used directly in the next step.

[0577] MS (ESI, [M+H] + )m / z:421.28.

[0578] Step D: Preparation of Compound I-2

[0579] To the reaction flask, compound 2b (1.0 g), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (0.2 g), ammonium chloride (0.06 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.19 g) were added in sequence. After the addition, the reaction was carried out at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 5 / 1) to obtain compound I-2 (0.07 g).

[0580] HRMS (ESI, [M+H] + )m / z:420.21460.

[0581] 1H NMR (500MHz, DMSO) δ11.30(s,1H),8.47(d,J=5.1Hz,1H),7.77(d,J=2.7Hz,1H),7.66–7.58(m,3H),7.53(dd,J=5.3,1.7Hz,1H),7.36 (d,J=2.8Hz,1H),7.19(q,J=4.5Hz,1H),6.97–6.91(m,2H),3.78–3.71(m,4H),3.10–3.04(m,4H),2.91(d,J=4.4Hz,3H),2.52(s,3H).

[0582] Example 3: Preparation of Compound I-3

[0583] Step A: Preparation of compound 3a

[0584] Pyrazole (10.0 g), 60 wt% sodium hydride (11 g), and N,N-dimethylformamide (120 mL) were added to the reaction flask. 1,1-bis-bromomethylcyclopropane (10.0 g) was slowly added at 0°C. After the addition, the mixture was reacted at room temperature and monitored by TLC until the reaction was complete. 1 M dilute hydrochloric acid was added to the reaction solution to adjust it to neutral (pH approximately 7). Ethyl acetate was added for extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 6 / 1) to obtain compound 3a (8.6 g).

[0585] MS (ESI, [M+H] + )m / z:215.1.

[0586] Step B: Preparation of compound 3b

[0587] To a reaction flask containing compound 3a (8.6 g) and tetrahydrofuran (100 mL) was slowly added dropwise a solution of lithium diisopropylamide in tetrahydrofuran (2 M, 41 mL) at -78°C. After the addition, the reaction was allowed to react at room temperature and monitored by TLC until the reaction was complete. Saturated aqueous ammonium chloride was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was separated, dried, filtered, and concentrated, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 9 / 1) to obtain compound 3b (2.6 g).

[0588] MS (ESI, [M+H] + )m / z:135.1.

[0589] Step C: Preparation of compound 3c

[0590] Under an ice-water bath, compound 3b (2.6 g), N-bromosuccinimide (4 g) and dichloromethane (40 mL) were added to the reaction flask. After the addition, the mixture was reacted at room temperature and monitored by TLC until the reaction was complete. Saturated aqueous ammonium chloride was added to the reaction solution to quench the reaction. The mixture was extracted with ethyl acetate, and the organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 9 / 1) to obtain compound 3c (2.5 g).

[0591] MS (ESI, [M+H] + )m / z:213.1.

[0592] Step D: Preparation of compound 3d

[0593] To a reaction flask containing compound 3c (0.2 g) and tetrahydrofuran (5 mL) was slowly added dropwise a solution of n-butyllithium in tetrahydrofuran (1.6 M, 1 mL) at -78°C. After addition, the mixture was allowed to react at -78°C for 1 h. Isopropyl pinacol borate (0.4 mL) was slowly added dropwise, and the reaction was continued at -78°C for 1 h. The reaction was then brought to room temperature. The reaction was monitored by TLC until completion. Saturated aqueous ammonium chloride was added to quench the reaction, and ethyl acetate was added for extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 9 / 1) to afford compound 3d (0.15 g).

[0594] MS (ESI, [M+H] + )m / z:260.98.

[0595] Step E: Preparation of compound 3e

[0596] To a reaction flask, compound 3d (0.09 g), intermediate 1A (0.12 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.03 g), tripotassium phosphate (0.15 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After addition, the mixture was stirred under nitrogen at 90°C. The reaction was monitored by TLC until completion, the reaction solution was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 3e (0.1 g).

[0597] MS (ESI, [M+H] + )m / z:476.09.

[0598] Step F: Preparation of compound 3f

[0599] To a reaction flask, compound 3e (0.1 g), tetrahydrofuran (5 mL), methanol (5 mL), and a solution of potassium hydroxide (0.7 g) dissolved in water (1.5 mL) were added sequentially. The mixture was stirred and heated at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidic pH (approximately 3) by adding 1 M hydrochloric acid. The solvent was removed by drying under reduced pressure to afford compound 3f (0.9 g), which was used directly in the next step.

[0600] MS (ESI, [M+H] + )m / z:462.25.

[0601] Step G: Preparation of compound I-3

[0602] To the reaction flask, compound 3f (0.9 g), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (0.2 g), ammonium chloride (0.06 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.19 g) were added in sequence. After the addition, the reaction was carried out at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 5 / 1) to obtain compound I-3 (0.06 g).

[0603] HRMS (ESI, [M+H] + )m / z:461.2413.

[0604] 1H NMR (500MHz, DMSO) δ11.12(s,1H),7.89(s,1H),7.63–7.57(m,2H),7.47(d,J=3.1Hz,1H),7.24(d,J=3.1Hz,1H),6.95–6.89(m,2H),6.7 6(q,J=4.5Hz,1H),4.07(s,2H),3.76–3.71(m,4H),3.07–3.03(m,4H),3.01(s,2H),2.92(d,J=4.6Hz,3H),0.82(dt,J=8.8,1.9Hz,4H).

[0605] Example 4: Preparation of Compound I-4

[0606] Step A: Preparation of compound 4a

[0607] To a reaction flask, intermediate 1A (0.12 g), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine (0.10 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.03 g), tripotassium phosphate (0.14 g), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After the addition was complete, the mixture was stirred and heated at 90°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 4a (0.12 g).

[0608] MS (ESI, [M+H] + )m / z:464.19.

[0609] Step B: Preparation of compound 4b

[0610] To a reaction flask, compound 4a (0.12 g), tetrahydrofuran (2 mL), methanol (2 mL), and a solution of potassium hydroxide (0.14 g) dissolved in water (1 mL) were added sequentially. The mixture was stirred and heated at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidity (pH approximately 3) by adding 1 M hydrochloric acid. The mixture was dried under reduced pressure and the solvent removed to afford compound 4b (0.25 g), which was used directly in the next step.

[0611] MS (ESI, [M+H] + )m / z:450.21.

[0612] Step C: Preparation of Compound I-4

[0613] To the reaction flask, compound 4b (0.25 g), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (0.19 g), ammonium chloride (0.05 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.19 g) were added in sequence. After the addition, the reaction was carried out at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound I-4 (0.06 g).

[0614] HRMS (ESI, [M+H] + )m / z:449.24053.

[0615] 1 H NMR(500MHz,DMSO-d6)δ11.13(s,1H),7.66(s,1H),7.63–7.57(m,2H),7.45(d,J= 3.1Hz,1H),7.22(d,J=3.2Hz,1H),6.95–6.89(m,2H),6.75(q,J=4.7Hz,1H),4.11 (t,J=6.1Hz,2H),3.78–3.68(m,4H),3.10–3.00(m,4H),2.90(d,J=4.6Hz,3H),2. 82(t,J=6.4Hz,2H), 1.99(tq,J=6.0,2.6Hz,2H), 1.80(tq,J=6.6,3.7,3.1Hz,2H).

[0616] Example 5: Preparation of Compound I-5

[0617] Step A: Preparation of compound 5a

[0618] To a reaction flask, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (102 mg), intermediate 1A (100 mg), 1,1-bis(diphenylphosphino)diboraneferronichloridopalladium (19.21 mg), cesium fluoride (80 mg), 1,4-dioxane (5 mL), and water (1 mL) were added sequentially. After the addition was complete, the mixture was stirred and heated at 110°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 5a (60 mg).

[0619] MS (ESI, [M+H] + )m / z:474.19.

[0620] Step B: Preparation of compound 5b

[0621] To a reaction flask, compound 5a (0.06 g), tetrahydrofuran (2 mL), methanol (2 mL), and a solution of potassium hydroxide (0.04 g) dissolved in water (0.3 mL) were added sequentially. The mixture was stirred and heated at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidic pH (approximately 3) by adding 1 M hydrochloric acid. The solvent was removed by drying under reduced pressure to afford compound 5b (0.2 g), which was used directly in the next step.

[0622] MS (ESI, [M+H] + )m / z:460.20.

[0623] Step C: Preparation of Compound I-5

[0624] To a reaction flask, compound 5b (0.2 g), N,N-dimethylformamide (2 mL), N,N-diisopropylethylamine (98 mg), ammonium chloride (27.1 mg), and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (96 mg) were added sequentially. The mixture was allowed to react at room temperature. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound I-5 (24.5 mg).

[0625] HRMS (ESI, [M+H] + )m / z:459.20.

[0626] 1 H NMR (500MHz, DMSO-d6) δ11.26(s,1H),8.34(d,J=4.9Hz,1H),7.76–7.63(m,2H),7.56(d,J=3.5Hz,1H),7.44(d,J=3.1Hz,1H),7.32(dd,J=11.6,4.1 Hz,2H),7.08–6.92(m,2H),6.85(q,J=4.7Hz,1H),6.42(d,J=3.5Hz,1H), 3.86(s,3H),3.83–3.69(m,4H),3.18–3.02(m,4H),2.89(d,J=4.7Hz,3H).

[0627] Example 6: Preparation of Compound I-6

[0628] Step A: Preparation of compound 6a

[0629] To a reaction flask, 7-bromothieno[3,2-B]pyridine (100 mg), pinacol diboron (356 mg), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (51 mg), potassium acetate (138 mg), and 1,4-dioxane (10 mL) were added sequentially. After addition, the mixture was stirred at 100°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 5 / 1) to obtain compound 6a (100 mg).

[0630] MS (ESI, [M+H] + )m / z:180.0.

[0631] Step B: Preparation of compound 6b

[0632] Compound 6a (100 mg), intermediate 1A (100 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (21 mg), tripotassium phosphate (112 mg), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially to a reaction flask. After the addition was complete, the reaction was stirred at 90°C under nitrogen. TLC was used to monitor the reaction until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 6b (62 mg).

[0633] MS (ESI, [M+H] + )m / z:477.2.

[0634] Step C: Preparation of compound 6c

[0635] To a reaction flask, compound 6b (62 mg), tetrahydrofuran (2 mL), methanol (2 mL), and a solution of potassium hydroxide (0.5 g) dissolved in water (1 mL) were added sequentially. The reaction was stirred at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidic pH (approximately 3) by adding 1 M hydrochloric acid. The solvent was removed by rotary evaporation under reduced pressure to yield compound 6c (0.3 g), which was used directly in the next reaction.

[0636] MS (ESI, [M+H] + )m / z:463.2.

[0637] Step D: Preparation of compound I-6

[0638] To the reaction flask, compound 6c (0.3 g), N,N-dimethylformamide (2 mL), N,N-diisopropylethylamine (0.1 g), ammonium chloride (0.03 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.09 g) were added in sequence. After the addition, the reaction was carried out at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 5 / 1) to obtain compound I-6 (25 mg).

[0639] HRMS (ESI, [M+H] + )m / z:462.1704.

[0640] 1 H NMR (500MHz, DMSO) δ11.30(s,1H),8.73(d,J=4.9Hz,1H),8.18(d,J=5.6Hz,1H),7.67(dd,J=17.2,6.9Hz,3H),7.61(d,J=5. 6Hz,2H),7.43(dd,J=10.1,3.6Hz,2H),6.96(d,J=9.0Hz,2H),3.79–3.71(m,4H),3.11–3.06(m,4H),2.94(d,J=4.5Hz,3H).

[0641] Example 7: Preparation of Compound I-7

[0642] Step A: Preparation of compound 7a

[0643] To a reaction flask, methyl 3-amino-5,6-dichloro-2-pyrazinecarboxylate (5.0 g), methanol (50.0 mL), N,N-diisopropylethylamine (29.1 g), and azetidine (6.43 g) were added sequentially. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was filtered, and the filter cake was washed and dried to obtain compound 7a (5.25 g).

[0644] MS (ESI, [M+H] + )m / z:243.1.

[0645] Step B: Preparation of compound 7b

[0646] To a reaction flask at 0°C, compound 7a (5.25 g), 28 wt% dilute sulfuric acid solution (40.0 mL), and water (40.0 mL) were added sequentially. A solution of sodium nitrite (2.3 g) dissolved in water (10.0 mL) was then added dropwise. After addition, the mixture was returned to room temperature with stirring. TLC was used to monitor the reaction until completion. The reaction mixture was filtered, and the filter cake was washed and dried to yield compound 7b (5.1 g).

[0647] MS (ESI, [M+H] + )m / z:244.1.

[0648] Step C: Preparation of compound 7c

[0649] Compound 7b (4.1 g), dichloromethane (26 mL), N,N-diisopropylethylamine (4.3 g), and trifluoromethanesulfonic anhydride (8.58 g) were added sequentially to a reaction flask at 0°C. The reaction was stirred at 0°C. TLC was used to monitor the reaction until completion. The solvent was removed by rotary evaporation to afford compound 7c (4.8 g), which was used directly in the next step without purification.

[0650] MS (ESI, [M+H] + m / z:376.1.

[0651] Step D: Preparation of compound 7d

[0652] Compound 7c (0.14 g), N,N-diisopropylethylamine (0.1 g), 1,4-dioxane (10 mL), and intermediate 6A-2 (0.1 g) were added sequentially to a reaction flask. After addition, the reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to afford compound 7d (0.09 g).

[0653] MS (ESI, [M+H] + )m / z:450.2.

[0654] Step E: Preparation of compound 7e

[0655] To a reaction flask, compound 7d (0.09 g), intermediate 3A (0.04 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.02 g), tripotassium phosphate (0.10 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 7e (57 mg).

[0656] MS (ESI, [M+H] + )m / z:547.4.

[0657] Step F: Preparation of compound I-7

[0658] Compound 7e (57 mg) and a 7M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-7 (30 mg).

[0659] HRMS (ESI, [M+H] + )m / z:532.2330.

[0660] 1 H NMR(500MHz,DMSO-d6)δ11.19(s,1H),8.98(s,1H),8.42(s,2H),7.64(d,J= 8.6Hz,2H),7.53(s,1H),7.30(s,1H),6.96(d,J=8.7Hz,2H),3.98(s,3H),3 .85–3.81(m,2H),3.59(t,2H),3.42–3.37(m,2H),2.09–1.94(m,2H),1.93– 1.83(m,2H),1.81–1.70(m,2H),1.51(d,J=13.0Hz,3H),1.28–1.21(m,2H).

[0661] Example 8: Preparation of Compound I-8

[0662] Step A: Preparation of compound 8a

[0663] To a reaction flask, intermediate 6A (90 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (60 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (18 mg), tripotassium phosphate (99 mg), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 8a (80 mg).

[0664] MS (ESI, [M+H] + )m / z:531.2.

[0665] Step B: Preparation of compound 8b

[0666] Compound 8a (80 mg), tetrahydrofuran (2 mL), methanol (2 mL), and a solution of potassium hydroxide (0.5 g) dissolved in water (1 mL) were added sequentially to a reaction flask. The reaction was stirred at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidic pH (approximately 3) by adding 1 M hydrochloric acid. The solvent was removed by rotary evaporation under reduced pressure to yield compound 8b (0.3 g), which was used directly in the next step.

[0667] MS (ESI, [M+H] + )m / z:517.3.

[0668] Step C: Preparation of Compound I-8

[0669] To the reaction flask, compound 8b (0.3 g), N,N-dimethylformamide (2 mL), N,N-diisopropylethylamine (0.1 g), ammonium chloride (0.03 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.09 g) were added in sequence. After the addition, the reaction was carried out at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 5 / 1) to obtain compound I-8 (20 mg).

[0670] HRMS (ESI, [M+H] + )m / z:516.2277.

[0671] 1 H NMR (500MHz, DMSO) δ11.08(s,1H),8.38(d,J=4.9Hz,1H),7.96(s,1H),7.86(d,J=1.8Hz,1H),7.59(d,J= 3.5Hz,1H),7.53(d,J=9.0Hz,2H),7.36(d,J=4.9Hz,1H),6.99(d,J=9.1Hz,2H),6.47(d,J=3.5Hz,1H),3 .94–3.82(m,5H),3.41(dt,J=14.0,7.1Hz,2H),2.08–1.99(m,1H),1.88(d,J=14.4Hz,2H),1.76(ddd,J= 21.2, 12.9, 8.5Hz, 2H), 1.52 (d, J=13.0Hz, 3H), 1.16 (dt, J=7.3, 3.6Hz, 2H), 1.01 (td, J=6.5, 3.3Hz, 2H).

[0672] Example 9: Preparation of Compound I-9

[0673] Step A: Preparation of compound 9a

[0674] To a reaction flask, intermediate 4A (100 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (96 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (19 mg), tripotassium phosphate (105 mg), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen. The reaction was monitored by TLC until completion, the reaction solution was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 9a (140 mg).

[0675] MS (ESI, [M+H] + )m / z:500.2.

[0676] Step B: Preparation of compound 9b

[0677] Compound 9a (80 mg), tetrahydrofuran (2 mL), methanol (2 mL), and a solution of potassium hydroxide (80 mg) dissolved in water (1 mL) were added sequentially to a reaction flask. The reaction was stirred at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidic pH (approximately 3) by adding 1 M hydrochloric acid. The solvent was removed by rotary evaporation under reduced pressure to yield compound 9b (0.3 g), which was used directly in the next step.

[0678] MS (ESI, [M+H] + )m / z:487.3.

[0679] Step C: Preparation of Compound I-9

[0680] To the reaction flask, compound 9b (0.3 g), N,N-dimethylformamide (2 mL), N,N-diisopropylethylamine (159 mg), ammonium chloride (44 mg) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (156 mg) were added in sequence. After the addition, the reaction was carried out at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 5 / 1) to obtain compound I-9 (20 mg).

[0681] HRMS (ESI, [M+H] + )m / z:486.1987.

[0682] 1H NMR (500MHz, DMSO) δ11.11(s,1H),8.47(s,1H),8.32(d,J=4.9Hz,1H),7.55(d,J =3.5Hz,1H),7.49(s,1H),7.37(d,J=1.8Hz,1H),7.31(d,J=4.9Hz,1H),6.93(d,J =2.7Hz,1H),6.34(d,J=3.4Hz,1H),5.07(q,J=9.2Hz,2H),3.86(s,3H),2.86(dt ,J=6.8,3.2Hz,1H),2.24(d,J=8.5Hz,3H),0.83–0.77(m,2H),0.60–0.54(m,2H).

[0683] Example 10: Preparation of Compound I-10

[0684] Step A: Preparation of compound 10a

[0685] To a reaction flask, intermediate 6A (120 mg), intermediate 3A (115 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (22 mg), tripotassium phosphate (118 mg), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 10a (105 mg).

[0686] MS (ESI, [M+H] + )m / z:532.3.

[0687] Step B: Preparation of compound I-10

[0688] Compound 10a (105 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-10 (25 mg).

[0689] HRMS (ESI, [M+H] + )m / z:517.2234.

[0690] 1H NMR (500MHz, DMSO) δ11.08(s,1H),9.07(d,J=4.5Hz,1H),8.56(d,J=3.1Hz,1H),8.48(d, J=4.9Hz,1H),8.07(s,1H),7.80(s,1H),7.54(d,J=9.1Hz,2H),6.99(d,J=9.1Hz,2H),4.0 1(s,3H),3.92–3.81(m,2H),3.44(dd,J=18.2,6.6Hz,2H),1.95–1.83(m,3H),1.76(dd,J= 10.6,4.4Hz,2H),1.51(d,J=13.0Hz,3H),1.11–1.05(m,2H),0.91(dd,J=7.8,3.2Hz,2H).

[0691] Example 11: Preparation of Compound I-11

[0692] Step A: Preparation of compound 11a

[0693] To a reaction flask, intermediate 3A (0.20 g), intermediate 4A (0.11 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.21 g), 1,4-dioxane (12 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion, and the reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 11a (0.16 g).

[0694] MS (ESI, [M+H] + )m / z:502.4.

[0695] Step B: Preparation of compound 11b

[0696] To a reaction flask, compound 11a (0.08 g), tetrahydrofuran (2 mL), methanol (1 mL), and a solution of potassium hydroxide (0.08 g) dissolved in water (1 mL) were added sequentially. The reaction was stirred at 50°C. TLC was monitored until the reaction was complete. The mixture was cooled to room temperature and adjusted to acidic pH (approximately 3) by adding 1N hydrochloric acid. The solvent was then removed by concentration under reduced pressure to afford compound 11b (0.13 g), which was used directly in the next step without purification.

[0697] MS (ESI, [M+H] + )m / z:488.2.

[0698] Step C: Preparation of Compound I-11

[0699] To the reaction flask, compound 11b (0.13 g), N,N-dimethylformamide (3 mL), N,N-diisopropylethylamine (0.11 g), ammonium chloride (0.03 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.10 g) were added in sequence. After the addition, the reaction was stirred at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound I-11 (0.03 g).

[0700] HRMS (ESI, [M+H] + )m / z:487.1936.

[0701] 1 H NMR(500MHz,DMSO-d6)δ11.16(s,1H),9.00(s,1H),8.83(s,1H),8.80(d,J=2.7Hz,1H),8.56(s,1H),8.47(s,1H),7.87–7.78(m,1H),7 .43–7.33(m,1H),5.07(q,J=9.2Hz,2H),4.01(s,3H),2.97(tq,J=6.9,3.6Hz,1H),2.26(s,3H),0.87–0.84(m,2H),0.54–0.47(m,2H).

[0702] Example 12: Preparation of Compound I-12

[0703] Step A: Preparation of compound 12a

[0704] To a reaction flask, 4-(dimethylphosphinoyl)aniline (150 mg), intermediate 2A-2 (225 mg), 1,4-dioxane (10 mL), and N,N-diisopropylethylamine (230 mg) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 12a (80 mg).

[0705] MS (ESI, [M+H] + )m / z:380.2.

[0706] Step B: Preparation of compound 12b

[0707] To a reaction flask, compound 12a (80 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (82 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (17 mg), tripotassium phosphate (90 mg), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 12b (60 mg).

[0708] MS (ESI, [M+H] + )m / z:476.3.

[0709] Step C: Preparation of Compound I-12

[0710] Compound 12b (60 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-12 (15 mg).

[0711] HRMS (ESI, [M+H] + )m / z:461.1860.

[0712] 1 H NMR (500MHz, DMSO) δ11.59(s,1H),8.41(d,J=4.9Hz,1H),8.09(s,1H),7.99(s,1H),7.82(dd,J=8.6,2.1Hz,2H),7.78–7.73(m,2H),7.61(d,J=3.5Hz ,1H),7.39(d,J=4.8Hz,1H),6.48(d,J=3.5Hz,1H),3.88(s,3H),3.25(d,J =9.3Hz, 1H), 2.04 (ddd, J = 22.2, 11.9, 5.9Hz, 4H), 1.64 (d, J = 13.3Hz, 6H).

[0713] Example 13: Preparation of Compound I-13

[0714] Step A: Preparation of compound 13a

[0715] To the reaction flask, add Intermediate 1A-3 (0.4 g), N,N-diisopropylethylamine (0.3 g), and Intermediate 7A (0.3 g) in sequence. After addition, stir the reaction at 100°C. Monitor the reaction by TLC until completion. The reaction solution is concentrated, and the residue is purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain Compound 13a (0.44 g).

[0716] MS (ESI, [M+H] + )m / z:403.4.

[0717] Step B: Preparation of compound 13b

[0718] To a reaction flask, compound 13a (0.24 g), intermediate 3A (0.2 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.34 g), 1,4-dioxane (6 mL), and water (0.5 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 13b (0.2 g).

[0719] MS (ESI, [M+H] + )m / z:500.3.

[0720] Step C: Preparation of Compound I-13

[0721] Compound 13b (0.20 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. The mixture was stirred at 90°C until completion of the reaction, monitored by TLC. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-13 (0.11 g).

[0722] HRMS (ESI, [M+H] + )m / z:485.2525.

[0723] 1H NMR (500MHz, CDCl3) δ10.79(s,1H),8.90(s,1H),8.83(s,1H),8.02(d,J=3.8Hz,2H),7.57(d,J=2 .1Hz,1H),7.55(s,1H),7.52(dd,J=8.3,2.2Hz,1H),6.43(d,J=8.4Hz,1H),5.23(s,1H),4.01(s, 3H),3.65–3.52(m,2H),3.12–2.97(m,2H),2.84–2.78(m,1H),2.75(ddd,J=12.6,3.2,1.6Hz,1H) ,2.59(dd,J=14.9,7.8Hz,1H),2.32(s,3H),2.20(td,J=11.5,3.3Hz,1H),2.11(t,J=10.7Hz,1H).

[0724] Example 14: Preparation of Compound I-14

[0725] Step A: Preparation of compound 14a

[0726] Compound 1A-3 (0.10 g), 3-amino-6-morpholinylpyridine (0.06 g), N,N-diisopropylethylamine (0.11 g), and 1,4-dioxane (5 mL) were added sequentially to a reaction flask and stirred at 100°C. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to afford compound 14a (0.10 g).

[0727] MS (ESI, [M+H] + )m / z:379.2.

[0728] Step B: Preparation of compound 14b

[0729] To a reaction flask, compound 14a (0.10 g), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1H-pyrrolo[2,3-b]pyridine (0.09 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.02 g), tripotassium phosphate (0.12 g), 1,4-dioxane (8 mL), and water (1 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion, and the reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 14b (0.11 g).

[0730] MS (ESI, [M+H] + )m / z:475.2.

[0731] Step C: Preparation of compound 14c

[0732] To a reaction flask, compound 14b (0.11 g), tetrahydrofuran (2 mL), methanol (1 mL), and a solution of potassium hydroxide (0.13 g) dissolved in water (1 mL) were added sequentially. The reaction was stirred at 50°C. TLC was used to monitor the reaction until complete. The temperature was then cooled to room temperature and adjusted to acidic (pH approximately 3) by adding 1N hydrochloric acid. The solvent was then removed by rotary evaporation under reduced pressure to yield compound 14c (0.23 g), which was used directly in the next step.

[0733] MS (ESI, [M+H] + )m / z:461.2.

[0734] Step D: Preparation of Compound I-14

[0735] To the reaction flask, compound 14c (0.23 g), N,N-dimethylformamide (3 mL), N,N-diisopropylethylamine (0.18 g), ammonium chloride (0.05 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.17 g) were added in sequence. After the addition, the reaction was stirred at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound I-14 (0.06 g).

[0736] HRMS (ESI, [M+H] + )m / z:460.2203.

[0737] 1 H NMR(500MHz,DMSO-d6)δ11.13(s,1H),8.54(d,J=2.7Hz,1H),8.34(d,J=4.9Hz, 1H),8.01(dd,J=9.1,2.8Hz,1H),7.56(d,J=3.5Hz,1H),7.44(d,J=3.0Hz,1H),7 .35(d,J=3.1Hz,1H),7.30(d,J=4.8Hz,1H),6.92–6.84(m,2H),6.41(d,J=3.4Hz ,1H),3.86(s,3H),3.75–3.68(m,4H),3.43–3.37(m,4H),2.85(d,J=4.5Hz,3H).

[0738] Example 15: Preparation of Compound I-15

[0739] Step A: Preparation of compound 15a

[0740] To a reaction flask, 2-fluoro-5-nitropyridine (0.50 g), 2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride (0.57 g), potassium carbonate (1.22 g), and N,N-dimethylformamide (10 mL) were added sequentially, and the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. Water and ethyl acetate were added to the reaction solution, and the mixture was extracted. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain compound 15a (0.67 g).

[0741] MS (ESI, [M+H] + )m / z:222.1.

[0742] Step B: Preparation of compound 15b

[0743] Compound 15a (0.12 g), methanol (10 mL), and 10% palladium hydroxide (0.12 g) were added sequentially to a reaction flask. After addition, the atmosphere was replaced with hydrogen, and the mixture was stirred at room temperature under a hydrogen atmosphere. The reaction was monitored by TLC until completion, filtered, and concentrated to afford compound 15b (0.42 g).

[0744] MS (ESI, [M+H] + )m / z:192.1.

[0745] Step C: Preparation of compound 15c

[0746] To a reaction flask, compound 1A-3 (0.11 g), compound 15b (0.07 g), N,N-diisopropylethylamine (0.12 g), and 1,4-dioxane (5 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain compound 15c (0.09 g).

[0747] MS (ESI, [M+H] + )m / z:391.3.

[0748] Step D: Preparation of compound 15d

[0749] To a reaction flask, compound 15c (0.09 g), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1H-pyrrolo[2,3-b]pyridine (0.07 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.02 g), tripotassium phosphate (0.10 g), 1,4-dioxane (8 mL), and water (1 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion, and the reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 15d (0.09 g).

[0750] MS (ESI, [M+H] + )m / z:487.3.

[0751] Step E: Preparation of compound 15e

[0752] To a reaction flask, compound 15d (0.09 g), tetrahydrofuran (2 mL), methanol (1 mL), and a solution of potassium hydroxide (0.10 g) dissolved in water (1 mL) were added sequentially. The reaction was stirred at 50°C. TLC was used to monitor the reaction until complete. The temperature was then cooled to room temperature and adjusted to acidic (pH approximately 3) by adding 1N hydrochloric acid. The solvent was then removed by rotary evaporation under reduced pressure to afford compound 15e (0.23 g), which was used directly in the next step.

[0753] MS (ESI, [M+H] + )m / z:473.3.

[0754] Step F: Preparation of compound I-15

[0755] To a reaction flask, compound 15e (0.23 g), N,N-dimethylformamide (3 mL), N,N-diisopropylethylamine (0.14 g), ammonium chloride (0.04 g), and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.14 g) were added sequentially. After the addition, the reaction was stirred at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound I-15 (0.05 g).

[0756] HRMS (ESI, [M+H] + )m / z:472.2280.

[0757] 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.44(d,J=2.7Hz,1H),8.34(d,J=4.9Hz,1H),7.96(dd,J=9.0,2.7Hz,1H),7.5 6(d,J=3.5Hz,1H),7.43(d,J=3.1Hz,1H),7.32(dd,J=14.7,4.0Hz,2H),6.85(q,J=4.5Hz,1H),6.58(d,J=8.9Hz,1H), 6.41(d,J=3.5Hz,1H),4.82–4.77(m,1H),4.66–4.60(m,1H),3.86(s,3H),3.77(dd,J=7.4,1.6Hz,1H),3.66(d,J=7.3 Hz,1H),3.46(dd,J=9.9,1.6Hz,1H),3.26–3.20(m,1H),2.85(d,J=4.6Hz,3H),1.92–1.90(m,1H),1.85–1.82(m,1H).

[0758] Example 16: Preparation of Compound I-16

[0759] Step A: Preparation of compound 16a

[0760] To a reaction flask, 3-bromo-6-fluoropyrazolo[1,5-a]pyridine (0.20 g), neopentyl glycol diboron (0.42 g), bistriphenylphosphine palladium dichloride (0.07 g), potassium acetate (0.27 g), and 1,4-dioxane (10 mL) were added sequentially. After addition, the mixture was stirred at 120°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered to obtain compound 16a, which was used directly in the next step without purification.

[0761] MS (ESI, [M+H] + )m / z:181.0.

[0762] Step B: Preparation of compound 16b

[0763] To a reaction flask, intermediate 6A (0.12 g), compound 16a (0.06 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.02 g), tripotassium phosphate (0.12 g), 1,4-dioxane (8 mL), and water (1 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion, and the reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 16b (0.11 g).

[0764] MS (ESI, [M+H] + )m / z:535.2.

[0765] Step C: Preparation of Compound I-16

[0766] Compound 16b (0.11 g) and a methanol solution of ammonia (7 M, 10 mL) (1.19 g) were added to the reaction flask in sequence. After the addition, the reaction was stirred at 60°C and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound I-16 (0.04 g).

[0767] HRMS (ESI, [M+H] + )m / z:520.2023.

[0768] 1 H NMR(500MHz,DMSO-d6)δ10.97(s,1H),9.10(dd,J=4.9,2.2Hz,1H),8.44(s,1H ),8.02–7.93(m,2H),7.86(s,1H),7.54–7.42(m,3H),6.97(d,J=9.0Hz,2H),3 .87(t,J=18.7Hz,2H),3.48–3.38(m,2H),2.30–2.25(m,1H),1.87(s,2H),1.8 2–1.70(m,2H),1.51(d,J=13.0Hz,3H),1.18–1.15(m,2H),1.13–1.10(m,2H).

[0769] Example 17: Preparation of Compound I-17

[0770] Step A: Preparation of compound 17a

[0771] To a reaction flask, intermediate 5A (50 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (13.54 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (22.33 mg), tripotassium phosphate (121 mg), intermediate 6A (148 mg), 1,4-dioxane (5 mL), and water (1 mL) were added sequentially. After addition, the mixture was stirred at 85°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 17a (120 mg).

[0772] MS (ESI, [M+H] + )m / z:531.38.

[0773] Step B: Preparation of Compound I-17

[0774] To the reaction flask, compound 17a (0.12 g) and ammonia methanol solution (7 M, 20 mL) were added in sequence. After the addition, the reaction was stirred at 60°C and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-17 (80 mg).

[0775] HRMS (ESI, [M+H] + )m / z:516.2284.

[0776] 1 H NMR(500MHz,DMSO-d6)δ11.04(s,1H),8.90(s,1H),8.37(s,1H),7.97(s,1H),7.81(s ,1H),7.63(d,J=3.0Hz,1H),7.58–7.49(m,2H),7.06–6.93(m,2H),6.53–6.42(m,1H) ,3.97(s,3H),3.94–3.80(m,2H),3.48–3.38(m,2H),1.99–1.92(m,1H),1.87(s,2H), 1.81–1.71(m,2H),1.52(d,J=13.0Hz,3H),1.15(p,J=3.7Hz,2H),1.00–0.94(m,2H).

[0777] Example 18: Preparation of Compound I-18

[0778] Step A: Preparation of compound 18a

[0779] Compound 2A-2 (2.0 g), N,N-diisopropylethylamine (2.8 g), N,N-dimethylformamide (10 mL), and 4-amino-1-methylpyridine-ethanone (1.7 g) were added sequentially to a reaction flask. After the addition, the reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 18a (2.4 g).

[0780] MS (ESI, [M+H] + )m / z:335.1.

[0781] Step B: Preparation of compound 18b

[0782] To a reaction flask were added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (100 mg), compound 18a (90 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (21.2 mg), potassium phosphate (171 mg), 1,4-dioxane (20 mL), and water (4 mL) in sequence. After the addition was complete, the reaction was stirred at 100°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 18b (80 mg).

[0783] MS (ESI, [M+H] + )m / z:431.2.

[0784] Step C: Preparation of Compound I-18

[0785] Compound 18b (80 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-18 (40 mg).

[0786] HRMS (ESI, [M+H] + )m / z:416.1831.

[0787] 1H NMR(500MHz,DMSO-d6)δ11.48(s,1H),8.41(d,J=4.8Hz,1H),8.20–8.09(m,1H) ,8.04(s,1H),7.69–7.52(m,2H),7.38(d,J=4.7Hz,1H),7.02(d,J=2.4Hz,1H),6 .46(d,J=3.4Hz,1H),6.24(dd,J=7.4,2.5Hz,1H),3.88(s,3H),3.36(s,3H),2.0 5(ddd,J=12.7,8.1,4.6Hz,1H),1.25–1.15(m,2H),1.09(dt,J=8.2,3.3Hz,2H).

[0788] Example 19: Preparation of Compound I-19

[0789] Step A: Preparation of compound 19a

[0790] To a reaction flask, 4-methyl-1,4-azaphosphane 4-oxide (200 mg), 2,3,4,5-tetrafluoronitrobenzene (322 mg), N,N-diisopropylethylamine (200 mg), and dimethyl sulfoxide (10 mL) were added sequentially. After addition, the mixture was stirred at room temperature. TLC was used to monitor the reaction until completion. The reaction solution was poured into water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 19a (0.38 g).

[0791] MS (ESI, [M+H] + )m / z:309.0.

[0792] Step B: Preparation of compound 19b

[0793] Compound 19a (0.38 g), methanol (5 mL), and 10% palladium on carbon (0.19 g) were added to the reaction flask in sequence. After addition, the mixture was replaced with hydrogen and then stirred at room temperature under a hydrogen atmosphere. TLC was monitored until the reaction was complete, the palladium on carbon was removed by filtration, and the mixture was concentrated under reduced pressure to give compound 19b (0.32 g).

[0794] MS (ESI, [M+H] + )m / z:279.1.

[0795] Step C: Preparation of compound 19c

[0796] To a reaction flask, compound 19b (0.32 g), intermediate 2A-2 (0.38 g), 1,4-dioxane (10 mL), and N,N-diisopropylethylamine (0.40 g) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 19c (150 mg).

[0797] MS (ESI, [M+H] + )m / z:489.2.

[0798] Step D: Preparation of compound 19d

[0799] To a reaction flask, compound 19c (150 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (120 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (24 mg), tripotassium phosphate (130 mg), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 19d (120 mg).

[0800] MS (ESI, [M+H] + )m / z:585.3.

[0801] Step E: Preparation of Compound I-19

[0802] Compound 19d (120 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound I-19 (60 mg).

[0803] HRMS (ESI, [M+H] + )m / z:570.2000.

[0804] 1H NMR (500MHz, DMSO) δ11.73(s,1H),8.41(d,J=4.8Hz,1H),8.13(dd,J=14.4,7.1Hz,2H),8.02(s,1H),7 .62(d,J=3.5Hz,1H),7.38(d,J=4.8Hz,1H),6.46(d,J=3.5Hz,1H),3.88(s,3H),3.46(td,J=15.0,7.2 Hz,2H),3.28(dd,J=14.4,6.4Hz,2H),2.05(ddd,J=12.7,8.0,4.6Hz,1H),1.98(dt,J=10.0,8.8Hz,2H ),1.93–1.84(m,2H),1.52(d,J=13.1Hz,3H),1.16(dd,J=7.1,2.9Hz,2H),1.09(dt,J=7.9,3.1Hz,2H).

[0805] Example 20: Preparation of Compound I-20

[0806] Step A: Preparation of compound 20a

[0807] To a reaction flask, dimethylphosphine oxide (0.35 g), 3,5-dimethyl-4-iodoaniline (1.0 g), tris(dibenzylideneacetone)dipalladium (0.37 g), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.47 g), tripotassium phosphate (1.30 g), and 1,4-dioxane (10 mL) were added sequentially. After addition, the mixture was stirred at 110°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 20a (0.30 g).

[0808] MS (ESI, [M+H] + )m / z:198.2.

[0809] Step B: Preparation of compound 20b

[0810] Compound 20a (0.30 g), intermediate 2A-2 (0.35 g), 1,4-dioxane (10 mL), and N,N-diisopropylethylamine (0.40 g) were added sequentially to a reaction flask. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 20b (0.23 g).

[0811] MS (ESI, [M+H] + )m / z:408.3.

[0812] Step C: Preparation of compound 20c

[0813] To a reaction flask, compound 20b (220 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (210 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (42 mg), tripotassium phosphate (230 mg), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 20c (130 mg).

[0814] MS (ESI, [M+H] + )m / z:504.4.

[0815] Step D: Preparation of compound I-20

[0816] Compound 20c (130 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound I-20 (50 mg).

[0817] HRMS (ESI, [M+H] + )m / z:489.2174.

[0818] 1 H NMR(500MHz,DMSO)δ11.41(s,1H),8.40(d,J=4.9Hz,1H),8.07(s,1H),7.98(d ,J=1.4Hz,1H),7.61(d,J=3.5Hz,1H),7.49(d,J=2.6Hz,2H),7.39(d,J=4.8Hz, 1H),6.48(d,J=3.5Hz,1H),3.88(s,3H),2.57(s,6H),2.05(td,J=8.0,4.1Hz,1 H), 1.77 (d, J = 12.9Hz, 6H), 1.23 (d, J = 2.9Hz, 2H), 1.09 (dd, J = 7.9, 3.2Hz, 2H).

[0819] Example 21: Preparation of Compound I-21

[0820] Step A: Preparation of compound 21a

[0821] To the reaction flask, methyl 3-amino-5,6-dichloropyrazine-2-carboxylate (5.0 g), 2,2,2-trifluoroethylamine (11.15 g) and methanol (50 mL) were added. The mixture was stirred at 60°C and monitored by TLC until the reaction was complete. The reaction solution was filtered and the filter cake was washed and dried to obtain compound 21a (4.5 g).

[0822] MS (ESI, [M+H] + )m / z:285.2.

[0823] Step B: Preparation of compound 21b

[0824] To a reaction flask at 0°C, compound 21a (1.2 g), 28 wt% dilute sulfuric acid solution (12.0 mL), and water (12.0 mL) were added sequentially. A solution of sodium nitrite (0.35 g) dissolved in water (2.0 mL) was then added dropwise. After addition, the mixture was returned to room temperature with stirring. TLC was used to monitor the reaction until completion. The reaction mixture was filtered, and the filter cake was washed and dried to yield intermediate 21b (0.6 g).

[0825] MS (ESI, [M+H] - )m / z:286.0.

[0826] Step C: Preparation of compound 21c

[0827] Compound 21b (0.22 g), dichloromethane (6 mL), N,N-diisopropylethylamine (0.2 g), and trifluoromethanesulfonic anhydride (0.4 g) were added sequentially to a reaction flask at 0°C. The reaction was stirred at 0°C. TLC was used to monitor the reaction until completion. The solvent was removed under reduced pressure to afford compound 21c (0.2 g), which was used directly in the next step without purification.

[0828] MS (ESI, [M+H] - )m / z:418.0.

[0829] Step D: Preparation of compound 21d

[0830] Compound 21c (0.15 g), N,N-diisopropylethylamine (0.18 g), 1,4-dioxane (10 mL), and intermediate 6A-2 (0.1 g) were added sequentially to a reaction flask. After addition, the reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to obtain compound 21d (0.17 g).

[0831] MS (ESI, [M+H]+ )m / z:492.2.

[0832] Step E: Preparation of compound 21e

[0833] To a reaction flask, compound 21d (0.17 g), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (0.12 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.03 g), tripotassium phosphate (0.15 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After the addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 21e (0.19 g).

[0834] MS (ESI, [M+H] + )m / z:588.3.

[0835] Step F: Preparation of compound 21f

[0836] To a reaction flask, compound 21e (0.19 g), tetrahydrofuran (5 mL), methanol (5 mL), and a solution of potassium hydroxide (0.18 g) dissolved in water (2 mL) were added sequentially. The reaction was stirred at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidic pH (approximately 3) by adding 1 M hydrochloric acid. The solvent was removed by rotary evaporation under reduced pressure to yield compound 21f (0.18 g), which was used directly in the next step.

[0837] MS (ESI, [M+H] + )m / z:574.2.

[0838] Step G: Preparation of compound I-21

[0839] To a reaction flask, compound 21f (0.18 g), N,N-dimethylformamide (3 mL), N,N-diisopropylethylamine (250 mg), ammonium chloride (70 mg), and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (240 mg) were added sequentially. The reaction was stirred at room temperature. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound I-21 (60 mg).

[0840] HRMS (ESI, [M+H] + )m / z:573.2111.

[0841] 1 H NMR(500MHz,DMSO-d6)δ11.18(s,1H),8.38(d,J=4.9Hz,1H),7.59(d,J=3.5Hz,2H), 7.55–7.50(m,2H),7.47(d,J=2.8Hz,1H),7.31(d,J=4.9Hz,1H),7.28–7.20(m,1H), 6.99–6.91(m,2H),6.37(d,J=3.5Hz,1H),4.21–4.06(m,2H),3.87(s,3H),3.49–3.3 9(m,2H),2.07(s,2H),1.93–1.83(m,2H),1.83–1.71(m,2H),1.51(d,J=12.9Hz,3H).

[0842] Example 22: Preparation of Compound I-22

[0843] Step A: Preparation of compound 22a

[0844] To a reaction flask, 2,6-diazaspiro[3,4]octan-7-one hydrochloride (0.3 g), p-nitrofluorobenzene (0.35 g), potassium carbonate (0.74 g), and N,N-dimethylformamide (10 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 22a (0.45 g).

[0845] MS (ESI, [M+H] + )m / z:248.2.

[0846] Step B: Preparation of compound 22b

[0847] To a reaction flask at 0°C, compound 22a (0.45 g) and tetrahydrofuran (10 mL) were added sequentially, followed by 60 wt% sodium hydride (0.44 g) in portions. After stirring for 30 min, iodomethane (0.78 g) was added dropwise. After the addition was complete, the mixture was allowed to stir at room temperature. TLC was used to monitor the reaction until completion. The reaction solution was quenched by pouring into water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 22b (0.46 g).

[0848] MS (ESI, [M+H] + )m / z:262.2.

[0849] Step C: Preparation of compound 22c

[0850] Compound 22b (0.46 g), methanol (5 mL), and 10% palladium on carbon (0.19 g) were added sequentially to a reaction flask. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. TLC was used to monitor the reaction until completion. The palladium on carbon was removed by filtration and the mixture was concentrated under reduced pressure to afford compound 22c (0.40 g).

[0851] MS (ESI, [M+H] + )m / z:232.2.

[0852] Step D: Preparation of compound 22d

[0853] To a reaction flask, compound 22c (0.40 g), intermediate 2A-2 (0.44 g), 1,4-dioxane (10 mL), and N,N-diisopropylethylamine (0.67 g) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 22d (0.45 g).

[0854] MS (ESI, [M+H] + )m / z:442.3.

[0855] Step E: Preparation of compound 22e

[0856] To a reaction flask, compound 22d (0.2 g), intermediate 3A (0.12 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.20 g), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 22e (155 mg).

[0857] MS (ESI, [M+H] + )m / z:539.4.

[0858] Step F: Preparation of Compound I-22

[0859] Compound 22e (150 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound I-22 (70 mg).

[0860] HRMS (ESI, [M+H] + )m / z:524.2521.

[0861] 1 H NMR(500MHz,DMSO)δ10.97(s,1H),9.04(s,1H),8.53(s,1H),8.44(s,1H),8. 04(d,J=1.7Hz,1H),7.78(d,J=1.8Hz,1H),7.47(d,J=8.8Hz,2H),6.48(d,J=8 .8Hz,2H),3.99(s,3H),3.79(q,J=7.1Hz,4H),3.60(s,2H),2.74(s,3H),2.5 9(s,2H),1.89(dt,J=12.0,3.7Hz,1H),1.07–0.99(m,2H),0.93–0.83(m,2H).

[0862] Example 23: Preparation of Compound I-23

[0863] Step A: Preparation of compound 23a

[0864] To a reaction flask, 4-(diethylphosphino)aniline (0.20 g), intermediate 2A-2 (0.26 g), 1,4-dioxane (10 mL), and N,N-diisopropylethylamine (0.39 g) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 23a (0.21 g).

[0865] MS (ESI, [M+H] + )m / z:408.3.

[0866] Step B: Preparation of compound 23b

[0867] To a reaction flask, compound 23a (0.20 g), compound 16a (0.13 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.20 g), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 23b (170 mg).

[0868] MS (ESI, [M+H]+ )m / z:508.3.

[0869] Step C: Preparation of Compound I-23

[0870] Compound 23b (170 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-23 (50 mg).

[0871] HRMS (ESI, [M+H] + )m / z:493.1927.

[0872] 1 H NMR (500MHz, DMSO) δ11.49(s,1H),9.12(dd,J=4.6,1.8Hz,1H),8.50(s,1H),8.11(s,1H),8.00(dd,J=9.7,5.8Hz,2H),7.80(dd,J=8.6,1.8H z,2H),7.68(dd,J=9.9,8.7Hz,2H),7.49(d,J=1.8Hz,1H),2.34(s,1H),2.00–1.80(m,4H),1.30–1.12(m,4H),0.95(dt,J=16.4,7.6Hz,6H).

[0873] Example 24: Preparation of Compound I-24

[0874] Step A: Preparation of compound 24a

[0875] Compound 2A-2 (2.0 g), N,N-diisopropylethylamine (2.8 g), N,N-dimethylformamide (10 mL), and 4'-amino-N-methylacetanilide (2.2 g) were added sequentially to a reaction flask. After the addition, the reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 24a (2.5 g).

[0876] MS (ESI, [M+H] + )m / z:375.1.

[0877] Step B: Preparation of compound 24b

[0878] Compound 1a (70 mg), compound 24a (100 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (20.0 mg), potassium phosphate (170 mg), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially to a reaction flask. After the addition was complete, the reaction was stirred at 100°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 24b (85 mg).

[0879] MS (ESI, [M+H] + )m / z:475.3.

[0880] Step C: Preparation of Compound I-24

[0881] Compound 24b (85 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-24 (54 mg).

[0882] HRMS (ESI, [M+H] + )m / z:460.1886.

[0883] 1 H NMR (500MHz, DMSO-d6) δ11.34(s,1H),9.11(dd,J=4.9,2.2Hz,1H),8.48(s,1H),8.08(s,1H),8.04–7.92(m,2H),7.71(d,J=8.3Hz,2H),7. 48(ddd,J=10.2,8.2,2.2Hz,1H),7.30(d,J=8.3Hz,2H),3.14(s,3H),2.36–2.27(m,1H),1.79(s,3H),1.18(ddt,J=19.2,5.6,3.9Hz,4H).

[0884] Example 25: Preparation of Compound I-25

[0885] Step A: Preparation of compound 25a

[0886] To a reaction flask, intermediate 2A-2 (2.0 g), N,N-diisopropylethylamine (2.8 g), N,N-dimethylformamide (10 mL), and 1-Boc-4-(4-aminophenyl)piperazine (3.7 g) were added sequentially. After the addition, the reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 25a (3.3 g).

[0887] MS (ESI, [M+H] + )m / z:488.2.

[0888] Step B: Preparation of compound 25b

[0889] To a reaction flask were added intermediate 3A (218 mg), compound 25a (500 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (80.1 mg), potassium phosphate (650 mg), 1,4-dioxane (40 mL), and water (8 mL) in sequence. After the addition was complete, the reaction was stirred at 100°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 25b (416 mg).

[0890] MS (ESI, [M+H] + )m / z:585.2.

[0891] Step C: Preparation of compound 25c

[0892] Compound 25b (416 mg), dichloromethane (2.0 mL), and 1,4-dioxane hydrochloride solution (10.00 mL, 4 M) were added sequentially to a reaction flask. After addition, the reaction was stirred at room temperature. TLC was used to monitor the reaction until completion. Saturated sodium bicarbonate solution was added to adjust the pH to approximately 10, followed by extraction with dichloromethane and concentration. Purification by column chromatography (dichloromethane ether / methanol = 20 / 1) afforded compound 25c (330 mg).

[0893] MS (ESI, [M+H] + )m / z:485.3.

[0894] Step D: Preparation of compound 25d

[0895] Compound 25c (330 mg) and a 7 M methanolic ammonia solution (20 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 25d (300 mg).

[0896] MS (ESI, [M+H] + )m / z:470.2.

[0897] Step E: Preparation of Compound I-25

[0898] Compound 25d (100 mg), N,N-diisopropylethylamine (68.8 mg), and dichloromethane (15.0 mL) were added sequentially to a reaction flask. Difluoroacetic anhydride (44.8 mg) was slowly added dropwise to the reaction solution at 0°C. After addition, the reaction was stirred at 0°C. TLC was used to monitor the reaction until completion. Saturated aqueous sodium chloride solution was added, and the mixture was extracted with dichloromethane. The mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-25 (49 mg).

[0899] HRMS (ESI, [M+H] + )m / z:548.2338.

[0900] 1 H NMR(500MHz,DMSO-d6)δ11.10(s,1H),9.04(s,1H),8.54(s,1H),8.44(s,1H),8.06 (d,J=2.5Hz,1H),7.81(d,J=2.5Hz,1H),7.59–7.49(m,2H),7.09–6.96(m,2H),6.8 0(t,J=52.7Hz,1H),4.00(s,3H),3.66(d,J=5.4Hz,4H),3.17(dt,J=13.7,5.2Hz,4 H), 1.91 (t, J = 4.6Hz, 1H), 1.06 (dq, J = 6.2, 3.6Hz, 2H), 0.91 (dt, J = 8.2, 3.4Hz, 2H).

[0901] Example 26: Preparation of Compound I-26

[0902] Step A: Preparation of Compound I-26

[0903] Compound 25d (100 mg), N,N-diisopropylethylamine (68.8 mg), and dichloromethane (15.0 mL) were added sequentially to a reaction flask. Propionyl chloride (21.7 mg) was slowly added dropwise to the reaction solution at 0°C. After addition, the reaction was stirred at 0°C. TLC was used to monitor the reaction until completion. Saturated aqueous sodium chloride solution was added, and the mixture was extracted with dichloromethane. The mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-26 (54 mg).

[0904] HRMS (ESI, [M+H] + )m / z:526.2689.

[0905] 1 H NMR(500MHz,DMSO-d6)δ11.09(s,1H),9.13(s,1H),8.59(s,1H),8.53(s,1H),8.09(d,J=2.5Hz,1H), 7.82(d,J=2.5Hz,1H),7.54(d,J=9.2Hz,2H),7.06–6.91(m,2H),4.02(s,3H),3.59(p,J=4.8Hz,4H), 3.09(dt,J=28.6,5.1Hz,4H),2.37(q,J=7.4Hz,2H),1.99–1.85(m,1H),1.07 (dq,J=6.0,3.7Hz,2H),1.01(t,J=7.4Hz,3H),0.91(dq,J=10.0,3.5Hz,2H).

[0906] Example 27: Preparation of Compound I-27

[0907] Step A: Preparation of compound 27a

[0908] To the reaction flask, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (8.84 g), intermediate 2A-1 (6 g), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (1.26 g), tripotassium phosphate (11.19 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (2.07 g), 1,4-dioxane (100 mL) and water (20 mL) were added in sequence. After the addition was completed, the reaction was stirred at 100°C under nitrogen protection. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 27a (2.1 g).

[0909] MS (ESI, [M+H] + )m / z:324.4.

[0910] Step B: Preparation of compound 27b

[0911] To a reaction flask, compound 27a (0.5 g), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (0.147 g), 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide (0.57 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.24 g), tripotassium phosphate (0.99 g), and 1,4-dioxane (10 mL) were added sequentially. After the addition, the mixture was stirred at 110°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to obtain compound 27b (0.52 g).

[0912] MS (ESI, [M+H] + )m / z:490.4.

[0913] Step C: Preparation of Compound I-27

[0914] Compound 27b (150 mg) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-27 (40 mg).

[0915] HRMS (ESI, [M+H] + )m / z:475.1556.

[0916] 1 H NMR (500MHz, DMSO-d6) δ11.41(s,1H),8.40(d,J=4.8Hz,1H),8.06(d,J=2.3Hz,1H),7.96(d,J=2.5Hz,1H),7.68(d,J=7.1Hz,2H),7.61(d,J=3.5H z,1H),7.40–7.34(m,2H),6.47(d,J=3.4Hz,1H),4.51(s,2H),4.46(s,2H ),3.88(s,3H),2.07–2.00(m,1H),1.20–1.15(m,2H),1.07–1.00(m,2H).

[0917] Example 28: Preparation of Compound I-28

[0918] Step A: Preparation of compound 28a

[0919] To a reaction flask, intermediate 1A-3 (0.5 g), N,N-diisopropylethylamine (0.5 g), and 4'-amino-N-methylacetanilide (0.3 g) were added sequentially. The reaction was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 28a (0.45 g).

[0920] MS (ESI, [M+H] + )m / z:364.1.

[0921] Step B: Preparation of compound 28b

[0922] To a reaction flask, compound 28a (0.45 g), 1-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (0.3 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.06 g), tripotassium phosphate (0.3 g), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After the addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 28b (0.35 g).

[0923] MS (ESI, [M+H] + )m / z:460.2.

[0924] Step C: Preparation of compound 28c

[0925] To a reaction flask, compound 28b (0.3 g), tetrahydrofuran (5 mL), methanol (5 mL), and a solution of potassium hydroxide (0.4 g) dissolved in water (1.5 mL) were added sequentially. The reaction was stirred at 50°C. TLC was used to monitor the reaction until complete. The reaction solution was cooled to room temperature and adjusted to acidity (pH approximately 3) by adding 1 M hydrochloric acid. The solvent was removed by rotary evaporation under reduced pressure to yield compound 28c (0.2 g), which was used directly in the next step.

[0926] MS (ESI, [M+H] + )m / z:446.2.

[0927] Step D: Preparation of compound I-28

[0928] To the reaction flask, compound 28c (0.2 g), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (0.25 g), ammonium chloride (0.1 g) and 2-(7-azobenzotriazole)-N,N,N,N'-tetramethyluronium hexafluorophosphate (0.25 g) were added in sequence. After the addition, the reaction was carried out at room temperature and monitored by TLC until the reaction was complete. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 5 / 1) to obtain compound I-28 (0.11 g).

[0929] HRMS (ESI, [M+H] + )m / z:445.2099.

[0930] 1 H NMR (500MHz, CDCl3) δ11.33(s,1H),8.44(d,J=4.9Hz,1H),7.89(d,J=8.4Hz,2H),7.56–7.51(m,1H),7.28(s,1H),7.15(d,J=8.4 Hz,2H),6.48(d,J=3.5Hz,1H),5.48(q,J=4.7Hz,1H),5.35(s,1H),3.27(s,3H),3.10(d,J=4.8Hz,3H),1.91(s,3H),3.95(s,3H).

[0931] Example 29: Preparation of Compound I-29

[0932] Step A: Preparation of compound 29a

[0933] To the reaction flask, Intermediate 2A-2 (0.4 g), N,N-diisopropylethylamine (0.3 g), and Intermediate 7A (0.3 g) were added sequentially. After addition, the reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain Intermediate 29a (0.4 g).

[0934] MS (ESI, [M+H] + )m / z:414.4.

[0935] Step B: Preparation of compound 29b

[0936] To a reaction flask, compound 29a (0.24 g), intermediate 3A (0.2 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.34 g), 1,4-dioxane (6 mL), and water (0.5 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 29b (0.25 g).

[0937] MS (ESI, [M+H] + )m / z:511.2.

[0938] Step C: Preparation of Compound I-29

[0939] Compound 29b (0.24 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-29 (0.15 g).

[0940] MS (ESI, [M+H] + )m / z:496.2575.

[0941] 1 H NMR (500MHz, CDCl3) δ10.57(s,1H),8.90(s,1H),8.65(s,1H),8.02(s,1H),7. 79(d,J=4.4Hz,1H),7.42(d,J=2.1Hz,1H),7.40–7.33(m,1H),6.43(d,J=8.3H z,1H),5.40(d,J=4.4Hz,1H),4.01(s,3H),3.65(h,J=7.6Hz,1H),3.57(dt,J= 12.8,2.6Hz,1H),3.12(td,J=12.3,3.2Hz,1H),3.03(dd,J=15.0,7.7Hz,1H), 2.90–2.83(m,1H),2.80(d,J=11.2Hz,1H),2.60(dd,J=15.0,7.7Hz,1H),2.36(s,3H),2.34–2.12(m ,2H),1.98(ddd,J=12.6,8.3,4.8Hz,1H),1.23(dd,J=4.5,2.8Hz,2H),0.90(tt,J=7.9,3.9Hz,2H).

[0942] Example 30: Preparation of Compound I-30

[0943] Step A: Preparation of compound 30a

[0944] To a reaction flask, intermediate 4A (1.5 g), intermediate 5A (1.3 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.12 g), tripotassium phosphate (0.4 g), 1,4-dioxane (15 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 30a (1.4 g).

[0945] MS (ESI, [M+H] + )m / z:501.3.

[0946] Step F: Preparation of compound I-30

[0947] Compound 30a (1.2 g) and a 7 M methanolic ammonia solution (20 mL) were added sequentially to the reaction flask. The mixture was stirred at 90°C until completion of the reaction, monitored by TLC. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-30 (0.95 g).

[0948] HRMS (ESI, [M+H] + )m / z:486.1973.

[0949] 1 H NMR (500MHz, CDCl3) δ10.83(s,1H),8.80(s,1H),8.45(d,J=38.0Hz,2H),7.47(d,J=4.2Hz,1H),6.44(d,J=3.0Hz,1H),5.55–5.47(m, 2H),5.27(s,1H),4.63(q,J=8.5Hz,2H),3.97(s,3H),2.96–2.81(m,1H),2.40(s,3H),0.85(td,J=6.9,5.1Hz,2H),0.64–0.49(m,2H).

[0950] Example 31: Preparation of Compound I-31

[0951] Step A: Preparation of compound 31a

[0952] To a reaction flask, intermediate 2A-1 (1.5 g), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)-1H-pyrrolo[2,3-b]pyridine (1.2 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.10 g), tripotassium phosphate (0.34 g), 1,4-dioxane (15 mL), and water (2 mL) were added sequentially. After the addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 31a (1.2 g).

[0953] MS (ESI, [M+H] + )m / z:324.3.

[0954] Step B: Preparation of compound 31b

[0955] To a reaction flask were added compound 31a (1.5 g), 6-bromo-2-methyl-3,4-dihydroisoquinolin-1(2H)-one (1.3 g), (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II)methanesulfonate (0.15 g), cesium carbonate (0.2 g), and 1,4-dioxane (15 mL). After addition, the reaction was stirred at 110°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 31b (1.2 g).

[0956] MS (ESI, [M+H] + )m / z:483.4.

[0957] Step F: Preparation of compound I-31

[0958] Compound 31b (1.2 g) and a 7 M methanolic ammonia solution (20 mL) were added sequentially to the reaction flask. The mixture was stirred at 90°C until completion of the reaction, monitored by TLC. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-31 (0.8 g).

[0959] HRMS (ESI, [M+H] + )m / z:468.2148.

[0960] 1H NMR(500MHz, CDCl3)) δ11.19(s,1H),8.46(d,J=4.8Hz,1H),8.06(d,J=8.5Hz,1H),7.83(d, J=4.3Hz,1H),7.66(dd,J=8.5,2.2Hz,1H),7.61(d,J=2.2Hz,1H),7.30(d,J=4.9Hz,1H),6. 52(d,J=3.5Hz,1H),5.61(d,J=4.3Hz,1H),3.96(s,3H),3.58(t,J=6.7Hz,2H),3.16(s,3H) ,3.02(t,J=6.7Hz,2H),2.24–2.15(m,1H),1.39–1.31(m,2H),1.08(dt,J=8.0,3.4Hz,2H).

[0961] Example 32: Preparation of Compound I-32

[0962] Step A: Preparation of compound 32a

[0963] To a reaction flask, intermediate 2A-2 (2.0 g), N,N-diisopropylethylamine (2.8 g), N,N-dimethylformamide (10 mL), and 1,1-dimethylethyl-6-(4-aminophenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (3.9 g) were added sequentially. After the addition, the reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 32a (3.4 g).

[0964] MS (ESI, [M+H] + )m / z:500.3.

[0965] Step B: Preparation of compound 32b

[0966] To a reaction flask were added intermediate 3A (218 mg), compound 32a (512 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (80.1 mg), potassium phosphate (650 mg), 1,4-dioxane (40 mL), and water (8 mL) in sequence. After the addition was complete, the reaction was stirred at 100°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 32b (424 mg).

[0967] MS (ESI, [M+H] +)m / z:597.3.

[0968] Step C: Preparation of compound 32c

[0969] Compound 32b (424 mg) and a 7 M methanolic ammonia solution (30 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 32c (400 mg).

[0970] MS (ESI, [M+H] + )m / z:582.4.

[0971] Step D: Preparation of Compound I-32

[0972] Compound 32c (100 mg), dichloromethane (2.0 mL), and a 1,4-dioxane hydrochloride solution (10.00 mL, 4 M) were added sequentially to the reaction flask. After addition, the reaction was stirred at room temperature. TLC was used to monitor the reaction until completion. Saturated sodium bicarbonate solution was added to adjust the pH to approximately 10, followed by extraction with dichloromethane and concentration. The residue was purified by silica gel column chromatography (dichloromethane ether / methanol = 20 / 1) to afford compound I-32 (70 mg).

[0973] HRMS (ESI, [M+H] + )m / z:518.2155.

[0974] 1 H NMR(500MHz,DMSO-d6)δ10.86(s,1H),9.03(s,1H),8.52(s,1H),8.43(s,1H), 8.01(d,J=2.6Hz,1H),7.75(d,J=2.6Hz,1H),7.36(d,J=8.4Hz,2H),6.67(d,J= 8.5Hz,2H),3.99(d,J=4.9Hz,4H),3.36(s,4H),3.29(d,J=9.0Hz,4H),1.88(t d,J=8.0,4.1Hz,1H),1.28–1.19(m,1H),1.07–0.98(m,2H),0.91–0.81(m,2H).

[0975] Example 33: Preparation of Compound I-33

[0976] Step A: Preparation of compound 33a

[0977] Compound 32c (300 mg), methanesulfonic acid (2 mL), and dichloromethane (10 mL) were added sequentially to a reaction flask. After the addition, the mixture was reacted at room temperature and monitored by TLC until the reaction was complete. Saturated aqueous sodium bicarbonate solution was added to the reaction solution to adjust the pH to approximately 9, and the mixture was extracted with dichloromethane. The organic phase was dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 33a (240 mg).

[0978] MS (ESI, [M+H] + )m / z:482.3.

[0979] Step B: Preparation of compound I-33

[0980] Compound 33a (100 mg), N,N-diisopropylethylamine (68.8 mg), and dichloromethane (15.0 mL) were added sequentially to a reaction flask. Difluoroacetic anhydride (44.8 mg) was slowly added dropwise to the reaction solution at 0°C. After addition, the reaction was stirred at 0°C. TLC was used to monitor the reaction until completion. Saturated aqueous sodium chloride solution was added, and the mixture was extracted with dichloromethane. The mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-33 (70 mg).

[0981] HRMS (ESI, [M+H] + )m / z:560.2336.

[0982] 1 H NMR(500MHz,DMSO-d6)δ10.97(s,1H),9.03(s,1H),8.53(s,1H),8.43(s,1H), 8.03(d,J=2.5Hz,1H),7.78(d,J=2.6Hz,1H),7.51–7.40(m,2H),6.53–6.42(m, 2H),6.31(d,J=53.1Hz,1H),4.52(s,2H),4.21(s,2H),3.99(s,3H),3.97(s,4H ),1.90(tt,J=8.2,4.7Hz,1H),1.30–1.18(m,2H),1.03(dd,J=4.6,2.9Hz,2H).

[0983] Example 34: Preparation of Compound I-34

[0984] Step A: Preparation of Compound I-34

[0985] Compound 33a (100 mg), N,N-diisopropylethylamine (68.8 mg), and dichloromethane (15.0 mL) were added sequentially to a reaction flask. Propionyl chloride (21.7 mg) was slowly added dropwise to the reaction solution at 0°C. After addition, the reaction was stirred at 0°C. TLC was used to monitor the reaction until completion. Saturated aqueous sodium chloride solution was added, and the mixture was extracted with dichloromethane. The mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-34 (40 mg).

[0986] HRMS (ESI, [M+H] + )m / z:538.2680.

[0987] 1 H NMR(500MHz,DMSO-d6)δ10.99(s,1H),9.15(s,1H),8.60(s,1H),8.56(s,1H),8. 08(d,J=2.5Hz,1H),7.80(d,J=2.5Hz,1H),7.52–7.42(m,2H),6.55–6.43(m,2H), 4.28(s,2H),4.02(d,J=2.5Hz,5H),3.93(s,4H),2.05(d,J=7.5Hz,2H),1.89(td ,J=8.0,4.1Hz,1H),1.08–1.01(m,2H),0.96(t,J=7.5Hz,3H),0.91–0.84(m,2H).

[0988] Example 35: Preparation of Compound I-35

[0989] Step A: Preparation of compound 35a

[0990] To a reaction flask, 3-methyl-4-nitropyrazole (2 g), 3-iodooxetane (4.34 g), potassium carbonate (4.35 g), and N,N-dimethylformamide (30 mL) were added sequentially. After addition, the mixture was stirred at 100°C. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 35a (0.60 g).

[0991] MS (ESI, [M+H] + )m / z:184.1.

[0992] Step B: Preparation of compound 35b

[0993] Compound 35a (0.60 g), methanol (5 mL) and 10% palladium on carbon (0.28 g) were added to a reaction flask in sequence. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. TLC was used to monitor the reaction until completion. The palladium on carbon was filtered out and the mixture was concentrated under reduced pressure to give compound 35b (0.48 g).

[0994] MS (ESI, [M+H] + )m / z:154.2.

[0995] Step C: Preparation of compound 35c

[0996] Compound 35b (0.20 g), intermediate 4A-3 (0.61 g), 1,4-dioxane (10 mL), and N,N-diisopropylethylamine (0.51 g) were added sequentially to a reaction flask. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 35c (0.50 g).

[0997] MS (ESI, [M+H] + )m / z:379.4.

[0998] Step D: Preparation of compound 35d

[0999] To a reaction flask, compound 35c (0.20 g), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (210 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.20 g), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 35d (120 mg).

[1000] MS (ESI, [M+H] + )m / z:475.4.

[1001] Step E: Preparation of Compound I-35

[1002] Compound 35d (80 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound I-35 (70 mg).

[1003] HRMS (ESI, [M+H] + )m / z:460.2209.

[1004] 1 H NMR (500MHz, DMSO) δ11.09 (s, 1H), 8.55 (s, 1H), 8.32 (d, J = 4.9Hz, 1H), 7.60–7. 44(m,2H),7.42–7.29(m,2H),6.93(d,J=2.4Hz,1H),6.34(d,J=3.4Hz,1H),5.4 8(t,J=6.9Hz,1H),4.93(t,J=7.1Hz,2H),4.84(t,J=6.4Hz,2H),3.85(s,3H),2 .88(dd,J=6.7,3.5Hz,1H),2.27(s,3H),0.85–0.77(m,2H),0.65–0.57(m,2H).

[1005] Example 36: Preparation of Compound I-36

[1006] Step A: Preparation of compound 36a

[1007] To a reaction flask, compound 22d (0.2 g), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-A]pyrimidine (0.16 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.30 g), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 36a (120 mg).

[1008] MS (ESI, [M+H] + )m / z:525.4.

[1009] Step B: Preparation of compound I-36

[1010] Compound 36a (120 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the reaction mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound I-36 (40 mg).

[1011] HRMS (ESI, [M+H] + )m / z:510.2358.

[1012] 1 H NMR (500MHz, DMSO) δ10.87(s,1H),9.20(dd,J=7.0,1.7Hz,1H),8.64(dd,J=3.8,1.9H z,2H),8.11(d,J=2.0Hz,1H),7.80(d,J=2.1Hz,1H),7.45(d,J=8.8Hz,2H),7.12(dd, J=7.0,4.0Hz,1H),6.47(d,J=8.8Hz,2H),3.78(q,J=7.1Hz,4H),3.60(s,2H),2.74(s ,3H),2.59(s,2H),2.32–2.26(m,1H),1.09–1.03(m,2H),0.99(dd,J=5.0,2.9Hz,2H).

[1013] Example 37: Preparation of Compound I-37

[1014] Step A: Preparation of compound 37a

[1015] To a reaction flask, 1,2-difluoro-4-nitrobenzene (1.0 g), (R)-morpholin-3-ylmethanol (1 g), N,N-dimethylformamide (20.0 mL), and potassium carbonate (1.5 g) were added sequentially. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was filtered, and the filter cake was washed and dried to obtain compound 37a (0.4 g).

[1016] MS (ESI, [M+H] + )m / z:237.2.

[1017] Step B: Preparation of compound 37b

[1018] Compound 37a (0.4 g), 10% palladium on carbon (0.2 g), and methanol (5 mL) were added sequentially to a reaction flask. After the addition, the hydrogen atmosphere was replaced, and the mixture was stirred at room temperature under a hydrogen atmosphere. TLC was monitored until the reaction was complete. The reaction solution was filtered, and the filter cake was washed and dried to obtain compound 37b (0.2 g).

[1019] MS (ESI, [M+H] + )m / z:207.2.

[1020] Step C: Preparation of compound 37c

[1021] To a reaction flask, intermediate 2A-2 (0.3 g), N,N-diisopropylethylamine (0.3 g), N,N-dimethylformamide (10.0 mL), and compound 37b (0.2 g) were added sequentially. After addition, the reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 37c (0.2 g).

[1022] MS (ESI, [M+H] + )m / z:417.4.

[1023] Step D: Preparation of compound 37d

[1024] To a reaction flask were added compound 37c (0.2 g), intermediate 3A (0.2 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.03 g), tripotassium phosphate (0.3 g), 1,4-dioxane (6 mL), and water (0.5 mL) in that order. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 37d (0.25 g).

[1025] MS (ESI, [M+H] + )m / z:514.3.

[1026] Step F: Preparation of Compound I-37

[1027] Compound 37d (0.2 g) and a 7 M methanolic ammonia solution (20 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 90°C. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-37 (0.11 g).

[1028] HRMS (ESI, [M+H] + )m / z:499.2205.

[1029] 1H NMR (500MHz, CDCl3) δ10.70(s,1H),8.90(s,1H),8.65(s,1H),8.02(s,1H),7.82(d,J=4.4Hz,1H),7.3 0(d,J=2.5Hz,1H),7.13(dd,J=8.7,2.6Hz,1H),6.73(d,J=8.9Hz,1H),5.48(d,J=4.4Hz,1H),4.16(dd, J=10.5,2.7Hz,1H),4.05(dd,J=11.4,3.5Hz,1H),4.01(s,3H),4.00–3.95(m,1H), 3.87(dd,J=10.8,3.1Hz,1H),3.76(td,J=11.6,2.8Hz,1H),3.50(dd,J=12.0,2.4H z,1H),3.30(t,J=10.6Hz,1H),3.27–3.17(m,1H),2.86(td,J=11.8,3.5Hz,1H),2. 00(tt,J=8.3,4.6Hz,1H), 1.30(dq,J=6.2,3.7Hz,2H), 0.95(dq,J=7.3,4.1Hz,2H).

[1030] Example 38: Preparation of Compound I-38

[1031] Step A: Preparation of compound 38a

[1032] Under nitrogen, 2-bromo-N,N-dimethyl-5-nitrobenzylamine (0.62 g), 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester (0.66 g), potassium carbonate (1.0 g), tetrakistriphenylphosphine palladium (0.56 g), 1,4-dioxane (40 mL), and water (8 mL) were added sequentially to a reaction flask. After the addition, the reaction was stirred at 100°C. The reaction was monitored by TLC until completion, and the product was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 5 / 1) to afford compound 38a (0.55 g).

[1033] MS (ESI, [M+H] + )m / z:263.1.

[1034] Step B: Preparation of compound 38b

[1035] Compound 38a (0.55 g), 10% palladium on carbon (0.5 g), and methanol (10 mL) were added sequentially to a reaction flask. After addition, the hydrogen atmosphere was replaced, and the mixture was stirred at room temperature under a hydrogen atmosphere. The reaction was monitored by TLC until complete, filtered, and concentrated to afford compound 38b (0.45 g).

[1036] MS (ESI, [M+H] + )m / z:235.2.

[1037] Step C: Preparation of compound 38c

[1038] To a reaction flask, intermediate 1A-3 (1.0 g), N,N-diisopropylethylamine (2.2 g), 1,4-dioxane (20 mL), and compound 38b (0.45 g) were added sequentially. The reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 38c (0.35 g).

[1039] MS (ESI, [M+H] + )m / z:434.3.

[1040] Step D: Preparation of compound 38d

[1041] To a reaction flask were added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (100 mg), compound 38c (115 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (21.2 mg), potassium phosphate (171 mg), 1,4-dioxane (20 mL), and water (4 mL) in sequence. After the addition was complete, the reaction was stirred at 100°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 38d (100 mg).

[1042] MS (ESI, [M+H] + )m / z:530.2.

[1043] Step E: Preparation of Compound I-38

[1044] Compound 38d (100 mg) and a 7 M methanolic ammonia solution (8 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-38 (50 mg).

[1045] HRMS (ESI, [M+H] + )m / z:515.2884.

[1046] 1H NMR (500MHz, DMSO-d6) δ11.44(s,1H),8.35(d,J=4.9Hz,1H),7.85(s,1H),7.56(d,J=3. 5Hz,2H),7.47(s,1H),7.38(s,1H),7.32(d,J=4.9Hz,1H),7.25(d,J=8.4Hz,1H),6.91( d,J=5.9Hz,1H),6.41(d,J=3.5Hz,1H),3.95(dd,J=11.1,4.0Hz,2H),3.87(s,3H),3.44 (t,J=11.6Hz,3H),3.12(s,1H),2.94(d,J=4.6Hz,3H),2.19(s,6H),1.76–1.57(m,4H).

[1047] Example 39: Preparation of Compound I-39

[1048] Step A: Preparation of compound 39a

[1049] To a reaction flask, 6-bromo-3-(tetrahydro-2H-pyran-4-yl)picolinaldehyde (0.49 g), acetic acid (7.29 μL), dichloromethane (10 mL), and a 2M solution of dimethylamine in tetrahydrofuran (2.55 mL) were added sequentially. After addition, the mixture was stirred at room temperature for 5 minutes. Sodium triacetoxyborocyanide (1.08 g) was slowly added. After addition, the mixture was stirred at room temperature. TLC was used to monitor the reaction until completion. Saturated aqueous sodium bicarbonate was added to the reaction mixture, which was adjusted to alkaline (pH approximately 9). The mixture was extracted with dichloromethane, and the organic phase was dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 39a (400 mg).

[1050] MS (ESI, [M+H] + )m / z:299.0.

[1051] Step B: Preparation of compound 39b

[1052] Compound 1a (280 mg), methyl 2-amino-5-chlorobenzoate (200 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (80.0 mg), potassium phosphate (680 mg), 1,4-dioxane (80 mL), and water (16 mL) were added sequentially to a reaction flask. After the addition was complete, the reaction was stirred at 100°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 39b (200 mg).

[1053] MS (ESI, [M+H] + )m / z:286.2.

[1054] Step C: Preparation of compound 39c

[1055] Compound 39b (200 mg), methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl) palladium(II) (62 mg), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (69 mg), cesium carbonate (725 mg), compound 39a (297 mg), and 1,4-dioxane (10 mL) were added sequentially to a reaction flask. After addition, the mixture was stirred at 100°C under nitrogen atmosphere. The reaction was monitored by TLC until completion, and the reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 39c (150 mg).

[1056] MS (ESI, [M+H] + )m / z:504.4.

[1057] Step D: Preparation of Compound I-39

[1058] Compound 39c (100 mg) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-39 (50 mg).

[1059] HRMS (ESI, [M+H] + )m / z:489.2405.

[1060] 1H NMR (500MHz, DMSO-d6) δ11.07(s,1H),8.78(d,J=8.8Hz,1H),8.65(dd,J=7.6,5.7Hz,1H),8.27(s,1H ),7.97(d,J=2.1Hz,1H),7.74(s,1H),7.71–7.64(m,2H),7.62(d,J=8.5Hz,1H),7.50(dd,J=10.0,2. 7Hz,1H),6.99(td,J=7.5,2.7Hz,1H),6.86(d,J=8.4Hz,1H),3.95(dd,J=10.1,3.9Hz,2H),3.57(s,2 H),3.43(td,J=11.4,2.7Hz,2H),3.17(d,J=4.7Hz,1H),2.24(s,6H),1.64(dt,J=16.0,12.0Hz,4H).

[1061] Example 40: Preparation of Compound I-40

[1062] Step A: Preparation of compound 40a

[1063] To a reaction flask, intermediate 1A-3 (6.9 g), N,N-diisopropylethylamine (15.4 g), 1,4-dioxane (30 mL), and intermediate 2A-4 (2.4 g) were added sequentially. The reaction was stirred at 100°C. TLC was monitored until the reaction was complete. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 40a (2.3 g).

[1064] MS (ESI, [M+H] + )m / z:379.3.

[1065] Step B: Preparation of compound 40b

[1066] To a reaction flask were added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (100 mg), compound 40a (100 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (21.2 mg), potassium phosphate (171 mg), 1,4-dioxane (20 mL), and water (4 mL) in sequence. After the addition was complete, the reaction was stirred at 100°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 40b (90 mg).

[1067] MS (ESI, [M+H] + )m / z:475.2.

[1068] Step C: Preparation of Compound I-40

[1069] Compound 40b (90 mg) and a 7 M methanolic ammonia solution (5 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-40 (43 mg).

[1070] HRMS (ESI, [M+H] + )m / z:460.1828.

[1071] 1 H NMR (500MHz, DMSO-d6) δ11.07(s,1H),8.34(d,J=4.9Hz,1H),8.27(s,1H),7.56(d,J=3.5Hz,1H),7.43(d,J=3.0Hz,1H),7.31(dd,J=1 0.8,3.9Hz,2H),6.88(d,J=4.6Hz,1H),6.40(d,J=3.4Hz,1H),5.07(q,J=9.1Hz,2H),3.86(s,3H),2.93(d,J=4.6Hz,3H),2.23(s,3H).

[1072] Example 41: Preparation of Compound I-41

[1073] Step A: Preparation of compound 41a

[1074] To the reaction flask at 0°C, 4-(4-nitrophenyl)piperidine (1.00 g), difluoroacetic anhydride (1.52 g), N,N-diisopropylethylamine (1.57 g), and dichloromethane (10 mL) were added sequentially. After addition, the mixture was stirred at 0°C. The reaction was monitored by TLC until completion. Saturated sodium bicarbonate solution was added dropwise to quench the reaction, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 2) to obtain compound 41a (1.25 g).

[1075] MS (ESI, [M+H] + )m / z:285.4.

[1076] Step B: Preparation of compound 41b

[1077] Compound 41a (1.25 g), methanol (10 mL), and 10% palladium hydroxide (0.55 g) were added to the reaction flask in sequence. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. The reaction was monitored by TLC until completion, filtered, and concentrated to afford compound 41b (0.86 g).

[1078] MS (ESI, [M+H] + )m / z:255.3.

[1079] Step C: Preparation of compound 41c

[1080] To a reaction flask, compound 2A-2 (0.27 g), compound 41b (0.30 g), N,N-diisopropylethylamine (0.30 g), and 1,4-dioxane (20 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to obtain compound 41c (0.35 g).

[1081] MS (ESI, [M+H] + )m / z:465.2.

[1082] Step D: Preparation of compound 41d

[1083] To a reaction flask were added compound 41c (0.15 g), intermediate 3A (0.09 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.03 g), tripotassium phosphate (0.14 g), 1,4-dioxane (20 mL), and water (4 mL) in that order. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 41d (0.15 g).

[1084] MS (ESI, [M+H] + )m / z:562.2.

[1085] Step E: Preparation of Compound I-41

[1086] Compound 41d (0.15 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-41 (0.11 g).

[1087] HRMS (ESI, [M+H] +)m / z:547.2395.

[1088] 1 H NMR (500MHz, DMSO-d6) δ11.28(s,1H),9.05(s,1H),8.55(s,1H),8.45(s,1H),8.11(d,J=2.3Hz,1H),7. 85(d,J=2.4Hz,1H),7.64–7.56(m,2H),7.29–7.22(m,2H),6.77(s,1H),4.49–4.42(m,1H),4.00(s,4H) ,3.22(td,J=13.5,2.6Hz,1H),2.83(td,J=12.2,4.8Hz,2H),1.94(dq,J=8.0,4.1Hz,1H),1.91–1.88(m ,1H),1.86(s,1H),1.58(dqd,J=46.2,12.8,4.2Hz,2H),1.09(dq,J=6.0,3.7Hz,2H),0.96–0.89(m,2H).

[1089] Example 42: Preparation of Compound I-42

[1090] Step A: Preparation of compound 42a

[1091] To a reaction flask, p-fluoronitrobenzene (2.40 g), 1-(piperidin-4-yl)propan-1-one (2.00 g), N,N-diisopropylethylamine (3.66 g), and N,N-dimethylformamide (5 mL) were added sequentially, and the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. Water and ethyl acetate were added to the reaction solution, and the mixture was extracted. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain compound 42a (2.81 g).

[1092] MS (ESI, [M+H] + )m / z:263.1.

[1093] Step B: Preparation of compound 42b

[1094] Compound 42a (1.00 g), methanol (10 mL), and 10% palladium hydroxide (0.30 g) were added to the reaction flask in sequence. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. The reaction was monitored by TLC until completion, filtered, and concentrated to afford compound 42b (0.60 g).

[1095] MS (ESI, [M+H] + )m / z:233.4.

[1096] Step C: Preparation of compound 42c

[1097] To a reaction flask, compound 2A-2 (0.59 g), compound 42b (0.60 g), N,N-diisopropylethylamine (0.668 g), and N,N-dimethylformamide (3 mL) were added sequentially. The mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 42c (0.98 g).

[1098] MS (ESI, [M+H] + )m / z:443.1.

[1099] Step D: Preparation of compound 42d

[1100] To a reaction flask, compound 42c (0.10 g), compound 3A (0.06 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.02 g), tripotassium phosphate (0.10 g), 1,4-dioxane (10 mL), and water (2 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 42d (0.07 g).

[1101] MS (ESI, [M+H] + )m / z:540.4.

[1102] Step E: Preparation of Compound I-42

[1103] Compound 42d (0.07 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound I-42 (0.04 g).

[1104] HRMS (ESI, [M+H] + )m / z:525.2729.

[1105] 1H NMR(500MHz,DMSO-d6)δ11.05(s,1H),9.04(s,1H),8.53(s,1H),8.44(s,1H),8.09–8.02(m,1 H),7.84–7.76(m,1H),7.50(d,J=8.5Hz,2H),6.96(d,J=8.6Hz,2H),4.00(s,3H),3.66(d,J=1 2.3Hz,2H),2.68(td,J=12.1,2.5Hz,2H),2.59–2.45(m,2H),1.89(dd,J=11.4,7.5Hz,3H),1. 57(dd,J=12.5,3.8Hz,2H),1.24(s,1H),1.06(d,J=4.1Hz,2H),0.92(dt,J=12.9,5.9Hz,5H).

[1106] Example 43: Preparation of Compounds I-43 and I-44

[1107] Step A: Preparation of compounds 43a and 44a

[1108] To a reaction flask, 1-Boc-(3-iodomethyl)azetidine (2.33 g), 3-methyl-4-nitropyrazole (1.00 g), potassium carbonate (2.18 g), and N,N-dimethylformamide (10.0 mL) were added sequentially. After addition, the mixture was stirred at 100°C. The reaction was monitored by TLC until completion. Ethyl acetate and water were added for extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to obtain a mixture of compounds 43a and 44a (2.2 g).

[1109] MS (ESI, [M+H] + )m / z:297.1.

[1110] Step B: Preparation of compounds 43b and 44b

[1111] To a reaction flask, a mixture of compounds 43a and 44a (2.2 g), dichloromethane (50 mL), and methanesulfonic acid (3.7 g) were added sequentially under ice-cooling conditions. The mixture was stirred at room temperature. TLC was used to monitor the reaction until completion. Saturated sodium bicarbonate solution was added to the reaction solution to adjust the pH to approximately 10. Water and dichloromethane were then added to the reaction solution for extraction. The organic phase was separated, dried, filtered, and concentrated to afford a mixture of compounds 43b and 44b (1.34 g).

[1112] MS (ESI, [M+H] + )m / z:197.1.

[1113] Step C: Preparation of compounds 43c and 44c

[1114] To a reaction flask under ice-cooling conditions, a mixture of compounds 43b and 44b (1.34 g), dichloromethane (30 mL), N,N-diisopropylethylamine (2.2 g), and propionyl chloride (0.57 g) were added sequentially. The mixture was stirred at room temperature. TLC was used to monitor the reaction until completion. Water and dichloromethane were added to the reaction solution, followed by extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to afford a mixture of compounds 43c and 44c (1.55 g).

[1115] MS (ESI, [M+H] + )m / z:253.1.

[1116] Step D: Preparation of compounds 43d and 44d

[1117] To a reaction flask, a mixture of compounds 43c and 44c (1.55 g), methanol (10 mL), and 10% palladium hydroxide (0.75 g) were added sequentially. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. The reaction was monitored by TLC until completion, filtered, and concentrated to afford a mixture of compounds 43d and 44d (1.23 g).

[1118] MS (ESI, [M+H] + )m / z:223.1.

[1119] Step E: Preparation of compounds 43e and 44e

[1120] To a reaction flask, compound 2A-2 (1.27 g), a mixture of compounds 43d and 44d (1.23 g), N,N-diisopropylethylamine (1.79 g), and N,N-dimethylformamide (10 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to afford a mixture of compounds 43e and 44e (1.91 g).

[1121] MS (ESI, [M+H] + )m / z:433.4.

[1122] Step F: Preparation of compounds 43f and 44f

[1123] To a reaction flask, a mixture of compounds 43e and 44e (0.20 g), intermediate 5A (0.12 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.38 g), tripotassium phosphate (2.0 g), 1,4-dioxane (50 mL), and water (10 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain a mixture of compounds 43f and 44f (0.22 g).

[1124] MS (ESI, [M+H] + )m / z:529.3.

[1125] Step G: Preparation of compounds I-43 and I-44

[1126] To the reaction flask, a mixture of compounds 43f and 44f (0.22 g) and a 7 M methanolic ammonia solution (30 mL) were added sequentially. After addition, the reaction was stirred at 60°C. TLC was monitored until the reaction was complete. The reaction solution was filtered and concentrated, and the residue was separated and purified by high pressure preparative chromatography (CHIRALART Amylose-SA column; phase A: ethanol: dichloromethane (1:1) + 0.1% aqueous ammonia; phase B: n-hexane; gradient elution) to obtain compounds I-43 (0.09 g) and I-44 (0.07 g), respectively.

[1127] Compound I-43: (peak time: 6.704 min)

[1128] HRMS (ESI, [M+H] + )m / z:514.2696.

[1129] 1H NMR (500MHz, DMSO-d6) δ10.80(s,1H),8.90(s,1H),8.35(s,1H),7.97(d,J=2.5Hz,1H),7.94(s,1H),7.80(d ,J=2.6Hz,1H),7.63(d,J=3.0Hz,1H),6.43(d,J=3.0Hz,1H),4.30(d,J=7.3Hz,2H),4.17(t,J=8.4Hz,1H),3. 96(s,3H),3.94–3.85(m,2H),3.66(dd,J=9.5,5.5Hz,1H),3.00(tt,J=7.7,5.3Hz,1H),2.19(s,3H),2.03(q ,J=7.5Hz,2H),1.95(tt,J=8.2,4.6Hz,1H),1.20(s,2H),1.00(dd,J=7.9,3.4Hz,2H),0.95(t,J=7.6Hz,3H).

[1130] Compound I-44: (peak time: 6.131 min)

[1131] HRMS (ESI, [M+H] + )m / z:514.2686.

[1132] 1 H NMR (500MHz, DMSO-d6) δ10.59(s,1H),8.89(s,1H),8.35(s,1H),7.95(d,J=2.5Hz,1H),7.78(d,J=2.6Hz,1 H),7.77(s,1H),7.63(d,J=3.0Hz,1H),6.43(d,J=3.1Hz,1H),4.28(d,J=7.5Hz,2H),4.15(t,J=8.4Hz,1H), 3.96(s,3H),3.95–3.91(m,1H),3.88(t,J=9.0Hz,1H),3.67(dd,J=9.6,5.6Hz,1H),3.12–3.01(m,1H),2.26 (s,3H),2.03(q,J=7.5Hz,2H),1.92(tt,J=8.2,4.6Hz,1H),1.08(dq,J=6.0,3.5Hz,2H),1.00–0.91(m,5H).

[1133] Example 44: Preparation of Compound I-45

[1134] Step A: Preparation of compound 45a

[1135] To the reaction flask at 0°C, 4-(4-nitrophenyl)piperidine (1.00 g), propionyl chloride (0.47 g), N,N-diisopropylethylamine (1.26 g), and dichloromethane (10 mL) were added sequentially. After addition, the mixture was stirred at 0°C. The reaction was monitored by TLC until completion. Saturated sodium bicarbonate solution was added dropwise to quench the reaction, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 2) to obtain compound 45a (1.09 g).

[1136] MS (ESI, [M+H] + )m / z:263.4.

[1137] Step B: Preparation of compound 45b

[1138] Compound 45a (1.09 g), methanol (10 mL), and 10% palladium hydroxide (0.5 g) were added to the reaction flask in sequence. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. The reaction was monitored by TLC until completion, filtered, and concentrated to afford compound 45b (0.86 g).

[1139] MS (ESI, [M+H] + )m / z:233.3.

[1140] Step C: Preparation of compound 45c

[1141] To a reaction flask, compound 2A-2 (0.27 g), compound 45b (0.30 g), N,N-diisopropylethylamine (0.30 g), and N,N-dimethylformamide (10 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to obtain compound 45c (0.41 g).

[1142] MS (ESI, [M+H] + )m / z:443.2.

[1143] Step D: Preparation of compound 45d

[1144] To a reaction flask were added compound 45c (0.15 g), intermediate 3A (0.09 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.03 g), tripotassium phosphate (0.14 g), 1,4-dioxane (20 mL), and water (4 mL) in that order. After the addition was complete, the reaction was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 45d (0.15 g).

[1145] MS (ESI, [M+H] + )m / z:540.2.

[1146] Step E: Preparation of Compound I-45

[1147] Compound 45d (0.10 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-45 (0.04 g).

[1148] HRMS(ESI,[M+H]+)m / z:525.2745.

[1149] 1 H NMR (500MHz, DMSO) δ11.28(s,1H),9.04(s,1H),8.54(s,1H),8.44(s,1H),8.08(d,J=2.3Hz,1H),7.84(d,J=2.6Hz,1H), 7.63–7.57(m,2H),7.23(d,J=8.5Hz,2H),4.56(d,J=12.8Hz,1H),4.00(s,4H),3.09(t,J=12.7Hz,1H),2.75(tt,J=11.8, 3.7Hz,1H),2.63–2.53(m,1H),2.35(qd,J=7.4,1.8Hz,2H),1.94(tt,J=8.1,4.6Hz,1H),1.81(t,J=14.5Hz,2H),1.62–1. 52(m,1H),1.44(td,J=13.2,9.1Hz,1H),1.09(dq,J=6.0,3.6Hz,2H),1.02(t,J=7.4Hz,3H),0.93(dq,J=7.1,3.5Hz,2H).

[1150] Example 45: Preparation of Compound I-46

[1151] Step A: Preparation of compound 46a

[1152] To a reaction flask, tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (4.00 g), 4-nitrochlorobenzene (2.00 g), bistriphenylphosphine palladium dichloride (0.80 g), sodium carbonate (2.69 g), 1,4-dioxane (30 mL), and water (6 mL) were added sequentially. The mixture was stirred at 100°C under nitrogen atmosphere. TLC was used to monitor the reaction until completion. Water and ethyl acetate were added to the reaction solution, and the mixture was extracted. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to afford compound 46a (3.61 g).

[1153] MS (ESI, [M+H] + )m / z:291.2.

[1154] Step B: Preparation of compound 46b

[1155] Compound 46a (1.00 g), dichloromethane (50 mL), and a 1,4-dioxane hydrochloride solution (4 M, 8.60 mL) were added sequentially to a reaction flask under ice. After addition, the mixture was stirred at room temperature. A large amount of white solid precipitated. The reaction was monitored by TLC until completion. The solid was filtered, washed, and dried to obtain compound 46b (0.61 g).

[1156] MS (ESI, [M+H] + )m / z:191.3.

[1157] Step C: Preparation of compound 46c

[1158] Compound 46b (0.50 g), dichloromethane (10 mL), N,N-diisopropylethylamine (1.80 mL), and propionyl chloride (0.30 g) were added sequentially to a reaction flask under ice-cooling. The mixture was stirred at room temperature. TLC was used to monitor the reaction until completion. Water and dichloromethane were added to the reaction solution, followed by extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to afford compound 46c (0.80 g).

[1159] MS (ESI, [M+H] + )m / z:247.3.

[1160] Step D: Preparation of compound 46d

[1161] Compound 46c (0.80 g), methanol (10 mL), and 10% palladium hydroxide (0.20 g) were added to the reaction flask in sequence. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. The reaction was monitored by TLC until completion, filtered, and concentrated to afford compound 46d (0.75 g).

[1162] MS (ESI, [M+H] + )m / z:219.1.

[1163] Step E: Preparation of compound 46e

[1164] To a reaction flask, compound 2A-2 (0.32 g), compound 46d (0.32 g), N,N-diisopropylethylamine (0.48 mL), and N,N-dimethylformamide (4 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to obtain compound 46e (0.19 g).

[1165] MS (ESI, [M+H] + )m / z:429.3.

[1166] Step F: Preparation of compound 46f

[1167] To a reaction flask were added compound 46e (0.19 g), intermediate 3A (0.2 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.20 g), 1,4-dioxane (25 mL), and water (5 mL) in that order. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 30 / 1) to afford compound 46f (0.10 g).

[1168] MS (ESI, [M+H] + )m / z:526.4.

[1169] Step G: Preparation of compound I-46

[1170] Compound 46f (0.10 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. The mixture was stirred at 60°C until completion of the reaction, monitored by TLC. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound I-46 (0.04 g).

[1171] HRMS (ESI, [M+H] + )m / z:511.2577.

[1172] 1H NMR(500MHz,DMSO-d6)δ11.31(d,J=3.2Hz,1H),9.05(s,1H),8.55(s,1H),8.45(s,1H),8.12(s,1H ),7.86(s,1H),7.63(dd,J=8.4,6.0Hz,2H),7.30(dd,J=13.5,8.3Hz,2H),4.00(s,3H),3.87(ddd,J =24.4,10.3,7.3Hz,1H),3.70–3.56(m,1H),3.53–3.35(m,2H),3.31–3.24(m,1H),2.35–2.15(m,3 H),2.08–1.82(m,2H),1.09(dq,J=6.1,3.7Hz,2H),1.00(td,J=7.4,5.5Hz,3H),0.95–0.89(m,2H).

[1173] Example 46: Preparation of Compound I-47

[1174] Step A: Preparation of compound 47a

[1175] To a reaction flask, N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (3.24 g), 4-nitrochlorobenzene (1.50 g), bistriphenylphosphine palladium dichloride (0.67 g), sodium carbonate (2.00 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. The mixture was stirred at 100°C under nitrogen atmosphere. TLC was used to monitor the reaction until completion. Water and ethyl acetate were added to the reaction solution, and the organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to obtain compound 47a (2.23 g).

[1176] MS (ESI, [M+H] + )m / z:305.1.

[1177] Step B: Preparation of compound 47b

[1178] Under ice-cooling, compound 47a (2.23 g), dichloromethane (100 mL), and a 1,4-dioxane hydrochloride solution (4 M, 18.00 mL) were added sequentially to a reaction flask. After addition, the mixture was stirred at room temperature. A large amount of white solid precipitated. The reaction was monitored by TLC until completion. The solid was filtered, washed, and dried to obtain compound 47b (1.50 g).

[1179] MS (ESI, [M+H] + )m / z:205.1.

[1180] Step C: Preparation of compound 47c

[1181] Under an ice bath, compound 47b (1.50 g), dichloromethane (50 mL), N,N-diisopropylethylamine (6.00 mL), and propionyl chloride (0.85 g) were added sequentially to a reaction flask, and the mixture was stirred at room temperature. TLC was used to monitor the reaction until completion. Water and dichloromethane were added to the reaction solution, followed by extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to afford compound 47c (1.25 g).

[1182] MS (ESI, [M+H] + )m / z:261.1.

[1183] Step D: Preparation of compound 47d

[1184] Compound 47c (1.15 g), methanol (10 mL), water (2 mL), zinc powder (1.30 g), and ammonium chloride (1.25 g) were added sequentially to a reaction flask. The mixture was stirred at room temperature. TLC was used to monitor the reaction until completion. The mixture was filtered and extracted with water and dichloromethane. The organic phase was separated, dried, filtered, and concentrated to afford compound 47d (0.99 g).

[1185] MS (ESI, [M+H] + )m / z:231.1.

[1186] Step E: Preparation of compound 47e

[1187] To a reaction flask, compound 2A-2 (0.46 g), compound 47d (0.46 g), N,N-diisopropylethylamine (0.66 mL), and N,N-dimethylformamide (4 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to afford compound 47e (0.55 g).

[1188] MS (ESI, [M+H] + )m / z:441.4.

[1189] Step F: Preparation of compound 47f

[1190] To a reaction flask, compound 47e (0.23 g), intermediate 3A (0.2 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.12 g), tripotassium phosphate (0.22 g), 1,4-dioxane (25 mL), and water (5 mL) were added sequentially. After the addition, the mixture was stirred at 90°C under nitrogen. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 30 / 1) to obtain compound 47f (0.20 g).

[1191] MS (ESI, [M+H] + )m / z:538.4.

[1192] Step G: Preparation of Compound I-47

[1193] Compound 47f (0.10 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. The mixture was stirred at 60°C until completion of the reaction, monitored by TLC. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-47 (0.06 g).

[1194] HRMS (ESI, [M+H] + )m / z:523.2594.

[1195] 1 H NMR(500MHz,DMSO-d6)δ11.38(d,J=2.4Hz,1H),9.06(s,1H),8.56(s,1H),8.46(s,1H),8.17–8.10(m,1H) ,7.89(d,J=2.4Hz,1H),7.67(d,J=8.4Hz,2H),7.50–7.43(m,2H),6.24–6.11(m,1H),4.20–4.08(m,2H),4 .01(s,3H),3.67(dt,J=21.9,5.7Hz,2H),2.56(s,1H),2.47(s,1H),2.39(dq,J=26.2,7.4Hz,2H),1.95(t q,J=8.5,4.3,3.8Hz,1H),1.12(dq,J=6.1,3.7Hz,2H),1.03(q,J=7.6Hz,3H),0.96(dt,J=8.2,3.4Hz,2H).

[1196] Example 47: Preparation of Compound I-48

[1197] Step A: Preparation of compound 48a

[1198] To a reaction flask, p-fluoronitrobenzene (0.86 g), 2,6-diazaspiro[3.4]octan-5-one hydrochloride (0.99 g), potassium carbonate (2.11 g), and N,N-dimethylformamide (10 mL) were added sequentially, and the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion. Water and ethyl acetate were added to the reaction solution, and the mixture was extracted. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain compound 48a (1.00 g).

[1199] MS (ESI, [M+H] + )m / z:248.3.

[1200] Step B: Preparation of compound 48b

[1201] To a reaction flask at 0°C, compound 48a (1.00 g), tetrahydrofuran (10 mL), and 60 wt% sodium hydride (0.97 g) were added sequentially. After addition, the mixture was stirred at 0°C for 1 hour. Iodomethane (1.72 g) was then added dropwise to the reaction flask. After addition, the mixture was stirred at room temperature. TLC was used to monitor the reaction until completion. Saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, followed by extraction. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to afford compound 48b (0.80 g).

[1202] MS (ESI, [M+H] + )m / z:262.3.

[1203] Step C: Preparation of compound 48c

[1204] Compound 48b (0.80 g), methanol (10 mL), and 10% palladium hydroxide (0.35 g) were added to the reaction flask in sequence. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. The reaction was monitored by TLC until completion, filtered, and concentrated to afford compound 48c (0.60 g).

[1205] MS (ESI, [M+H] + )m / z:232.0.

[1206] Step D: Preparation of compound 48d

[1207] To a reaction flask, compound 2A-2 (0.66 g), compound 48c (0.60 g), N,N-diisopropylethylamine (1.00 g), and 1,4-dioxane (10 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to obtain compound 48d (0.86 g).

[1208] MS (ESI, [M+H] + )m / z:442.1.

[1209] Step E: Preparation of compound 48e

[1210] To a reaction flask, compound 48d (0.25 g), intermediate 3A (0.15 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.24 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 48e (0.26 g).

[1211] MS (ESI, [M+H] + )m / z:539.1.

[1212] Step F: Preparation of Compound I-48

[1213] Compound 48e (0.26 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-48 (0.11 g).

[1214] HRMS (ESI, [M+H] + )m / z:524.2532.

[1215] 1H NMR(500MHz,DMSO-d6)δ10.97(s,1H),9.04(s,1H),8.53(s,1H),8.44(s,1H),8.03(d,J =2.5Hz,1H),7.77(d,J=2.6Hz,1H),7.50–7.44(m,2H),6.51–6.44(m,2H),4.00(s,3H),3 .85(d,J=6.9Hz,2H),3.76(d,J=7.0Hz,2H),3.30(s,1H),2.77(s,3H),2.40(t,J=6.8Hz, 2H),1.90(tt,J=8.1,4.6Hz,1H),1.23(s,1H),1.04(p,J=3.7Hz,2H),0.92–0.82(m,2H).

[1216] Example 48: Preparation of Compound I-49

[1217] Step A: Preparation of compound 49a

[1218] To a reaction flask, 1-[4-(4-amino-phenyl)-piperazin-1-yl]-propan-1-one (0.30 g), intermediate 8A (0.33 g), N,N-diisopropylethylamine (0.50 g), and 1,4-dioxane (10 mL) were added sequentially. After addition, the mixture was stirred at 100°C. The reaction was monitored by TLC until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to afford compound 49a (0.45 g).

[1219] MS (ESI, [M+H] + )m / z:468.0.

[1220] Step B: Preparation of compound 49b

[1221] To a reaction flask, compound 49a (0.25 g), intermediate 3A (0.15 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.22 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 49b (0.25 g).

[1222] MS (ESI, [M+H] + )m / z:565.1.

[1223] Step C: Preparation of Compound I-49

[1224] Compound 49b (0.25 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-49 (0.08 g).

[1225] HRMS (ESI, [M+H] + )m / z:550.2500.

[1226] 1 H NMR(500MHz,DMSO-d6)δ11.19(s,1H),8.99(s,1H),8.41(s,1H),8.36(s,1H), 8.10–8.06(m,1H),8.01(d,J=2.2Hz,1H),7.66–7.58(m,2H),7.03–6.97(m,2H ),4.00(s,3H),3.61(dt,J=14.3,4.9Hz,4H),3.15(t,J=5.1Hz,2H),3.09(t,J =5.2Hz,2H),2.37(q,J=7.4Hz,2H),2.07–1.98(m,3H),1.04(t,J=7.4Hz,3H).

[1227] Example 49: Preparation of Compounds I-50 and I-51

[1228] Step A: Preparation of compounds 50a and 51a

[1229] To a reaction flask, 3,3-difluorocyclobutanol (1.28 g), 3-methyl-4-nitropyrazole (1.00 g), triphenylphosphine (4.13 g), diethyl azodicarboxylate (2.74 g), and tetrahydrofuran (20 mL) were added sequentially. The mixture was stirred at room temperature. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain a mixture of compounds 50a and 51a (0.75 g).

[1230] MS (ESI, [M+H] + )m / z:218.2.

[1231] Step B: Preparation of compounds 50b and 51b

[1232] To a reaction flask, a mixture of compounds 50a and 51a (0.75 g), methanol (10 mL), and 10% palladium hydroxide (0.35 g) were added sequentially. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. The reaction was monitored by TLC until completion, filtered, and concentrated to afford a mixture of compounds 50b and 51b (0.56 g).

[1233] MS (ESI, [M+H] + )m / z:188.2.

[1234] Step C: Preparation of compounds 50c and 51c

[1235] To a reaction flask, compound 2A-2 (0.72 g), a mixture of compounds 50b and 51b (0.56 g), N,N-diisopropylethylamine (0.82 g), and 1,4-dioxane (10 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to obtain a mixture of compounds 50c and 51c (0.68 g).

[1236] MS (ESI, [M+H] + )m / z:398.0.

[1237] Step D: Preparation of compounds 50d and 51d

[1238] To a reaction flask, a mixture of compounds 50c and 51c (0.30 g), intermediate 3A (0.18 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.06 g), tripotassium phosphate (0.32 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After the addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain a mixture of compounds 50d and 51d (0.18 g).

[1239] MS (ESI, [M+H] + )m / z:495.3.

[1240] Step E: Preparation of Compounds I-50 and I-51

[1241] To the reaction flask, a mixture of compounds 50d and 51d (0.18 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially. After addition, the reaction was stirred at 60°C. TLC was monitored until the reaction was complete. The reaction solution was filtered and concentrated, and the residue was separated and purified by high pressure preparative chromatography (CHIRALART Amylose-SA column; phase A: ethanol: dichloromethane (1:1) + 0.1% aqueous ammonia; phase B: n-hexane; gradient elution) to obtain compounds I-50 (0.04 g) and I-51 (0.05 g), respectively.

[1242] Compound I-50: (peak time: 7.360 min)

[1243] HRMS (ESI, [M+H] + )m / z:480.2076.

[1244] 1 H NMR (500MHz, DMSO-d6) δ10.68(s,1H),9.04(s,1H),8.52(s,1H),8.43(s,1H),8.04(d,J=2.4Hz,1H),7.91(s,1H),7.77(d,J=2.3Hz,1H),4.95–4 .84(m,1H),4.00(s,3H),3.17(dq,J=16.0,7.2Hz,4H),2.27(s,3H),1.9 3–1.84(m,1H),1.03(dq,J=6.1,3.6Hz,2H),0.90(dt,J=8.2,3.3Hz,2H).

[1245] Compound I-51: (peak time: 6.833 min)

[1246] HRMS (ESI, [M+H] + )m / z:480.2079.

[1247] 1 H NMR(500MHz,DMSO-d6)δ10.89(s,1H),9.04(s,1H),8.53(s,1H),8.44(s,1H), 8.06(d,J=6.2Hz,2H),7.82–7.78(m,1H),4.95–4.84(m,1H),4.00(s,3H),3.23 –3.14(m,2H),3.08(dddd,J=21.8,17.2,10.9,4.2Hz,2H),2.24(s,3H),1.91(t t, J=8.3, 4.7Hz, 1H), 1.14 (dq, J=6.2, 3.7Hz, 2H), 0.93 (dt, J=8.2, 3.4Hz, 2H).

[1248] Example 50: Preparation of Compound I-52

[1249] Step A: Preparation of compound 52a

[1250] To a reaction flask, compound 2A-2 (0.2 g), 1-[4-(4-amino-phenyl)-piperazin-1-yl]-propan-1-one (0.24 g), N,N-diisopropylethylamine (0.48 g), and 1,4-dioxane (5 mL) were added sequentially. After addition, the mixture was stirred at 100°C. The reaction was monitored by TLC until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 2) to obtain compound 52a (0.32 g).

[1251] MS (ESI, [M+H] + )m / z:444.2.

[1252] Step B: Preparation of compound 52b

[1253] To a reaction flask, compound 52a (0.20 g), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-A]pyrimidine (0.13 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.04 g), tripotassium phosphate (0.21 g), 1,4-dioxane (20 mL), and water (4 mL) were added sequentially. After the addition, the mixture was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give compound 52b (0.13 g).

[1254] MS (ESI, [M+H] + )m / z:527.3.

[1255] Step C: Preparation of Compound I-52

[1256] Compound 52b (0.13 g) and a 7 M methanolic ammonia solution (10 mL) were added sequentially to the reaction flask. After addition, the mixture was stirred at 60°C. TLC was used to monitor the reaction until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound I-52 (0.05 g).

[1257] HRMS (ESI, [M+H] + )m / z:512.2517.

[1258] 1 H NMR(500MHz,DMSO-d6)δ10.98(s,1H),9.20(dd,J=7.0,1.7Hz,1H),8.64(d,J=5.0Hz,2H) ,8.13(d,J=2.6Hz,1H),7.83(d,J=2.6Hz,1H),7.55–7.49(m,2H),7.12(dd,J=7.1,4.0Hz ,1H),7.01–6.94(m,2H),3.59(dt,J=11.0,5.1Hz,4H),3.08(dt,J=28.6,5.1Hz,4H),2.3 6(q,J=7.4Hz,2H),2.34–2.27(m,1H),1.08(dt,J=5.3,2.8Hz,2H),1.01(t,J=7.3Hz,5H).

[1259] Example 51: Preparation of Compound I-53

[1260] Step A: Preparation of compound 53a

[1261] To a reaction flask, compound 2A-2 (0.93 g), 6-amino-2-N-Boc-1,2,3,4-tetrahydro-isoquinoline (1.00 g), N,N-diisopropylethylamine (0.70 mL), and N,N-dimethylformamide (20 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to obtain compound 53a (1.27 g).

[1262] MS (ESI, [M+H] + )m / z:459.0.

[1263] Step B: Preparation of compound 53b

[1264] To a reaction flask were added compound 53a (0.50 g), intermediate 3A (0.30 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.10 g), tripotassium phosphate (0.46 g), 1,4-dioxane (20 mL), and water (4 mL) in that order. After the addition was complete, the reaction was stirred at 90°C under nitrogen atmosphere. The reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 30 / 1) to afford compound 53b (0.58 g).

[1265] MS (ESI, [M+H] + )m / z:556.2.

[1266] Step C: Preparation of compound 53c

[1267] Compound 53b (0.58 g) and a 7 M methanolic ammonia solution (30 mL) were added sequentially to a reaction flask. The mixture was stirred at 60°C and the reaction was monitored by TLC until completion. The reaction solution was filtered and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain compound 53c (0.28 g).

[1268] MS (ESI, [M+H] + )m / z:541.2.

[1269] Step D: Preparation of compound 53d

[1270] Compound 53c (0.18 g), dichloromethane (10 mL), and a 1,4-dioxane hydrochloride solution (4 M, 2.00 mL) were added sequentially to a reaction flask under ice. After addition, the mixture was stirred at room temperature. A large amount of white solid precipitated. The reaction was monitored by TLC until completion. The solid was filtered, washed, and dried to obtain compound 53d (0.15 g).

[1271] MS (ESI, [M+H] + )m / z:441.3.

[1272] Step E: Preparation of Compound I-53

[1273] Under an ice bath, compound 53d (0.15 g), dichloromethane (5 mL), N,N-diisopropylethylamine (0.11 mL), and propionyl chloride (0.07 g) were added sequentially to a reaction flask. After addition, the mixture was stirred and reacted. TLC was monitored until the reaction was complete. Water and dichloromethane were added to the reaction solution, and extraction was performed. The organic phase was separated, dried, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 30 / 1) to obtain compound I-53 (0.05 g).

[1274] HRMS (ESI, [M+H] + )m / z:497.2427.

[1275] 1H NMR(500MHz,DMSO-d6)δ11.25(s,1H),9.05(s,1H),8.55(s,1H),8.45(s,1H),8.16–8.07(m,1H),7.90– 7.83(m,1H),7.56(dd,J=8.5,2.2Hz,1H),7.49–7.43(m,1H),7.17(d,J=8.3Hz,1H),4.60(d,J=17.4Hz,2 H),4.00(s,3H),3.68(q,J=6.4Hz,2H),2.87(t,J=5.9Hz,1H),2.77(t,J=5.9Hz,1H),2.42(q,J=7.4Hz, 2H),1.93(tt,J=8.1,4.7Hz,1H),1.10(q,J=4.1Hz,2H),1.02(td,J=7.3,3.4Hz,3H),0.96–0.89(m,2H).

[1276] Example 52: Preparation of Compound I-54

[1277] Step A: Preparation of compound 54a

[1278] To a reaction flask, 2,7-diazaspiro[4,4]nonan-3-one (1.00 g), 4-nitrofluorobenzene (1.00 g), potassium carbonate (2.50 g), and N,N-dimethylformamide (20 mL) were added sequentially. After addition, the mixture was stirred at 100°C. The reaction was monitored by TLC until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 30 / 1) to obtain compound 54a (2.25 g).

[1279] MS (ESI, [M+H] + )m / z:262.1.

[1280] Step B: Preparation of compound 54b

[1281] Compound 54a (1.00 g) and tetrahydrofuran (30 mL) were added sequentially to a reaction flask under an ice bath. 60 wt% sodium hydride (0.92 g) was slowly added and the reaction stirred for 0.5 h. Iodomethane (1.63 g) was added portionwise. After addition, the reaction was stirred at room temperature. TLC was monitored until the reaction was complete, the reaction was quenched, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to afford compound 54b (0.85 g).

[1282] MS (ESI, [M+H] + )m / z:276.0.

[1283] Step C: Preparation of compound 54c

[1284] Compound 54b (0.85 g), methanol (10 mL), and 10% palladium hydroxide (0.25 g) were added to the reaction flask in sequence. After addition, the atmosphere was replaced with hydrogen and the reaction was stirred at room temperature. The reaction was monitored by TLC until completion, filtered, and concentrated to afford compound 54c (0.71 g).

[1285] MS (ESI, [M+H] + )m / z:246.0.

[1286] Step D: Preparation of compound 54d

[1287] To a reaction flask, compound 2A-2 (0.67 g), compound 54c (0.71 g), N,N-diisopropylethylamine (1.00 mL), and N,N-dimethylformamide (14 mL) were added sequentially. After addition, the mixture was stirred at 100°C. TLC was used to monitor the reaction until completion, and the reaction solution was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to obtain compound 54d (1.32 g).

[1288] MS (ESI, [M...

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, in, X 1 , X 2 or X 3 Each independently selected from N or CR a’ ; Y is selected from a bond, -CH2-, -O-, -S-, -NR a -, -S(O)2NR a -, -S(O)-, -S(O)NR a -, -C(O)-, -C(O)O-, -C(O)NR a -, -C(O)N(R a )O-, -OC(O)-, -OC(O)NR a -, -N(R a )C(O)O-, -N(R a )C(O)- or -N(R a )S(O)2-; Ring A is selected from a 5-14 membered partially unsaturated heterocyclic group, a C 6-14 Aryl or 5-14 membered heteroaryl; R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d 、-NH2、-NHR d 、-N(R d )2, -OH, -SH, -OR d , halogen, -COR d 、-COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d 2. -SO2R d ,-PO(R d )2. C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 6-10 aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl or 3-14 membered heterocyclyl, wherein the C 1-12 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 3-14 membered cycloalkyl, 3-14 membered cycloalkenyl, 3-14 membered heterocyclyl, C 2-12 Alkenyl or C 2-12 The alkynyl group is optionally substituted with one or more R b replace; R 2 is selected from 5-6 membered heteroaryl, 5-6 membered monocyclic heterocycloalkenyl, 8-12 membered saturated, partially saturated or aromatic bicyclic group, or 9-16 membered saturated, partially saturated or aromatic tricyclic group, wherein the bicyclic group or tricyclic group contains 0-6 heteroatoms independently selected from N, O or S, and the R 2 Optionally one or more R c replace; Every R a’ Each is independently selected from hydrogen, deuterium, halogen, -CN, -NH2, -OH, -NO2, -SH or the following groups optionally substituted by one or more substituents: -OC 1-12 Alkyl, -C 1-12 Alkyl, -NH(C 1-12 Alkyl), -N(C 1-12 alkyl)2, 3-14 membered cycloalkyl, 3-14 membered heterocycloalkyl, -NH-3-14 membered cycloalkyl, -SO2C 1-12 Alkyl, -OSO2C 1-12 Alkyl, -OC 1-12 Alkyl-SO2C 1-12 Alkyl, -C 1-12 Alkyl-sulfonyl imide, -OSO2C 1-12 Alkyl, -C(C 1-12 Alkyl)2SO2C 1-12 Alkyl, -SO2NHC 1-12 Alkyl, -SO2N(C 1-12 Alkyl)2, -OC 1-12 Alkyl-N(C 1-12 Alkyl)2, -C 1-12 Alkyl (3-14 membered heterocycloalkyl), -C(O)(C 1-12 alkyl), -C(O)NH(C 1-12 alkyl), -CH2C(O)NH(C 1-12 -C(O)NH(3-14-membered heterocycloalkyl), -C(O)NH(3-14-membered heterocycloalkyl), -C(O)NH(3-14-membered heterocycloalkyl); Every R a are each independently selected from hydrogen, or C optionally substituted by one or more substituents 1-12 Alkyl, 3-14 membered heterocycloalkyl, 3-14 membered cycloalkyl or 3-14 membered cycloalkenyl; Every R b Each independently selected from deuterium, halogen, -OH, -NH2, -CN, Or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, -SC 1-12 Alkyl, C 1-12 Alkyl, -C(O)C 1-12 Alkyl, -NHC(O)(C 1-12 alkyl), -C(O)N(C 1-12 Alkyl)2, -C(O)NH(C 1-12 alkyl), 3-14-membered cycloalkyl, 3-14-membered cycloalkenyl, 3-14-membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)-3-14 membered cycloalkyl, -C(O)-3-14 membered heterocycloalkyl, -C(O)-3-14 membered heterocycloalkenyl, -NH-3-14 membered cycloalkyl, -NH-3-14 membered heterocycloalkyl or -NH-3-14 membered heterocycloalkenyl; Every R c Each independently selected from deuterium, halogen, -OH, -NH2 or the following groups optionally substituted by one or more substituents: -NH(C 1-12 Alkyl), -N(C 1-12 Alkyl)2, -OC 1-12 Alkyl, C 1-12 Alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl; Every R d Each is independently selected from the following groups optionally substituted by one or more substituents: C 1-12 Alkyl, C 3-14 Cycloalkyl or 3-14 membered heterocycloalkyl; m is selected from 0, 1, 2, 3, 4, 5 or 6.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: X 1 and X 3 Select from N, and X 2 Selected from CR a’ ; Or, X 1 and X 2 Select from N, and X 3 Selected from CR a’ ; Or, X 1 and X 3 Each independently selected from CR a’ , and X 2 Selected from N; Or, X 2 and X 3 Each independently selected from CR a’ , and X 1 Selected from N; Or, X 1 and X 2 Each independently selected from CR a’ , and X 3 Selected from N; Or, X 1 , X 2 and X 3 Each independently selected from CR a’ ; Or, when the structure part for When R a’ Not hydrogen; Or, when the structure part for When ring A is not C 6-10 Aryl; Alternatively, the compound of formula (I) does not include the following compounds:

3. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein: Y is selected from a bond, -S-, -NR a -, -S(O)2NR a -, -S(O)-, -S(O)NR a -, -C(O)-, -C(O)O-, -C(O)NR a -, -C(O)N(R a )O-, -OC(O)-, -OC(O)NR a -, -N(R a )C(O)O-, -N(R a )C(O)- or -N(R a )S(O)2-; Alternatively, Y is selected from a bond, -S- or -NR a -; Alternatively, Y is selected from -NR a -; Alternatively, Y is selected from -NH-; Optionally, each R a are each independently selected from hydrogen or C 1-4 Alkyl; or, R a Selected from hydrogen.

4. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein: Ring A is selected from a 5-10 membered partially unsaturated heterocyclic group, a C 6-10 Aryl or 5-14 membered heteroaryl; Alternatively, Ring A is selected from a 5-8 membered partially unsaturated heterocyclyl, a phenyl, a naphthyl or a 5-6 membered heteroaryl, wherein the phenyl is optionally fused with a 4-10 membered (e.g., a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered) heterocyclyl, and the naphthyl is optionally fused with a 4-6 membered (e.g., a 5-membered or 6-membered) heterocyclyl; Alternatively, Ring A is selected from a 5-8 membered partially unsaturated heterocyclic group, a phenyl group, a naphthyl group or a 5-6 membered heteroaryl group, wherein the phenyl group is optionally fused with a 4-10 membered (e.g., a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered) heterocyclic group to form 2 or 3 rings, and the naphthyl group is optionally fused with a 4-6 membered (e.g., a 5-membered or 6-membered) heterocyclic group to form 3 rings; Alternatively, Ring A is selected from a 5-8 membered partially unsaturated heterocyclic group, a phenyl group, a naphthyl group or a 5-6 membered heteroaryl group, wherein the ring heteroatoms of the 5-8 membered partially unsaturated heterocyclic group or the 5-6 membered heteroaryl group are N, O or S only; or, the ring heteroatoms are N and O only; or, the ring heteroatoms are N only; or, the ring heteroatoms are S only; Alternatively, ring A is selected from phenyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrazolyl, pyridinyl, pyrazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiazolyl, imidazolyl, oxazolyl, The ring A is optionally substituted with one or more R 1 replace; Alternatively, ring A is selected from The ring A is optionally substituted with one or more R 1 replace.

5. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein: R 1 Each independently selected from -CN, -CON(R d )2, oxo, -OSO2R d 、-NH2、-NHR d 、-N(R d )2, -OH, -SH, -OR d , halogen, -COR d 、-COOR d 、-OCOR d 、-N(R d )C(O)(R d )、-CONH(R d )、-NHSO2(R d )、-NS(O)(R d )2、-SO2NH(R d )、-SO2N(R d 2. -SO2R d 、-PO(R d )2. C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 6-10 aryl, 5-10 membered heteroaryl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocyclyl, wherein the C 1-10 Alkyl, C 6-10 aryl, 5-10 membered heteroaryl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered heterocyclyl, C 4-10 Cycloalkenyl, C 2-10 Alkenyl or C 2-10 The alkynyl group is optionally substituted with one or more R b replace; Or, R 1 Each is independently selected from -CN, -CON(CH3)2, oxo, -OSO2CH3, halogen, -NH2, -NHCH3, -N(CH3)2, -OH, C 1-4 Alkyl, -OC 1-4 Alkyl, -C(O)-C 1-4 alkyl, -C(O)-4-10 membered heterocycloalkyl, -COOCH3, -OCOCH3, -CONH(CH3), -NHSO2(CH3), -NS(O)(CH3)2, -SO2NH(CH3), -SO2N(CH3)2, -SO2CH3, -PO(C 1-4 Alkyl)2, -N(C 1-3 Alkyl)C(O)C 1-3 alkyl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-10 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, wherein the C 1-4 alkyl, 4-8 membered cycloalkyl, 4-8 membered cycloalkenyl, 4-10 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, C 2-6 Alkynyl or C 2-6 The alkenyl group is optionally substituted with one or more R b replace; Or, R 1 are independently selected from halogen, oxo, -N(C 1-2 Alkyl)C(O)C 1-2 Alkyl, C 1-4 Alkyl, -OC 1-4 Alkyl, -C(O)-C 1-4 Alkyl, -C(O)-4-10 membered heterocycloalkyl, -PO(C 1-4 alkyl)2, 4-10 membered heterocycloalkyl, 5-8 membered heterocycloalkenyl or C 2-4 Alkynyl, wherein the C 1-4 alkyl, 4-10 membered heterocycloalkyl, 5-8 membered heterocycloalkenyl or C 2-4 The alkynyl group is optionally substituted by 1, 2 or 3 R b replace; Or, R 1 are independently selected from halogen, oxo, -N(C 1-2 Alkyl)C(O)C 1-2 Alkyl, C 1-4 Alkyl, -OC 1-4 Alkyl, -C(O)-C 1-4 Alkyl, -C(O)-4-10 membered heterocycloalkyl, -PO(C 1-4 alkyl)2, 4-10 membered heterocycloalkyl, 5-8 membered heterocycloalkenyl or C 2-4 Alkynyl, wherein the C 1-4 alkyl, 4-10 membered heterocycloalkyl, 5-8 membered heterocycloalkenyl or C 2-4 The alkynyl group is optionally substituted by 1, 2 or 3 R b replace; Or, R 1 Each is independently selected from F, Cl, Br, oxo, -N(CH3)COCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -OC 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-morpholinyl, -PO(C 1-3 alkyl)2, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, tetrahydrothienyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, azaoxanyl, azaspirocycloheptyl, diazaspirocyclooctanyl, azetidinyl, diazaspirocycloheptyl, oxetanyl, azopentanyl, azohexenyl, diazaspirocyclononyl, cyclopropane, cyclobutane wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, tetrahydrofuranyl, morpholinyl, tetrahydropyranyl, phosphazenyl, piperidinyl, tetrahydrothienyl, piperazinyl, tetrahydropyrrolyl, tetrahydroimidazolyl, oxazolidinyl, azacyclohexane, azacyclohexane, azacycloheptanyl, diazacyclospirocyclooctanyl, azetidinyl, diazacyclohexane Heterospirocycloheptyl, oxetanyl, aziridine, azidine, diazaspirocyclononyl, cyclopropane, cyclobutane, cyclopentane, diazabicyclooctanyl or ethynyl is optionally substituted by 1, 2 or 3 R b replace; Or, R 1 Each is independently selected from F, -C(O)-CH2CH3, methyl, ethyl, n-propyl, oxo, -OCH3, -PO(CH3)2, wherein the methyl, ethyl, n-propyl, Optionally 1 or 2 R b replace; Or, R 1 Each independently selected from F, -CH3, -OCH3, -PO(CH3)2, oxo, 6. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein: R 2 is selected from a 5-6 membered monocyclic heteroaryl containing 1 or 2 N atoms, a 5-6 membered monocyclic heterocycloalkenyl containing 1 or 2 N atoms, an 8-10 membered partially saturated or aromatic bicyclic group, a 9-14 membered partially saturated or aromatic tricyclic group, wherein the bicyclic group contains 1-4 heteroatoms independently selected from N, O or S, the tricyclic group contains 1-6 heteroatoms independently selected from N, O or S, and the R 2 Optionally one or more R c Replace; or, R 2 is selected from a 6-membered monocyclic heteroaryl containing 1 N atom, a 6-membered monocyclic heterocycloalkenyl containing 1 N atom, a 9- or 10-membered partially saturated or aromatic bicyclic group, or a 10- or 12-membered partially saturated or aromatic tricyclic group, wherein the bicyclic group contains 1-3 heteroatoms independently selected from N, O or S, the tricyclic group contains 2-3 heteroatoms independently selected from N or O, and R 2 Optionally one or more R c replace; Or, R 2 Selected from Wherein R 2 Optionally one or more R c replace; Or, R 2 Selected from Or, when R 2 When R is selected from 5-6 membered heteroaryl, a’ Not hydrogen; Optionally, each R c Each independently selected from deuterium, halogen, -NH2, -OH or the following groups optionally substituted by one or more substituents: -NH(C 1-8 Alkyl), -N(C 1-8 Alkyl)2, -OC 1-8 Alkyl, C 1-8 alkyl, 3-8 membered cycloalkyl or 3-8 membered cycloalkenyl; or, each R c Each independently selected from F, Cl, or C 1-3 alkyl; Or, each R c Each independently selected from F, Or -CH3.

7. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein: When R 1 does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions: a) Ring A is a 5-membered heteroaryl group, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3; b) Ring A is C 6-10 Aryl, and the C 6-10 The aryl group is fused with the heterocyclic group; c) At least one R 1 C 1-6 Alkyl, 4-14 membered cycloalkyl, 3-14 membered heterocyclic group, C 2-12 Alkenyl or C 2-12 Alkynyl, and the C 1-6 The alkyl group is one or more selected from -SC 1-6 alkyl, or an optionally substituted 3-14 membered cycloalkyl substituted with one or more substituents selected from -OH, halogen, optionally substituted C 1-6 Alkyl, optionally substituted -OC 1-6 Alkyl, optionally substituted -(CH2) 0-2 N(C 1-6 alkyl)2, or optionally substituted -C(O)N(C 1-6 The 3-14 membered heterocyclic group is substituted by at least one or more substituents selected from =O, -C(O)C 2-4 alkyl, -C(O)CH3 substituted by one or more halogens, optionally substituted -C(O)N(C 1-6 Alkyl)2, C substituted by Cl or -NH2 1-4 alkyl, or -C(O)-3-8 membered cycloalkyl; the C 2-12 Alkenyl and C 2-12 The alkynyl group is optionally substituted with one or more R b replace; Among them, the Y 1 , Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ; R 3 Independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl; R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups; R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups; Or, when R 1 does not contain phosphorus atoms, and R 2 for When the compound of formula (I) satisfies at least one of the following conditions: a) Ring A is pyrazolyl, and R a’ Not selected from cyclopropyl, -OCH3 and -NHCH3; b) Ring A is phenyl, and the phenyl is fused with a 4-10 membered heterocyclic group; c) At least one R 1 is methyl, ethyl, cyclobutyl, cyclopentyl, azetidinyl, azocyclopentyl, piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, 2,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2,7-diazaspiro[3.5]nonane, 2,7-diazaspiro[4.4]nonane, octahydropyrrolo[3,4-c]pyrrole, or ethynyl, and the methyl or ethyl group is replaced by one or more -SC 1-4 The cyclobutyl or cyclopentyl is substituted by one or more substituents selected from -OH, F, C optionally substituted by halogen. 1-4 Alkyl, optionally substituted -OC 1-4 alkyl, optionally substituted -N(C 1-4 alkyl)2, optionally substituted -CH2N(C 1-4 alkyl)2, or optionally substituted -C(O)N(C 1-4 alkyl)2; the azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, 2,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2,7-diazaspiro[3.5]nonane, 2,7-diazaspiro[4.4]nonane, or octahydropyrrolo[3,4-c]pyrrole is at least one or more selected from =O, -C(O)C 2-4 alkyl, -C(O)CH3, -C(O)N(C 1-4 Alkyl)2, C substituted by Cl or -NH2 1-3 The ethynyl group is substituted by a substituent selected from C(O)-3-6 membered cycloalkyl, wherein the ethynyl group is substituted by one or more substituents selected from C(O)-3-6 membered cycloalkyl, wherein the substituents are selected from C(O) ... 1-4 Alkyl, -C(O)N(C 1-4 Alkyl)2, -C(O)NH(C 1-4 alkyl), 3-6 membered cycloalkyl, or -C(O)-3-6 membered heterocycloalkyl; Among them, the Y 1 , Y 2 and Y 3 Each independently selected from N or CR 3 , the condition is that when Y 1 When N, Y 3 CR 3 , when Y 3 When N, Y 1 CR 3 ; R 3 Independently selected from H, F, Cl or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 groups independently selected from F, CN, NH2 or -OC 1-2 The alkyl group is substituted with a substituent wherein the -OC 1-2 The alkyl group is substituted with 0, 1, 2 or 3 substituents independently selected from F or Cl; R c1 Cyclopropyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is substituted with 0, 1, 2 or 3 F groups; R c2 H, NH2 or C 1-2 Alkyl, wherein the C 1-2 The alkyl group is substituted with 0, 1, 2 or 3 F groups.

8. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein: Every R a’ Each is independently selected from hydrogen, halogen, -CN, -NH2, -OH, -NO2 or the following groups optionally substituted by one or more substituents: -OC 1-6 Alkyl, C 1-6 Alkyl, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, -NH-3-8 membered cycloalkyl, -SO2C 1-6 Alkyl, -OSO2C 1-6 Alkyl, -OC 1-6 Alkyl-SO2C 1-6 Alkyl, (C 1-6 Alkyl)sulfonyl imide, -OSO2C 1-6 Alkyl, -C(C 1-6 Alkyl)2SO2C 1-6 Alkyl, -SO2NHC 1-6 Alkyl, -SO2N(C 1-6 Alkyl)2, -OC 1-6 Alkyl-N(C 1-6 Alkyl)2, -C 1-6 Alkyl (3-14 membered heterocycloalkyl), -C(O)(C 1-6 alkyl), -C(O)NH(C 1-6 alkyl), -CH2C(O)NH(C 1-6 alkyl), -C(O)(3-8 membered heterocycloalkyl), -NH-3-8 membered heterocycloalkyl, -C(O)(3-8 membered cycloalkyl), -C(O)NH(3-8 membered cycloalkyl) or -C(O)NH(3-8 membered heterocycloalkyl); Or, each R a’ Each independently selected from H, F, Cl, C 1-3 Alkyl, -NHC 1-3 alkyl, 3-5 membered cycloalkyl, 3-5 membered heterocycloalkyl, or -NH-3-5 membered cycloalkyl, the C 1-3 Alkyl, -NHC 1-3 Alkyl, 3-5 membered cycloalkyl or -NH-3-5 membered cycloalkyl is optionally substituted with one or more halogens; Or, each R a’ Each is independently selected from H, F, -NHCH3, cyclopropyl, -NHCH2CF3, 9. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein: Optionally, each R b Each independently selected from deuterium, halogen, -CN, -OH, -NH2 or the following groups optionally substituted by one or more substituents: -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 1-6 Alkyl, -C(O)C 1-6 Alkyl, -C(O)N(C 1-6 Alkyl)2, -C(O)NH(C 1-6 Alkyl), -NHC(O)(C 1-6 alkyl), 3-8 membered cycloalkyl, 3-8 membered cycloalkenyl, 3-8 membered heterocyclyl, C6 aryl, 5-6 membered heteroaryl, -C(O)-3-8 membered cycloalkyl, -C(O)-4-8 membered heterocycloalkyl, -C(O)-4-8 membered heterocycloalkenyl, -NH-3-8 membered cycloalkyl, -NH-4-8 membered heterocycloalkyl or -NH-4-8 membered heterocycloalkenyl; Or, each R b Each independently selected from F, Cl, C 1-3 Alkyl, -N(C 1-3 Alkyl)2 or NHC 1-3 alkyl; Or, each R b Each independently selected from F, methyl, -N(CH3)2、-NHCH3、-CF3、-CH2Cl、-CH2NH2、-C(O)CHF2、-C(O)CH2CH3、-C(O)CH2F、 -CH2N(CH3)2、-SCH3、 <h2 style=";text-align:left;direction:ltr">-OCH3、-N(CH3)(CH2CF3)、-OH、<h2 style=";text-align:left;direction:ltr"> -C(CH3)2OH or -CN.

10. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein each R d Each is independently selected from the following groups optionally substituted by one or more substituents: C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-8 membered heterocycloalkyl; Or, each R d Each independently selected from C 1-4 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl; Or, each R d Each is independently selected from methyl, ethyl or morpholinyl.

11. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, wherein: m is selected from 0, 1, 2, 3 or 4; Alternatively, m is selected from 1, 2, 3 or 4; alternatively, m is selected from 1, 2 or 3; alternatively, m is selected from 1 or 2; alternatively, m is 0.

12. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, which is selected from the following compounds of formula (II), formula (II-1), formula (II-2), formula (II-3), formula (II-4), formula (II-1a), formula (II-1b), formula (II-1c), formula (II-1d), or formula (II-1e) or a pharmaceutically acceptable salt thereof:

13. The following compound or a pharmaceutically acceptable salt thereof:

14. A pharmaceutical composition comprising the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof.

15. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, or the pharmaceutical composition according to claim 14, in the preparation of a medicament for treating a disease; optionally, the disease is selected from cancer.

Citation Information

Patent Citations

  • Benzamides useful as s1p receptor modulators

    CN101687774A

  • Application of compound in treatment of lung cancer

    CN107661333A

  • Carboxamide-pyrimidine derivatives as SHP2 antagonists

    CN113795483A

  • HPK1 inhibitor and application thereof in medicine

    CN115197132A

  • 4-aminopyrrolopyrimidines as kinase inhibitors

    CN1326457A

Cited By

  • 5-cyclopropylpicolinamide derivative, preparation method therefor, and pharmaceutical composition comprising same for preventng or treating cancer

    WO2026084434A1